
<html lang="en"     class="pb-page"  data-request-id="bee66a8f-aecc-4c1c-a8c4-cd8a546b3a06"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-15;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.0c00574;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents" /></meta><meta name="dc.Creator" content="Binbin  Cheng" /></meta><meta name="dc.Creator" content="Yichang  Ren" /></meta><meta name="dc.Creator" content="Xiaoge  Niu" /></meta><meta name="dc.Creator" content="Wei  Wang" /></meta><meta name="dc.Creator" content="Shuanghu  Wang" /></meta><meta name="dc.Creator" content="Yingfeng  Tu" /></meta><meta name="dc.Creator" content="Shuwen  Liu" /></meta><meta name="dc.Creator" content="Jin  Wang" /></meta><meta name="dc.Creator" content="Deying  Yang" /></meta><meta name="dc.Creator" content="Guochao  Liao" /></meta><meta name="dc.Creator" content="Jianjun  Chen" /></meta><meta name="dc.Description" content="Novel small molecule compounds based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether were designed and tested for their inhibitory activity against the Programmed ..." /></meta><meta name="Description" content="Novel small molecule compounds based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether were designed and tested for their inhibitory activity against the Programmed ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 15, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00574" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00574" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00574" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00574" /></link>
        
    
    

<title>Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00574" /></meta><meta property="og:title" content="Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0024.jpeg" /></meta><meta property="og:description" content="Novel small molecule compounds based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether were designed and tested for their inhibitory activity against the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) pathway. Among them, compound NP19 inhibited the human PD-1/PD-L1 interaction with IC50 values of 12.5 nM in homogeneous time-resolved fluorescence (HTRF) binding assays. In addition, NP19 dose-dependently elevated IFN-γ production in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. Furthermore, NP19 displayed significant in vivo antitumor efficacy in two different mouse models of cancer (a melanoma B16-F10 tumor model and an H22 hepatoma tumor model). Moreover, H&amp;E staining and flow cytometry data suggested that NP19 activated the immune microenvironment in the tumor, which may contribute to its antitumor effects. This work shows NP19 is a promising lead compound for further development as a new generation of small molecule inhibitors targeting the PD-1/PD-L1 pathway." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00574"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00574">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00574&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00574&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00574&amp;href=/doi/10.1021/acs.jmedchem.0c00574" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 15</span><span class="cit-fg-pageRange">, 8338-8358</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/15" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00511" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00584" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Binbin Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Binbin Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Binbin++Cheng">Binbin Cheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yichang Ren</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yichang Ren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yichang++Ren">Yichang Ren</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoge Niu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoge Niu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoge++Niu">Xiaoge Niu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Wang">Wei Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuanghu Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuanghu Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuanghu++Wang">Shuanghu Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0057-267X" title="Orcid link">http://orcid.org/0000-0002-0057-267X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yingfeng Tu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingfeng Tu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingfeng++Tu">Yingfeng Tu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2605-0172" title="Orcid link">http://orcid.org/0000-0003-2605-0172</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuwen Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuwen Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuwen++Liu">Shuwen Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6346-5006" title="Orcid link">http://orcid.org/0000-0001-6346-5006</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jin Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jin Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">AbbVie Inc., North Chicago, Illinois 60064, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jin++Wang">Jin Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Deying Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Deying Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People’s Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Deying++Yang">Deying Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guochao Liao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guochao Liao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People’s Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guochao++Liao">Guochao Liao</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jianjun Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianjun Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#167c757e7378242756657b6338737263387578"><span class="__cf_email__" data-cfemail="deb4bdb6bbb0ecef9eadb3abf0bbbaabf0bdb0">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianjun++Chen">Jianjun Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5668-6572" title="Orcid link">http://orcid.org/0000-0001-5668-6572</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00574&amp;href=/doi/10.1021%2Facs.jmedchem.0c00574" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 15</span><span class="cit-pageRange">, 8338–8358</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 15, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>8 April 2020</li><li><span class="item_label"><b>Published</b> online</span>15 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 August 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00574" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00574</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8338%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBinbin%2BCheng%252C%2BYichang%2BRen%252C%2BXiaoge%2BNiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D15%26contentID%3Dacs.jmedchem.0c00574%26title%3DDiscovery%2Bof%2BNovel%2BResorcinol%2BDibenzyl%2BEthers%2BTargeting%2Bthe%2BProgrammed%2BCell%2BDeath-1%252FProgrammed%2BCell%2BDeath%25E2%2580%2593Ligand%2B1%2BInteraction%2Bas%2BPotential%2BAnticancer%2BAgents%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8358%26publicationDate%3DAugust%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00574"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2008</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">11</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00574" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Binbin&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Yichang&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Xiaoge&quot;,&quot;last_name&quot;:&quot;Niu&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Shuanghu&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yingfeng&quot;,&quot;last_name&quot;:&quot;Tu&quot;},{&quot;first_name&quot;:&quot;Shuwen&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jin&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Deying&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Guochao&quot;,&quot;last_name&quot;:&quot;Liao&quot;},{&quot;first_name&quot;:&quot;Jianjun&quot;,&quot;last_name&quot;:&quot;Chen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;15&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;8338-8358&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00574&quot;},&quot;abstract&quot;:&quot;Novel small molecule compounds based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether were designed and tested for their inhibitory activity against the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) pathway. Among them, compound NP19 inhibited the human PD-1/PD-L1 interaction with IC50 values of 12.5 nM in homogeneous time-resolved fluorescence (HTRF) binding assays. In addition, NP19 dose-dependently elevated IFN-γ production in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. Furthermore, NP19 displayed significant in vivo antitumor efficacy in two different mouse models of cancer (a melanoma B16-F10 tumor model and an H22 hepatoma tumor model). Moreover, H&amp;E staining and flow cytometry data suggested that NP19 activated the immune microenvironment in the tumor, which may contribute to its antitumor effects. This work shows NP19 is a promising lead compound for further development as a new generation of small molecule inhibitors targeting the PD-&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00574&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00574" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00574&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00574" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00574&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00574" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00574&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00574&amp;href=/doi/10.1021/acs.jmedchem.0c00574" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00574" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00574" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (11 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00574%26sid%3Dliteratum%253Aachs%26pmid%3D32667799%26genre%3Darticle%26aulast%3DCheng%26date%3D2020%26atitle%3DDiscovery%2Bof%2BNovel%2BResorcinol%2BDibenzyl%2BEthers%2BTargeting%2Bthe%2BProgrammed%2BCell%2BDeath-1%252FProgrammed%2BCell%2BDeath%25E2%2580%2593Ligand%2B1%2BInteraction%2Bas%2BPotential%2BAnticancer%2BAgents%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D15%26spage%3D8338%26epage%3D8358%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/15" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/jmcmar.2020.63.issue-15/20200813/jmcmar.2020.63.issue-15.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Novel small molecule compounds based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether were designed and tested for their inhibitory activity against the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) pathway. Among them, compound <b>NP19</b> inhibited the human PD-1/PD-L1 interaction with IC<sub>50</sub> values of 12.5 nM in homogeneous time-resolved fluorescence (HTRF) binding assays. In addition, <b>NP19</b> dose-dependently elevated IFN-γ production in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. Furthermore, <b>NP19</b> displayed significant <i>in vivo</i> antitumor efficacy in two different mouse models of cancer (a melanoma B16-F10 tumor model and an H22 hepatoma tumor model). Moreover, H&E staining and flow cytometry data suggested that <b>NP19</b> activated the immune microenvironment in the tumor, which may contribute to its antitumor effects. This work shows <b>NP19</b> is a promising lead compound for further development as a new generation of small molecule inhibitors targeting the PD-1/PD-L1 pathway.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Immunotherapy has been widely used for the treatment of cancer and is currently revolutionizing the treatment of various types of cancers.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Cancer immunotherapy seeks to elicit the immune system to combat cancerous tumors and is one of the fastest developing fields in cancer therapy.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> With the growing success in cancer immunotherapy, a large number of proteins/receptors are currently being investigated as potential targets of immuno-oncology therapies.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Among them, Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) is one of the most promising targets in the field of immuno-oncology.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9">(6−9)</a> PD-1 binds to two ligands from the B7 family: PD-L1 and PD-L2. Studies have shown that tumor microenvironments can induce infiltrated T cells to overexpress PD-1 protein, while PD-L1 (the ligand of PD-1) is overexpressed in tumor cells. The binding of PD-1 to its ligand PD-L1 leads to a down-regulation of T-cell functions in cancer patients, thus inhibiting the antitumor immunity and causing T-cell exhaustion.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> PD-1/PD-L1 inhibitors can block PD-1 binding to PD-L1, interfere with the negative regulatory mechanism, and boost the activity of T cells, thus strengthening the immune response.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></div><div class="NLM_p">PD-1/PD-L1 inhibitors, also known as immune checkpoint inhibitors, are effective in various types of cancers.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> So far, the US FDA has approved six immune checkpoint inhibitors for cancer treatment, with all of them being monoclonal antibodies including Ipilimumab (anti-CTLA-4, BMS), Pembrolizumab (anti-PD-1, Merck), Nivolumab (anti-PD-1, BMS), Duvalumab (anti-PD-L1, Astrazeneca), Atezolizumab (anti-PD-L1, Roche), and Avelumab (anti-PD-L1, Pfizer and Merck). Antibody-mediated immune checkpoint blockade has demonstrated clinical benefits in different types of tumors such as malignant melanoma, head and neck squamous cell carcinoma, and late-stage metastatic NSCLC, which respond to anti-PD-1 or anti-PD-L1 treatment.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> These regimens have become standards of care. However, therapeutic antibodies suffer from several disadvantages such as immunogenicity, long circulation half-life, poor tissue and tumor penetration, lack of oral bioavailability, and costly production.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Moreover, currently available antitumor monoclonal antibodies target only extracellular receptors/proteins, which account for only a small fraction of cancer biomarkers.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">Compared to monoclonal antibodies, small molecule PD-1/PD-L1 modulators for cancer immunotherapy in general have reasonable pharmacokinetic properties including better tissue and tumor penetration, higher oral bioavailability, acceptable half-lives, etc. In addition, small molecules can be administered orally, which provides the possibility of improved clinical dosing within the therapy regimen. Therefore, small molecule PD-1/PD-L1 modulators as cancer immunotherapies have the potential to overcome the above-mentioned disadvantages of therapeutic antibodies and may also be combined with antibodies to achieve synergistic anticancer effects.<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a></div><div class="NLM_p">In the last 3 years, dozens of small molecule PD-1/PD-L1 inhibitors have been discovered and most of them are in various stages of preclinical development.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Three classes of non-mAb small molecules (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) have been reported so far: (1) peptides as direct competitive PD-1/PD-L1 modulators (e.g., <b>Peptide-1</b>);<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (2) small molecules disrupting PD-1/PD-L1 interaction and inducing dimerization of PD-L1 (e.g., <b>BMS-8</b>,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><b>BMS-202</b>,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><b>Resorcinol derivatives</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>); and (3) small molecules with unknown mode of action (e.g., <b>SA-49</b>).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Among them, <b>CA-170</b> is the first drug-like small molecule inhibitor of PD-L1, which is currently being investigated in a phase I trial (NCT02812875) for the treatment of patients with advanced solid tumors and lymphomas. However, recent studies have shown that there was no direct binding between CA-170 and PD-L1; therefore, further investigation for the mechanism of action of CA-170 is needed.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> As for other small molecule inhibitors such as the BMS series, current research mainly focused on the <i>in vitro</i> profiling of the compounds; no animal studies have been reported.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of small molecule PD-1/PD-L1 pathway inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although small-molecule PD-1/PD-L1 inhibitors for cancer immunotherapy are promising, it is still challenging to design small molecule inhibitors as the binding pocket in PD-L1 is hydrophobic, flat, and extended without a deep binding pocket. Meanwhile, inhibitors with more structural diversity will be favored in future drug design.</div><div class="NLM_p last">Starting from a docking-based virtual screening and drug design followed by an extensive structure–activity relationships (SARs) study, we designed, synthesized, and evaluated more than 100 novel compounds based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether as small molecule inhibitors of PD-1/PD-L1. One of the best compounds, <b>NP19</b>, showed potent <i>in vitro</i> activity (IC<sub>50</sub> = 12.5 nM) and high <i>in vivo</i> antitumor efficacy, which represents a promising lead worthy of further investigation.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10631" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10631" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The synthesis of chalcone compounds <b>CET1–13</b> and flavonoid compounds <b>HT1–13</b> is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The preparation of 1-(5-(chloromethyl)-2-hydroxyphenyl)ethan-1-one (<b>2</b>) was accomplished by chloromethylation of compound <b>1</b> with paraformaldehyde and hydrochloric acid. The conversion of intermediate <b>2</b> to <b>3a</b>–<b>i</b> was achieved by nucleophilic substitution of benzyl chloride compound <b>2</b> with appropriate aryl and heterocyclic compounds <b>H-R</b><sup><b>1</b></sup>. Compounds <b>CET1–13</b> were obtained by chalcone reaction of <b>3a</b>–<b>i</b> with substituted benzaldehydes <b>m2</b>. The iodine-mediated cyclization was applied to convert the chalcone compounds <b>CET1–13</b> to flavonoid compounds <b>HT1–13</b>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Chalcone Compounds <b>CET1–13</b> and Flavonoid Compounds <b>HT1–13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) paraformaldehyde, concentrated hydrochloric acid, 50 °C, 10 h, 37%; (b) DCM, 40 °C, 2 h, 60%∼70%; (c) KOH, MeOH, 25 °C, 24 h, 40%∼50%; (d) iodine, DMSO, 100 °C, 24 h, 8%∼12%.</p></p></figure><div class="NLM_p">The preparation of the naphthalene compounds <b>N1–17</b> is depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. A Mistunobu etherification reaction between benzyl alcohol <b>m3</b> and naphthalene compound <b>4</b> afforded <b>5a</b>–<b>b</b>. The sodium cyanoborohydride-mediated reductive amination was used to convert <b>5a</b>–<b>b</b> into naphthalene compounds <b>N1–17</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Naphthalene Compounds <b>N1–17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PPh<sub>3</sub>, DIAD, THF, 0 °C∼25 °C, 10 h, 36%∼40%; (b) MeOH, AcOH, NaBH<sub>3</sub>CN, 60 °C, 12 h, 15%∼25%.</p></p></figure><div class="NLM_p">The synthesis of the amide compound <b>XA1</b> is outlined in <a class="ref internalNav" href="#notes1" aria-label="Scheme S1">Scheme S1</a>. (see <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a>)</div><div class="NLM_p">The resorcinol dibenzyl ether compounds <b>NC1–12</b> and <b>NP1–25</b> were synthesized as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. The synthesis of intermediates <b>7a</b>–<b>b</b> was achieved through Mistunobu etherification of compound <b>6</b> with benzyl alcohol <b>m4</b>. Compounds <b>NC1–12</b> and <b>NP1–25</b> were obtained by nucleophilic substitution of <b>7a</b>–<b>b</b> with 3-cyanobenzyl bromide, followed by reductive amination using NaBH<sub>3</sub>CN and appropriate aryl and heterocyclic compounds <b>H-R</b><sup><b>1</b></sup>.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0015.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds NC1–12 and <b>NP1–25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PPh<sub>3</sub>, DIAD, THF, 0 °C∼25 °C, 10 h, 16%∼20%; (b) DMF, Na<sub>2</sub>CO<sub>3</sub>, 80 °C, 30 min, 70%∼80%; (c) DMF, AcOH, NaBH<sub>3</sub>CN, 80 °C, 2 h, 15%∼25%.</p></p></figure><div class="NLM_p">To prepare compounds <b>NT1–22</b>, a multistep synthetic route was applied which is outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The starting material, compound <b>9</b>, was reacted with benzyl bromide compound <b>m5</b> to conveniently yield intermediate <b>10</b>, which was then reacted with 3-cyanobenzyl bromide to yield intermediate <b>11</b>. The Suzuki–Miyaura coupling between commercially available boronic acids <b>m6</b> with intermediate <b>11</b> provided the intermediates <b>12</b>. The NaBH<sub>3</sub>CN-mediated reductive amination was applied to convert <b>12</b> to the desired compounds <b>NT1–22</b>.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0016.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>NT1–22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaHCO<sub>3</sub>, DMF, 60 °C, 2 h, 40%; (b) DMF, Na<sub>2</sub>CO<sub>3</sub>, 80 °C, 30 min, 60%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, DMSO, H<sub>2</sub>O, 100 °C, 12 h, 25%∼30%; (d) DMF, AcOH, NaBH<sub>3</sub>CN, 80 °C, 2 h, 15%∼25%.</p></p></figure><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i9" class="anchor-spacer"></div><h4 class="article-section__title" id="_i9"> Docking-Based Virtual Screening and Drug Design</h4><div class="NLM_p">At the beginning of this study, we discovered several hit compounds targeting the human PD-1/PD-L1 interaction through virtual screening-based drug design as detailed below. First, we used Targetmol’s natural compound library (1867 compounds) and Schrodinger virtual screening workflow module to conduct high-throughput virtual screening to select potential new PD-1/PD-L1 inhibitors. The virtual screening included five steps: (1) The crystal structure of dimeric PD-L1 protein and <b>BMS-202</b> complex (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89">5J89</a>) was selected as the virtual screening model. (2) Protein preparation was performed to remove water, followed by adding of hydrogens and adjustment of bond orders and charges as well. (3) Receptor grid generation was done to define the active binding site. (4) Ligand preparation was performed to generate all the isomers and proper ionization states. (5) The ligands were docked into receptor through the Schrodinger virtual screening workflow module. The compounds with high Glide gscore from the high-throughput virtual screening were ordered from commercial sources and evaluated using the homogeneous time-resolved fluorescence (HTRF) binding assay; the results are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. PD-1/PD-L1 Inhibitors Identified from Virtual Screening</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0017.gif" alt="" id="gr6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The data are generated from three independent experiments.</p></div></div><div></div></div><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the top-ranking compounds have a flavonoid scaffold with IC<sub>50</sub> values in the midmicromolar range (96.6 μM). We then utilized the Schrodinger molecular modeling suite module to explore the binding mode of the hit compound <b>Bavachinin</b> in comparison with <b>BMS-202</b> in the PD-1/PD-L1 binding site. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <b>Bavachinin</b> fitted relatively well into the hydrophobic cleft formed by dimeric PD-L1 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A), the flavonoid backbone has hydrophobic interactions with ALA121 and TYR56. However, it lacks some key interactions with PD-L1, such as the π–π interactions with TYR56 (from the other chain of the PD-L1 dimer) as observed for <b>BMS-202</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Careful analysis of the binding mode of <b>BMS-202</b> in the binding pocket revealed that the terminal phenyl moiety of the biphenyl group formed strong π–π interactions with TYR56 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C).</div><figure id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0002.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Docking analysis of <b>Bavachinin</b> with the PD-L1 dimer. (B) Detailed interactions of <b>BMS-202</b> with dimeric PD-L1 protein. (C) Binding overlap of <b>Bavachinin</b> (yellow stick) and <b>BMS-202</b> (light pink stick) in the binding site. The crystal structure of the dimeric PD-L1 protein was taken from the RCSB Protein Data Bank (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89">5J89</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Based on the above docking analysis of <b>Bavachinin</b> and <b>BMS-202</b> in the binding pocket of PD-L1, we hypothesize that the flavonoid scaffold of <b>Bavachinin</b> could be retained, and a 2-methyl biphenyl moiety may be added into the flavonoid scaffold to mimic the key π–π interactions formed by the TYR56 residue of PD-L1 with <b>BMS-202</b>. Based on these considerations, we designed a series of novel flavonoids and chalcones by incorporating the 2-methyl biphenyl moiety into the flavonoid backbone and varying the tail groups, aiming to improve the activity of the hit compound <b>Bavachinin</b>. Compounds <b>CET1–13</b> (chalcones) and <b>HT1–13</b> (flavonoids) with various tail groups were synthesized and evaluated as elaborated below. <b>BMS-202</b> and <b>BMS-1166</b> were available from commercial sources and thus were used as the positive controls.</div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> Preliminary Biochemical Evaluation of Chalcone Compounds <b>CET1–13</b></h4><div class="NLM_p">The activities of chalcone compounds <b>CET1–13</b> as inhibitors of the PD-1/PD-L1 interaction were evaluated using the well-established HTRF assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> The biochemical data are presented as IC<sub>50</sub> values and listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. Most of the <b>CET1–13</b> compounds were not active at concentrations up to 20 μM, except <b>CET 3</b>, <b>8</b>, <b>10</b>, and <b>13</b>, which exhibited IC<sub>50</sub> values of 5.3 μM, 14.6 μM, 14.4 μM, and 19.3 μM, respectively. These results demonstrated that the structural modifications (e.g., addition of the biphenyl moiety) based on hit compound <b>Bavachinin</b> led to a moderate improvement in the activity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Activities of Compounds <b>CET1–13</b> in Inhibition of PD-1/PD-L1 Interaction</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0018.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The data are generated from three independent experiments.</p></div></div><div></div></div><div class="NLM_p">To further understand the potential binding mode of the <b>CET</b> chalcone compounds with PD-L1 protein, a molecular docking study using <b>CET3</b> (the most active <b>CET</b> compound) was performed with <b>BMS-202</b> as a control (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B, the chalcone skeleton fits well in the binding pocket, and the biphenyl moiety displayed π–π interactions with TYR56, which may account for the improved activity of <b>CET</b> compounds versus the hit compound <b>Bavachinin</b>. However, the binding mode of the tail group with surrounding amino acids changed dramatically compared to that of <b>BMS-202</b> (highlighted by a red circle) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B), which may explain the reduction of anti<b>-</b>PD-1/PD-L1 activity for <b>CET</b> compounds in comparison to <b>BMS-202</b>.</div><figure id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Detailed interactions of <b>BMS-202</b> with the dimeric PD-L1 protein. (B) Docking analysis of <b>CET3</b> with the PD-L1 dimer. (C) Docking analysis of <b>HT11</b> with the PD-L1 dimer. The crystal structure of the dimeric PD-L1 protein was taken from the RCSB Protein Data Bank (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89">5J89</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13"> Preliminary Biochemical Evaluation of Flavonoid Compounds <b>HT1–13</b></h4><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, most of the <b>HT1–13</b> compounds were not active at concentrations up to 10 μM, except <b>HT11,</b> which showed moderate activity with an IC<sub>50</sub> value of 1.4 μM.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Activities of Compounds <b>HT1–13</b> in Inhibition of PD-1/PD-L1 Interaction</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0019.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The data are generated from three independent experiments.</p></div></div><div></div></div><div class="NLM_p">To further understand the potential binding mode of the <b>HT</b> flavonoid compounds with PD-L1 protein, a molecular docking study using the most active <b>HT</b> compound, <b>HT11,</b> was performed with <b>BMS-202</b> as a control (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). As seen from <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C, <b>HT11</b> fitted well into the hydrophobic cleft formed by dimeric PD-L1, and the key interactions such as π–π interactions with TYR56 were retained. In addition, the pyrone moiety of the flavonoid backbone had π–π interactions with TYR56 (from the other chain of the PD-L1 dimer), which may explain the improved activity of <b>HT</b> compounds (e.g., 1.4 μM for <b>HT11</b>) versus <b>CET</b> compounds (e.g., 5.3 μM for <b>CET3</b>). However, the carbonyl moiety of the flavonoid skeleton makes the hydrophobic pocket larger (highlighted by a red circle in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C) by forcing the surrounding amino acid residues to flip out, which may account for the reduced activity of the <b>HT</b> compounds in comparison to <b>BMS-202</b>. Therefore, substituting small rings in this region, such as 5-membered rings and 4-membered rings, may increase activity against the PD-1/PD-L1 interaction.</div><div class="NLM_p last">In order to further explore the SAR of PD-1/PD-L1 inhibitors and thus to help design new analogs with improved activity, we analyzed the interaction of <b>BMS-202</b> with dimeric PD-L1 protein. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A revealed that <b>BMS-202</b> is located at the core of the PD-L1 homodimer, filling a deep hydrophobic channel-like pocket with roughly cylindrical shape in the cross section. The binding mode showed that there was a large space between the methoxy group and the tail group (highlighted by a red circle in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A), which could be occupied by an appropriate 5- or 6-membered ring. Therefore, it seems plausible to design novel PD-1/PD-L1 inhibitors by a ring fusion strategy. Based on the above analysis, we designed and synthesized a series of naphthalene-based PD-1/PD-L1 inhibitors (<b>N1–N17</b>) as detailed below.</div></div><div id="sec2_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> Preliminary Biochemical Evaluation of Naphthalene Compounds <b>N1–17</b></h4><div class="NLM_p">As listed in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, all naphthalene compounds exhibited IC<sub>50</sub> values of >10 μM, which indicated that the naphthalene skeleton may not be an optimal design. We performed molecular docking studies using compound <b>N9</b> and analyzed the binding mode. As shown in <a class="ref internalNav" href="#notes1" aria-label="Figure S1">Figure S1</a>, the <i>N</i>-(2-aminoethyl)acetamide tail group of N9 interacts with Asp122 and Lys124 through hydrogen bonds. Compared to BMS-202, The NH moiety of N9 forms a hydrogen bond with the hydroxyl group of ASP122; however, the NH moiety of BMS-202 forms two hydrogen bonds with the hydroxyl and carbonyl moiety of ASP122, suggesting that the orientation of the hydrogen-bonding interactions created by the hydrophilic tail of the inhibitor strongly influence the binding affinity of the inhibitors, and the orientation observed for the naphthalene compounds in the binding pocket may not be as optimal as that of <b>BMS-202</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Activities of Compounds <b>N1–17</b> in Inhibition of PD-1/PD-L1 Interaction</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0020.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">The data are generated from three independent experiments.</p></div></div><div></div></div><div class="NLM_p last">To further optimize the activity, a more extensive SAR study was performed as detailed below. First, we conducted molecular modeling/docking to explore the binding mode of the recently reported BMS compounds: <b>BMS-1001</b> and <b>BMS-1166</b>. As shown in <a class="ref internalNav" href="#notes1" aria-label="Figure S2">Figure S2</a>, the tail group of <b>BMS-1166</b> and <b>BMS-1001</b> had a strong interaction with dimeric PD-L1 protein. Meanwhile, the incorporation of the benzyl cyanide moiety also enhanced the interaction with PD-L1 protein by forming a hydrogen bond with ARG125. Further, the highlight by a white circle in <a class="ref internalNav" href="#notes1" aria-label="Figure S2">Figure S2</a> revealed a large space between the tail group and dimeric PD-L1 protein, which could be occupied by an appropriate ring or chain. On the basis of these considerations, a series of novel PD-1/PD-L1 inhibitors with various tail groups (the <b>NC</b> and <b>NP</b> series of compounds) were designed, synthesized, and evaluated as detailed below.</div></div><div id="sec2_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> Preliminary Biochemical Evaluation of Compounds <b>NC1–12</b></h4><div class="NLM_p">As listed in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, <b>NC1</b>, <b>NC5</b>, and <b>NC6</b>, bearing an amino acid, a short chain, and a four-membered ring, respectively, displayed the most potent anti-PD-1/PD-L1 activity, with IC<sub>50</sub> values of 25.2 nM, 26.3 nM, and 30.4 nM, respectively. However, <b>NC2–4</b>, <b>NC7–10</b>, and <b>NC12</b>, bearing a piperazine ring, exhibited a decreased activity with IC<sub>50</sub> values in the range of 200–1000 nM. Our preliminary investigations indicated that the optimization of the tail group was straightforward, and anti-PD-1/PD-L1 activity could be fine-tuned by modifying this region. Therefore, we focused on the modification of the tail groups with different small rings and amino acids and also examined whether the introduction of a 2,3-dihydro-1,4-benzodioxinyl moiety is crucial to the anti-PD-1/PD-L1 activity.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Activities of Compounds <b>NC1–12</b> in Inhibition of PD-1/PD-L1 Interaction</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0021.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">The data are generated from three independent experiments.</p></div></div><div></div></div></div><div id="sec2_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Preliminary Biochemical Evaluation of Compounds <b>NP1–25</b></h4><div class="NLM_p">As listed in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, compounds <b>NP1–25</b> displayed significantly improved activity with IC<sub>50</sub> values in the nanomolar range (10–100 nM) for most of the <b>NP</b> compounds. These results indicated that various tail groups such as amino acids (e.g., glycine for <b>NP1</b>,<b>13</b>; 2,2-dimethyl glycine for <b>NP19</b>) and small rings (e.g., pyrrolidine for <b>NP2–5</b>, <b>8</b>–<b>9</b>, <b>11</b>–<b>12</b>, <b>14</b>–<b>17</b>, <b>21</b>–<b>22</b>, <b>25</b>; azetidine for <b>NP6</b>, <b>10</b>, <b>18</b>, <b>23</b>–<b>24</b>) are well tolerated in general. Biochemical evaluations demonstrated that the incorporation of the 2,3-dihydro-1,4-benzodioxinyl moiety had a diverse impact on the activity of the different compounds. For example, <b>NP19</b>, bearing the biphenyl skeleton, displayed improved activity with an IC<sub>50</sub> value of 12.5 nM, as compared to the 2,3-dihydro-1,4-benzodioxinyl compound, <b>NC1</b> (IC<sub>50</sub>, 25.2 nM).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Activities of Compounds <b>NP1–25</b> in Inhibition of PD-1/PD-L1 Interaction</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0022.gif" alt="" id="gr13" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">The data are generated from three independent experiments.</p></div></div><div></div></div><div class="NLM_p last">Further modifications were conducted by replacing the biphenyl moiety with a variety of heterocycles (<b>NT</b> series of compounds) to investigate whether the biphenyl moiety was crucial for activity.</div></div><div id="sec2_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Preliminary Biochemical Evaluation of Compounds <b>NT1–22</b></h4><div class="NLM_p">As shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, most of the <b>NT</b> compounds exhibited high anti-PD-1/PD-L1 activity with IC<sub>50</sub> values in the nanomolar range, with compounds <b>NT8</b>, <b>NT9</b>, and <b>NT11</b> being the most potent (IC<sub>50</sub> values of 8.0 nM, 8.5 nM, and 9.0 nM, respectively). While a moderate decrease of activity was observed when replacing the terminal phenyl group of the biphenyl moiety with a variety of heterocycles such as pyridine and pyrimidine (IC<sub>50</sub> > 100 nM), suggesting that the hydrophobic biphenyl moiety was crucial for high activity.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Activities of Compounds <b>NT1–22</b> in Inhibition of PD-1/PD-L1 Interaction</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0023.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">The data are generated from three independent experiments.</p></div></div><div></div></div><div class="NLM_p">Combining the preliminary biochemical evaluation of our newly designed compounds and recently reported small molecule PD-1/PD-L1 inhibitors, we summarized the SAR of PD-1/PD-L1 inhibitors with <b>BMS-202</b> as a template molecule (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). The sites of structural modifications mainly focused on six regions with regions 1–4 on different positions of the central pyridine ring, region 5 on the terminal phenyl ring, and region 6 on the tail group (site chain). As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, in region 1, a ring fusion strategy could be applied but the ring sizes have a great influence on the binding affinity. In this work, we first designed a series of flavonoid analogs (6-membered ring in region 1), which exhibited moderate inhibitory activity (e.g., <b>HT11</b>, IC<sub>50</sub> = 1.4 μM), while Incyte company constructed a five-membered ring in region 1, which displayed high activity (e.g., <b>Incyte-1</b>, IC<sub>50</sub> = 10 nM), suggesting a smaller ring is optimal for activity.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> In region 2, we designed a series of compounds based on the naphthalene skeleton, but a sharply decreased activity was observed for all compounds (e.g., <b>N8</b>, IC<sub>50</sub> > 10 μM). However, researchers from Shenyang Pharmaceutical University discovered [1,2,4]triazolo[4,3-<i>a</i>]pyridines derivatives which showed relatively high activity at the biochemical level (e.g., <b>A22</b>, IC<sub>50</sub> = 92.3 nM), indicating that the orientation and size of the fused rings (naphthalene ring of compound <b>N8</b> and triazolo[4,3-<i>a</i>]pyridine of compound <b>A22</b>) may affect the binding affinity.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In region 3, we synthesized an aromatic amide compound <b>XA1</b> which exhibited an IC<sub>50</sub> value of >10 μM, while Incyte company constructed a compound with a quinoline ring, and the activity was retained (e.g., <b>Incyte-2</b>, IC<sub>50</sub> = 10 nM), suggesting the amide linker is not preferred.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Recently, researchers from Incyte Corporation designed and tested a series of amide compounds in region 3, which displayed good activity.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In region 4, BMS company designed <b>BMS-1016</b> by incorporating a picolinonitrile moiety into the structure, which markedly increased the anti-PD-1/PD-L1 activity (e.g., <b>BMS-1016</b>, IC<sub>50</sub> = 10 nM).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In region 5, BMS company replaced the terminal phenyl moiety with a quinoxaline group (e.g., <b>BMS-1006</b>, IC<sub>50</sub> = 118.5 nM),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and in region 6, a piperidine ring was introduced into the tail group (e.g., <b>BMS-8</b>, IC<sub>50</sub> = 146 nM);<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> both BMS-1006 and BMS-8 showed decreased activity, suggesting the hydrophobic biphenyl system and the hydrophilic tail group are optimal for binding to PD-L1. In regions 4, 5, and 6, we also designed a series of novel resorcinol dibenzyl ether analogs, such as <b>NP2</b>, <b>NT20</b>, and <b>NP19</b>, which exhibited IC<sub>50</sub> values of 7.9 nM, >100 nM, and 12.52 nM, respectively. Based on the above SAR of PD-1/PD-L1 inhibitors, we found that small structural modifications can lead to drastic changes in activity, indicating the precision and complexity in the binding of small molecule inhibitors to the PD-L1 protein.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0004.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SAR of PD-1/PD-L1 inhibitors. Compounds <b>Incyte-1</b>, <b>A22</b>, <b>Incyte-2</b>, <b>BMS-1016</b>, <b>BMS-1006</b>, and <b>BMS-8</b> were reported by patents or literature.<a onclick="showRef(event, 'ref30 ref31 ref32 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref34 ref35 ref36">(30−32,34−36)</a> Compounds <b>HT11</b>, <b>N8</b>, <b>XA1</b>, <b>NP2</b>, <b>NT20</b>, and <b>NP19</b> were newly synthesized and reported in this paper.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>In Vitro</i> Effect of NP19 on IFN-γ Production</h4><div class="NLM_p">Recent studies have revealed that blockade of the PD-1/PD-L1 interaction can enhance T-cell proliferation and IFN-γ secretion.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> Therefore, we evaluated the effects of one of the most potent compounds, <b>NP19</b> (IC<sub>50</sub> = 12.5 nM), on IFN-γ production using a well-established tumor/T cell coculture assay.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Briefly, CD3 T cells isolated from peripheral blood mononuclear cells (PBMCs) were cocultured with Hep3B cells stably expressing OS-8 (anti-CD3 single chain variable fragment) as well as human PD-L1, followed by the addition of <b>NP19</b> and Keytruda at the indicated concentrations. IFN-γ levels were detected by ELISA after a 72 h stimulation. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, compound <b>NP19</b> significantly elevated the production of IFN-γ in a dose-dependent manner. In the presence of 10 μM <b>NP19</b>, IFN-γ secretion was increased by 160%, which was better than that of Keytruda (127%). The estimated EC<sub>50</sub> of ∼3 μM in the IFN-γ secretion cellular assay seems to be much larger than the IC<sub>50</sub> (12.5 nM) in the HTRF assay, which indicated a ∼240-fold loss of activity when transitioning from HTRF assay to cellular assay. This may be attributed to the poor solubility of <b>NP19</b> or off-target protein binding in more complex cellular environments.<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39−41)</a> Similar to our results, Mingze Qin  et al.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and Subhadwip Basu  et al.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> also observed a ∼100-fold (compound <b>A22</b>) and >1200-fold (compound <b>1b</b>) loss of activity for their respective PD-1/PD-L1 inhibitors (<b>A22</b> and <b>1b</b>) when transitioning from HTRF assays to cell-based assays.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0005.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compound <b>NP19</b> and Keytruda on IFN-γ secretion from T cells cocultured with tumor cells. Data are shown as mean ± SD, **<i>P</i> < 0.05 compared with vehicle group (<i>n</i> = 3, Dunnett’s multiple comparison test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>In Vivo</i> Pharmacokinetic Properties of <b>NP19</b></h4><div class="NLM_p">As compound <b>NP19</b> showed high potency <i>in vitro</i>, the pharmacokinetic (PK) profiles were next evaluated in male Sprague–Dawley rats by intravenous and oral administration. The key p.o. and i.v. administration PK parameters are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. After a single i.v. administration with 1 mg/kg compound <b>NP19</b>, the half time (<i>t</i><sub>1/2</sub>), the clearance rate (CL), and the apparent distribution volume (V<sub>ss</sub>) of <b>NP19</b> are 1.5 ± 0.5 h, 0.9 ± 0.2 L/h/kg, and 2.1 ± 0.5 L/kg, respectively. When <b>NP19</b> was administrated by the oral route at 10 mg/kg, the oral absorption (<i>T</i><sub>max</sub> = 0.6 ± 0.2 h), long half-life (<i>t</i><sub>1/2</sub> = 10.9 ± 7.7 h), and oral bioavailability (F = 5%) were observed. In addition, no apparent adverse effects were observed in rats. <b>NP19</b> showed a much longer half-life (10.9 h) following oral gavage as compared to the i.v. half-life (1.5 h); this may be due to the high lipophilicity (logP = 7.9) or poor aqueous solubility of <b>NP19</b>. As a result, <b>NP19</b> exhibited flip-flop pharmacokinetics. Such flip-flop pharmacokinetics can sometimes occur for poorly water-soluble compounds such as <b>Rebamipide</b>,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> which has a <i>t</i><sub>1/2</sub> (p.o.)/<i>t</i><sub>1/2</sub> (i.v.) ratio of 13.5 due to poor water solubility (7.6 μg/mL). Another example is the lipophilic compound <b>IAT</b> (an antitubulin agent with 19 μg/mL of water solubility) reported by Chien-ming Li et al.,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> which has a <i>t</i><sub>1/2</sub> (p.o.)/<i>t</i><sub>1/2</sub> (i.v.) ratio of ∼5, similar to <b>NP19</b> [<i>t</i><sub>1/2</sub> (p.o.)/<i>t</i><sub>1/2</sub> (i.v.) = 7.1]. Due to the low oral bioavailability of the compound <b>NP19</b>, we presumed that a high dosage is needed to offer sufficient drug concentration to exhibit antitumor efficacy. Therefore, we further studied the <i>in vivo</i> activity of compound <b>NP19</b>.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Primary Pharmacokinetic Parameters after Oral or Intravenous Administration of Compound <b>NP19</b> in Rats (<i>n</i> = 6)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Parameter</b></th><th class="colsep0 rowsep0" align="center"><b>1</b><b>mg/kg</b><b>(i.v.)</b></th><th class="colsep0 rowsep0" align="center"><b>10</b><b>mg/kg</b><b>(p.o.)</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b><i>t</i></b><sub><b>1/2</b></sub><b>(h)</b></td><td class="colsep0 rowsep0" align="left">1.5 ± 0.5</td><td class="colsep0 rowsep0" align="left">10.9 ± 7.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b><i>T</i></b><sub><b>max</b></sub><b>(h)</b></td><td class="colsep0 rowsep0" align="left">0.083</td><td class="colsep0 rowsep0" align="left">0.6 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b><i>C</i></b><sub><b>max</b></sub><b>(μg/L)</b></td><td class="colsep0 rowsep0" align="left">1751 ± 455.7</td><td class="colsep0 rowsep0" align="left">69.5 ± 21.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>AUC</b><sub><b>0–t</b></sub><b>(h·μg/L)</b></td><td class="colsep0 rowsep0" align="left">967 ± 263.4</td><td class="colsep0 rowsep0" align="left">410.1 ± 127.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>AUC</b><sub><b>0–∞</b></sub><b>(h·μg/L)</b></td><td class="colsep0 rowsep0" align="left">1049.8 ± 227.1</td><td class="colsep0 rowsep0" align="left">520.2 ± 243.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>CL</b><b>(L/h/kg)</b></td><td class="colsep0 rowsep0" align="left">0.9 ± 0.2</td><td class="colsep0 rowsep0" align="left">23.1 ± 11.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>V</b><sub><b>SS</b></sub><b>(L/kg)</b></td><td class="colsep0 rowsep0" align="left">2.1 ± 0.5</td><td class="colsep0 rowsep0" align="left">290.3 ± 91.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>F (%)</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">5</td></tr></tbody></table></div></div></div><div id="sec2_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>In Vivo</i> Antitumor Activity of <b>NP19</b> in a B16-F10 Mouse Melanoma Model</h4><div class="NLM_p">To determine whether the <i>in vitro</i> anti-PD-1/PD-L1 activity of the newly synthesized compounds can be translated into <i>in vivo</i> efficacy, we tested the antitumor activity of compound <b>NP19</b> on a mice melanoma B16–F10 tumor model. <b>NP19</b> was chosen for the <i>in vivo</i> efficacy study due to the ease of synthesis and less cytotoxicity (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) when compared to the more potent compound <b>NP2</b> or equally potent compound <b>NP12</b>. We treated BALB/c mice bearing melanoma tumors with vehicle control and <b>NP19</b> (25 mg/kg, 50 mg/kg, 100 mg/kg) administered via intragastric gavage once a day for 15 days. As shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, after 15 days of treatment, the growth of melanoma tumors was inhibited dramatically following <b>NP19</b> treatment.</div><figure id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0006.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <i>In vivo</i> efficacy study of <b>NP19</b> against B16-F10 melanoma tumors in BALB/c mice. Images of tumor growth in mice treated with vehicle control or <b>NP19</b> (25 mg/kg, 50 mg/kg, 100 mg/kg) are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. <i>In Vitro</i> Growth Inhibitory Effects of the Synthetic Compounds<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">Cytotoxic effects: IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Compounds</b></th><th class="colsep0 rowsep0" align="center">Anti-PD-1/PD-L1 IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">A549</th><th class="colsep0 rowsep0" align="center">MCF-7</th><th class="colsep0 rowsep0" align="center">B16-F10</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>NP2</b></td><td class="colsep0 rowsep0" align="left">7.9 ± 1.1</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">10.8 ± 1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>NP8</b></td><td class="colsep0 rowsep0" align="left">11.1 ± 2.7</td><td class="colsep0 rowsep0" align="left">4.6 ± 1.5</td><td class="colsep0 rowsep0" align="left">6.6 ± 1.2</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>NP12</b></td><td class="colsep0 rowsep0" align="left">12.9 ± 0.7</td><td class="colsep0 rowsep0" align="left">4.2 ± 1.3</td><td class="colsep0 rowsep0" align="left">4.4 ± 1.0</td><td class="colsep0 rowsep0" align="left">2.3 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>NP19</b></td><td class="colsep0 rowsep0" align="left">12.5 ± 0.7</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>NT8</b></td><td class="colsep0 rowsep0" align="left">8.0 ± 1.2</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">Cells were treated with different concentrations of tested compounds for 48 h. Cell viability was measured by the MTT assay as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>.</p></div></div></div><div class="NLM_p">The average tumor weights of the three <b>NP19</b> treated (25 mg/kg, 50 mg/kg, 100 mg/kg) groups were 0.41 ± 0.09 g, 0.21 ± 0.11 g, and 0.16 ± 0.13 g respectively (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A), which were significantly lower than that of the vehicle control (0.84 ± 0.32 g). The average tumor growth inhibition (TGI) values of the three <b>NP19</b> treated (25 mg/kg, 50 mg/kg, 100 mg/kg) groups were 51.1%, 75%, and 80.9%, respectively, as compared to vehicle control (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A). Dunnett’s multiple comparison test indicated that treatment with 25 mg/kg, 50 mg/kg, and 100 mg/kg doses of <b>NP19</b> was significantly better than the vehicle control (<i>P</i> < 0.05) based on the final tumor weights. During the treatment period, mice exhibited normal physical activity and body weights increased slightly (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>B), indicating negligible acute toxicities. One-way ANOVA analysis gave a <i>P</i> value of >0.05, suggesting no significant difference in the weight of spleen and thymus in mice (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>C and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>D).</div><figure id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0007.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Melanoma tumor weight ± SD (<i>n</i> = 10) in vehicle control or <b>NP19</b> treated mice, **<i>P</i> < 0.05 compared with vehicle group (<i>n</i> = 10, Dunnett’s multiple comparison test). (B) Mice body weight ± SD (<i>n</i> = 10) in vehicle control or <b>NP19</b> treated mice. (C) Spleen weight ± SD (<i>n</i> = 10) in vehicle control or <b>NP19</b> treated mice. (D) Thymus weight ± SD (<i>n</i> = 10) in vehicle control or <b>NP19</b> treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>In Vivo</i> Antitumor Activity of <b>NP19</b> in an H22 Hepatoma Mouse Model</h4><div class="NLM_p">Encouraged by the excellent <i>in vivo</i> antitumor efficacy of <b>NP19</b> on the melanoma B16-F10 tumor model, and the fact that PD-1/PD-L1 inhibitors have broad spectrum of antitumor activities, we further evaluated the <i>in vivo</i> antitumor efficacy of compound <b>NP19</b> using an H22 hepatoma tumor model in BALB/c mice. Each mouse was injected with 0.8 million H22 cells subcutaneously into the right flank. After tumors reached approximately 100 mm<sup>3</sup> in volume, mice were randomized and treated by intraperitoneal (i.p.) injection of <b>NP19</b> or a vehicle solution for 14 days. As shown in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, <b>NP19</b> demonstrated significant <i>in vivo</i> antitumor efficacy with a TGI of 76.5% at the dose of 25 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>B, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>C). In addition, <b>NP19</b> did not cause an obvious body weight loss (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D), indicating that the compound was well tolerated.</div><figure id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0008.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In vivo</i> efficacy study of <b>NP19</b> against H22 hepatoma tumor in mice. After intraperitoneal injection with vehicle and compound <b>NP19</b> (25 mg/kg per day) for 14 days, the mice were sacrificed, and the excised tumors were weighed. (A) Images of excised tumors in each group. (B) Weight of the excised tumors of each group. (C) Tumor volume changes during treatment. (D) Body weight changes of mice during treatment. The data were presented as the mean ± SD, **<i>P</i> < 0.05 vs control group, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> NP19 Exhibited Reduced Antimouse PD-1/PD-L1 Activity <i>In Vitro</i></h4><div class="NLM_p last">Having identified the excellent <i>in vitro</i> activity of <b>NP19</b> against human PD-1/PD-L1 interaction and the high <i>in vivo</i> antitumor efficacy in two different mouse models of cancer, we next determined the effects of <b>NP19</b> on the binding interaction of recombinant mouse PD-1 and PD-L1 using an <i>in vitro</i> ELISA assay. The sequence homology is 64% between mouse and human PD-1 and 77% between mouse and human PD-L1.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, compound <b>NP19</b> exhibited much lower activity for inhibiting mouse PD-1/PD-L1 interaction with an IC<sub>50</sub> value in the micromolar range (>1 μM), as compared to the inhibition of human PD-1/PD-L1 interaction (IC<sub>50</sub> = 12.5 nM). There is a >80-fold loss of activity when transitioning from human PD-1/PD-L1 binding assay to mouse PD-1/PD-L1 assay, which indicates that mouse and human PD-L1s are different enough to result in different binding affinities for small molecule inhibitors, despite the relatively high homology between mouse and human PD-L1. Although compound <b>NP19</b> showed reduced antimouse PD-1/PD-L1 activity <i>in vitro</i>, it displayed significant <i>in vivo</i> antitumor efficacy in two different mouse models of cancer and high antihuman PD-1/PD-L1 activity <i>in vitro</i> as described above, suggesting that <b>NP19</b> may be more effective in suppressing tumor growth in human.</div></div><div id="sec2_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <b>NP19</b> Suppressed Tumor Growth by Activating the Immune Microenvironment in Mice</h4><div class="NLM_p">To investigate the role of <b>NP19</b> in antitumor immunity, we first assessed the <i>in vitro</i> antiproliferative activities of 5 newly synthesized compounds with high anti-PD-1/PD-L1 activities using the human nonsmall cell lung cancer cell line A549, human breast cancer cell line MCF-7, and mouse melanoma cell line B16-F10. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, all the compounds showed negligible cytotoxicity (IC<sub>50</sub> values >10 μM for most tested cell lines). In particular, <b>NP19</b> displayed no apparent cytotoxic effects on the three cell lines at a concentration of 10 μM, indicating <b>NP19</b> has no direct cytotoxic effect.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. <i>In Vitro</i> Anti-mouse and Anti-human PD-1/PD-L1 Activities of <b>NP19</b><a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Mouse PD-1/PD-L1 binding assay</th><th class="colsep0 rowsep0" align="center">Human PD-1/PD-L1 binding assay</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0">>1 μM</td><td class="colsep0 rowsep0">12.5 ± 0.7 nM</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">The data are generated from three independent experiments.</p></div></div></div><div class="NLM_p">Further, we determined the expression level of PD-L1 protein in melanoma tumor tissues, because clinical studies have shown that the expression of PD-L1 is a potential predictive marker for response and outcome after treatment with PD-1/PD-L1 inhibitors, and there is a positive correlation between the therapeutic effects of PD-1/PD-L1 inhibitors and PD-L1 expression (e.g., >1% staining is considered to be positive; >10% means highly positive).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Compared to the negative control group (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A), the positive rate of PD-L1 protein was 16.2% in the mAb-treated group (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). The high expression level of PD-L1 protein correlates well with the high antitumor efficacy of the PD-1/PD-L1 inhibitor <b>NP19</b> in the BALB/c mice bearing melanoma tumors.</div><figure id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0009.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Expression levels of PD-L1 protein in melanoma tumors. (A) Negative control without adding the primary antibody PD-L1 (D5 V3B) rabbit mAb; (B) mAb-treated group with PD-L1 (D5 V3B) rabbit mAb (primary antibody) and anti-rabbit-IgG H&L (Alexa Fluor488) antibody (second antibody) added.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition, The H&E staining of kidney and liver showed that <b>NP19</b> had no significant toxic effects on the major organs of melanoma bearing mice (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). The H&E staining of melanoma tumor tissue (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B) also showed that a large number of tumor-infiltrating lymphocytes (TILs) were seen in <b>NP19</b> treatment groups (highlighted by red arrow), indicating a shift toward an activated immune microenvironment rather than an immunosuppressive microenvironment.</div><figure id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0010.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Pathological sections of major tissues (kidney, liver) obtained from mice bearing melanoma tumors. (B) Pathological sections of melanoma tumors. Organs were stained with Hematoxylin and Eosin (H&E), and representative images were captured.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Moreover, in the flow cytometry analysis of TILs (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A, representative example), the percentages of helper T cells (CD3<sup>+</sup> CD4<sup>+</sup>) in the melanoma tumor tissues of the three <b>NP19</b>-treated (25 mg/kg, 50 mg/kg, 100 mg/kg) groups were (18.2 ± 7.9)%, (11.98 ± 7.24)%, and (12.5 ± 7.89)%, respectively, as compared to (9.22 ± 2.27)% for the vehicle control group (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A, multiple repeated experiments/animals). Dunnett’s multiple comparison test indicated that the percentage of helper T cells was higher than the vehicle control (<i>P</i> < 0.05) in the 25 mg/kg group. The activated cytotoxic T cells (CD3<sup>+</sup> CD8<sup>+</sup>) in the tumor tissues of the three <b>NP19</b>-treated (25 mg/kg, 50 mg/kg, 100 mg/kg) groups were (19.6 ± 5.57)%, (23.6 ± 4.89)%, and (24.1 ± 7.09)%, respectively, as compared to (15.25 ± 5.56)% for the vehicle control group (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>B, multiple repeated experiments/animals). Dunnett’s multiple comparison test indicated that the percentage of activated cytotoxic T cells was significantly higher than the vehicle control (<i>P</i> < 0.05) when treated with 50 mg/kg or 100 mg/kg of <b>NP19</b>. In cancer patients, clinical responses to PD-1 immunotherapy positively correlate with tumor PD-L1 expression, along with other key biomarkers such as CD3<sup>+</sup>CD8<sup>+</sup> T cells infiltration.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> The high percentage of CD3<sup>+</sup>CD8<sup>+</sup> T cells infiltration correlates well with the high antitumor efficacy of <b>NP19</b> (50 mg/kg, 100 mg/kg) in the BALB/c mice bearing melanoma tumors. For helper T cells, as mentioned above, the percentage of helper T cells was higher than the vehicle control (<i>P</i> < 0.05) for the 25 mg/kg group, but not for the 50 mg/kg and 100 mg/kg groups. The possible reason for this phenomenon may be attributable to the more important role of helper T cells in the antitumor activity of <b>NP19</b> at low doses (e.g., 25 mg/kg) than high doses (50 mg/kg and 100 mg/kg). Further investigations are needed to fully elucidate the exact mechanism behind this, which is beyond the scope of this work.</div><figure id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0011.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Representative examples for melanoma tumor CD3<sup>+</sup>CD4<sup>+</sup> cells (helper T cells) and CD3<sup>+</sup>CD8<sup>+</sup> cells (activated cytotoxic T cells) in vehicle control or <b>NP19</b> treated mice. (B) Representative image for spleen CD3<sup>+</sup>CD4<sup>+</sup> cells and CD3<sup>+</sup>CD8<sup>+</sup> cells in vehicle control or <b>NP19</b> treated melanoma-bearing mice. The percentages of immune cells were quantified by flow cytometry: (upper left quadrant) CD4<sup>+</sup> or CD8<sup>+</sup> cells; (upper right quadrant) CD3<sup>+</sup>CD4<sup>+</sup> or CD3<sup>+</sup>CD8<sup>+</sup> cells; (bottom left quadrant) spleen or melanoma tumor cells; and (bottom right quadrant) CD3<sup>+</sup> cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig12" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0012.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) Melanoma tumor CD3<sup>+</sup>CD4<sup>+</sup> cells ± SD (<i>n</i> = 6) in vehicle control or <b>NP19</b> treated mice, **<i>P</i> < 0.05 compared with vehicle group (<i>n</i> = 6, Dunnett’s multiple comparison test). (B) Melanoma tumor CD3<sup>+</sup>CD8<sup>+</sup> cells ± SD (<i>n</i> = 6) in vehicle control or <b>NP19</b> treated mice. (C) Spleen CD3<sup>+</sup>CD4<sup>+</sup> cells ± SD (<i>n</i> = 6) in vehicle control or <b>NP19</b> treated melanoma bearing mice. (D) Spleen CD3<sup>+</sup>CD8<sup>+</sup> cells ± SD (<i>n</i> = 6) in vehicle control or <b>NP19</b> treated melanoma bearing mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the flow cytometry analysis of spleen tissues (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B, representative example), the percentage of helper T cells and activated cytotoxic T cells in the <b>NP19</b> treatment groups or vehicle control was of no significant difference (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>C and <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>D, multiple repeated experiments/animals), while flow cytometry analysis (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>A and <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>B, multiple repeated experiments/animals) indicated that <b>NP19</b> at low doses (e.g., 25 mg/kg) could activate helper T cells and <b>NP19</b> at high doses (≥50 mg/kg) could activate cytotoxic T cells in TILs. Taken together the above analysis suggested that the antitumor activity of <b>NP19</b> was associated with the modulation of the tumor microenvironment, with an increase in the number of tumor-infiltrating lymphocytes.</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63281" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63281" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Anti-PD-1/PD-L1 monoclonal antibody drugs have enjoyed considerable clinical success, but the development of small-molecule PD-1/PD-L1 inhibitors is still in its infancy, as most of the compounds discovered so far are still in preclinical stages. Small-molecule PD-1/PD-L1 inhibitors may possess distinct pharmacokinetic and pharmacodynamic profiles from mAbs, but it is still challenging to design small molecules because the interface between the PD-1 and PD-L1 is hydrophobic, flat, and extended (∼1.700 Å) without a deep binding pocket. The hydrophobic interface may also lead to the discovery of false positive hits. Furthermore, small molecule PD-L1 inhibitors are potentially hydrophobic molecules, which may cause downstream development problems such as toxicity and poor pharmacokinetics. Therefore, the future direction for the discovery of new PD-1/PD-L1 inhibitors will focus on improving the pharmacokinetic properties and toxicity profiles.</div><div class="NLM_p last">Starting from a hit compound Bavachinin, we designed and synthesized a series of chalcones, flavonoids, naphthalene, and resorcinol dibenzyl ethers as novel PD-1/PD-L1 inhibitors by using the docking-based drug design, as well as an extensive SAR study. Among them, we found the resorcinol dibenzyl ether compounds potently inhibited the PD-1/PD-L1 interaction with IC<sub>50</sub> in the low nanomolar range; for example, compound <b>NP19</b> inhibited the PD-1/PD-L1 interaction with IC<sub>50</sub> values of 12.5 nM in HTRF binding assays. Furthermore, <b>NP19</b> significantly promoted T cell response. In a well-established T cell-tumor coculture assay, treatment with <b>NP19</b> induced IFN-γ release in a dose-dependent manner. Moreover, <b>NP19</b> displayed significant <i>in vivo</i> antitumor efficacy in two different mouse models of cancer (a B16-F10 melanoma tumor model and an H22 hepatoma tumor model). In addition, H&E staining and flow cytometry (FCM) data suggested that <b>NP19</b> activated the immune microenvironment in tumor, which may contribute to its antitumor effects. Overall, this work shows <b>NP19</b> is a promising lead compound for further development as a new generation of small molecule inhibitors targeting the PD-1/PD-L1 pathway.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83751" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83751" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> General Methods</h3><div class="NLM_p">Reagents and solvents were obtained from commercial sources and used without further purification. The reference compounds (BMS-202, BMS-1166, Keytruda) and the hit compounds (Bavachinin, Apiin, Sesamin) were purchased from InvivoChem (Libertyville, IL 60048, USA). All the reactions were monitored by TLC using silica gel GF/UV 254. Flash chromatography was performed using silica gel (300–400 mesh). The <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker AV-400 or a Bruker AV-600 spectrometer, with TMS as an internal standard. The purity of compounds was determined by LCMS (liquid chromatography–mass spectrometry) analysis and confirmed to be more than 95%, which was also used to record MS spectra of compounds. LC-MS analyses were performed with shimadzu LCMS-2020 using a C18 column (Kinetex C18, 2.1 × 30 mm, 5 μm). The gradient mobile phases consisted of A (95:5 water/methanol) and B (5:95 water/methanol) with 0.1% formic acid as the solvent modifiers.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Synthesis of Compounds <b>CET1–13</b>, <b>HT1–13</b>, <b>N1–17</b>, Compound XA1, and Intermediates of the NC/NT/NP Series of Compounds (See <a class="ref internalNav" href="#notes1" aria-label="Supporting Information">Supporting Information</a> for the Spectroscopic Data of Compounds Presented in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> and <a class="ref internalNav" href="#notes1" aria-label="Scheme S1">Scheme S1</a>)</h4><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> Synthesis of Compounds <b>NC1–12</b> and <b>NP1–25</b></h5></div><div id="sec4_1_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 2-((5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)amino)-2-methylpropanoic Acid (<b>NC1</b>)</h5><div class="NLM_p last">A solution of <b>8a</b> (15 mg, 28.52 μmol), 2-amino-2-methylpropanoic acid (12 mg, 114.1 μmol), sodium cyanoborohydride (9 mg, 142.6 μmol), and AcOH (2 drops) in DMF (3 mL) was stirred at 80 °C for 1 h. The mixture was concentrated under reduce pressure. Purification by Prep-TLC provided the <b>NC1</b> (2 mg, 16%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.03 (s, 1H), 7.89 (d, <i>J</i> = 7.3 Hz, 1H), 7.84 (d, <i>J</i> = 7.5 Hz, 1H), 7.64 (d, <i>J</i> = 7.7 Hz, 1H), 7.55 (s, 1H), 7.44 (d, <i>J</i> = 7.4 Hz, 1H), 7.25 (t, <i>J</i> = 7.4 Hz, 1H), 7.18 (d, <i>J</i> = 7.8 Hz, 1H), 7.11 (s, 1H), 6.93 (d, <i>J</i> = 8.0 Hz, 1H), 6.78 (s, 1H), 6.75 (d, <i>J</i> = 8.2 Hz, 1H), 5.29 (s, 2H), 5.27 (s, 2H), 4.29 (s, 4H), 3.86 (s, 2H), 2.25 (s, 3H), 1.27 (s, 6H). MS: <i>m</i>/<i>z</i> = 613.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.919 min, purity 95.6%.</div></div><div id="sec4_1_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 3-((2-((4-Acetylpiperazin-1-yl)methyl)-4-chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)phenoxy)methyl)benzonitrile (<b>NC2</b>)</h5><div class="NLM_p last"><b>NC2</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with 1-(piperazin-1-yl)ethan-1-one replacing 2-amino-2-methylpropanoic acid. Off-white solid (8 mg, yield 19%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (s, 1H), 7.83 (t, <i>J</i> = 6.9 Hz, 2H), 7.64 (t, <i>J</i> = 7.7 Hz, 1H), 7.46 (d, <i>J</i> = 7.4 Hz, 1H), 7.33 (s, 1H), 7.25 (t, <i>J</i> = 7.5 Hz, 1H), 7.18 (d, <i>J</i> = 7.4 Hz, 1H), 7.10 (s, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.76 (dd, <i>J</i> = 11.7, 3.4 Hz, 2H), 5.29 (s, 2H), 5.23 (s, 2H), 4.29 (s, 4H), 3.47 (s, 2H), 3.42 (d, <i>J</i> = 3.3 Hz, 4H), 2.38 (d, <i>J</i> = 5.1 Hz, 2H), 2.32 (d, <i>J</i> = 4.6 Hz, 2H), 2.25 (s, 3H), 1.97 (s, 3H).<sup>13</sup>C NMR (101 MHz, DMSO) δ 168.45, 156.28, 153.78, 143.38, 142.93, 142.07, 139.16, 135.45, 134.82, 134.79, 134.48, 132.62, 132.08, 131.22, 130.19, 128.05, 125.89, 122.53, 120.11, 119.10, 118.12, 117.21, 113.30, 111.88, 101.19, 99.93, 70.03, 69.26, 64.52, 55.29, 53.19, 52.73, 46.12, 21.56, 16.29. MS: <i>m</i>/<i>z</i> = 638.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.892 min, purity 98.5%.</div></div><div id="sec4_1_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 3-((4-Chloro-2-((4-(cyclopropylmethyl)piperazin-1-yl)methyl)-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)phenoxy)methyl)benzonitrile (<b>NC3</b>)</h5><div class="NLM_p last"><b>NC3</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with 1-(cyclopropylmethyl)piperazine replacing 2-amino-2-methylpropanoic acid. White solid (11 mg, yield 20%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.95 (s, 1H), 7.83 (t, <i>J</i> = 8.3 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.45 (d, <i>J</i> = 7.4 Hz, 1H), 7.29 (s, 1H), 7.25 (t, <i>J</i> = 7.5 Hz, 1H), 7.18 (d, <i>J</i> = 7.5 Hz, 1H), 7.09 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.81–6.72 (m, 2H), 5.29 (s, 2H), 5.22 (s, 2H), 4.29 (s, 4H), 3.43 (s, 2H), 3.00 (d, <i>J</i> = 12.6 Hz, 1H), 2.94 (d, <i>J</i> = 12.1 Hz, 1H), 2.56 (dd, <i>J</i> = 22.5, 10.1 Hz, 2H), 2.38 (d, <i>J</i> = 5.4 Hz, 4H), 2.24 (s, 3H), 2.19 (d, <i>J</i> = 6.8 Hz, 2H), 0.80 (s, 1H), 0.44 (d, <i>J</i> = 8.2 Hz, 2H), 0.08–0.05 (m, 2H). MS: <i>m</i>/<i>z</i> = 650.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.911 min, purity 100%.</div></div><div id="sec4_1_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 3-((4-Chloro-2-((4-cyclopropylpiperazin-1-yl)methyl)-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)phenoxy)methyl)benzonitrile (<b>NC4</b>)</h5><div class="NLM_p last"><b>NC4</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with 1-cyclopropylpiperazine replacing 2-amino-2-methylpropanoic acid. White solid (6 mg, yield 15%).<sup>1</sup>H NMR (400 MHz, DMSO) δ 7.95 (s, 1H), 7.83 (t, <i>J</i> = 7.6 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.45 (d, <i>J</i> = 7.4 Hz, 1H), 7.29 (s, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 7.08 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.84–6.69 (m, 2H), 5.29 (s, 2H), 5.22 (s, 2H), 4.29 (s, 4H), 3.41 (s, 2H), 2.58 (s, 4H), 2.33 (s, 4H), 2.25 (s, 3H), 1.59 (s, 1H), 0.38 (d, <i>J</i> = 5.1 Hz, 2H), 0.26 (s, 2H). MS: <i>m</i>/<i>z</i> = 636.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.916 min, purity 100%.</div></div><div id="sec4_1_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-(((2-(dimethylamino)ethyl)amino)methyl)phenoxy)methyl)benzonitrile (<b>NC5</b>)</h5><div class="NLM_p last"><b>NC5</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with <i>N</i><sup>1</sup>,<i>N</i><sup>1</sup>-dimethylethane-1,2-diamine replacing 2-amino-2-methylpropanoic acid. White solid (16 mg, yield 25%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.99 (s, 1H), 7.84 (d, <i>J</i> = 1.5 Hz, 1H), 7.82 (d, <i>J</i> = 1.2 Hz, 1H), 7.65 (d, <i>J</i> = 7.8 Hz, 1H), 7.46 (d, <i>J</i> = 6.6 Hz, 1H), 7.31 (s, 1H), 7.26 (t, <i>J</i> = 7.5 Hz, 1H), 7.22–7.18 (m, 1H), 7.10 (s, 1H), 6.94 (dd, <i>J</i> = 8.2, 1.7 Hz, 1H), 6.80–6.78 (m, 1H), 6.76 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 5.29 (s, 2H), 5.23 (s, 2H), 4.29 (s, 4H), 3.39 (s, 2H), 2.47 (s, 1H), 2.38 (s, 3H), 2.37 (s, 3H), 2.25 (s, 3H), 2.17 (s, 4H). MS: <i>m</i>/<i>z</i> = 598.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.909 min, purity 95.3%.</div></div><div id="sec4_1_1_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-((3-hydroxyazetidin-1-yl)methyl)phenoxy)methyl)benzonitrile (<b>NC6</b>)</h5><div class="NLM_p last"><b>NC6</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with azetidin-3-ol replacing 2-amino-2-methylpropanoic acid. White solid (7 mg, yield 18%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.98 (s, 1H), 7.83 (d, <i>J</i> = 7.8 Hz, 2H), 7.65 (d, <i>J</i> = 7.6 Hz, 1H), 7.44 (d, <i>J</i> = 7.5 Hz, 1H), 7.28–7.21 (m, 2H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 7.07 (s, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.78 (s, 1H), 6.76 (d, <i>J</i> = 8.3 Hz, 1H), 5.28 (s, 2H), 5.22 (s, 2H), 4.29 (s, 4H), 4.21 (dd, <i>J</i> = 12.4, 6.1 Hz, 1H), 3.53 (d, <i>J</i> = 10.3 Hz, 4H), 2.81 (s, 2H), 2.24 (s, 3H). MS: <i>m</i>/<i>z</i> = 583.0 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.888 min, purity 95.0%.</div></div><div id="sec4_1_1_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-((4-ethylpiperazin-1-yl)methyl)phenoxy)methyl)benzonitrile (<b>NC7</b>)</h5><div class="NLM_p last"><b>NC7</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with 1-ethylpiperazine replacing 2-amino-2-methylpropanoic acid. White solid (13 mg, yield 15.6%). <sup>1</sup>H NMR (600 MHz, DMSO) δ 7.95 (s, 1H), 7.83 (dd, <i>J</i> = 11.9, 7.9 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.45 (d, <i>J</i> = 6.8 Hz, 1H), 7.29 (s, 1H), 7.24 (t, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 7.08 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.78 (d, <i>J</i> = 2.1 Hz, 1H), 6.75 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 5.28 (s, 2H), 5.22 (s, 2H), 4.28 (s, 4H), 3.42 (s, 2H), 2.99 (d, <i>J</i> = 12.7 Hz, 2H), 2.83 (d, <i>J</i> = 12.6 Hz, 2H), 2.37 (d, <i>J</i> = 5.4 Hz, 4H), 2.33 (d, <i>J</i> = 7.2 Hz, 2H), 2.24 (s, 3H), 0.98 (d, <i>J</i> = 7.2 Hz, 3H). MS: <i>m</i>/<i>z</i> = 624.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.888 min, purity 95.4%.</div></div><div id="sec4_1_1_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-((4-isopropylpiperazin-1-yl)methyl)phenoxy)methyl)benzonitrile (<b>NC8</b>)</h5><div class="NLM_p last"><b>NC8</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with 1-isopropylpiperazine replacing 2-amino-2-methylpropanoic acid. White solid (8 mg, yield 16%).<sup>1</sup>H NMR (600 MHz, DMSO) δ 7.94 (s, 1H), 7.83 (dd, <i>J</i> = 12.8, 7.8 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.45 (d, <i>J</i> = 6.8 Hz, 1H), 7.28 (s, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 7.20–7.15 (m, 1H), 7.08 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.78 (d, <i>J</i> = 2.1 Hz, 1H), 6.75 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 5.28 (s, 2H), 5.22 (s, 2H), 4.28 (s, 4H), 3.41 (s, 2H), 2.98 (s, 2H), 2.75 (s, 2H), 2.64 (d, <i>J</i> = 6.5 Hz, 1H), 2.37 (q, <i>J</i> = 6.8 Hz, 4H), 2.24 (s, 3H), 0.96 (s, 3H), 0.95 (s, 3H). MS: <i>m</i>/<i>z</i> = 638.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.883 min, purity 95%.</div></div><div id="sec4_1_1_1_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-((4-methylpiperazin-1-yl)methyl)phenoxy)methyl)benzonitrile (<b>NC9</b>)</h5><div class="NLM_p last"><b>NC9</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with 1-methylpiperazine replacing 2-amino-2-methylpropanoic acid. White solid (14 mg, yield 18%). <sup>1</sup>H NMR (600 MHz, DMSO) δ 7.95 (s, 1H), 7.86–7.77 (m, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.45 (d, <i>J</i> = 7.0 Hz, 1H), 7.29 (s, 1H), 7.24 (t, <i>J</i> = 7.6 Hz, 1H), 7.21–7.16 (m, 1H), 7.08 (s, 1H), 6.92 (d, <i>J</i> = 8.2 Hz, 1H), 6.78 (d, <i>J</i> = 2.1 Hz, 1H), 6.75 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 5.28 (s, 2H), 5.22 (s, 2H), 4.28 (s, 4H), 3.41 (s, 2H), 2.31 (d, <i>J</i> = 62.1 Hz, 8H), 2.24 (s, 3H), 2.14 (s, 3H). MS: <i>m</i>/<i>z</i> = 610.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.889 min, purity 100%.</div></div><div id="sec4_1_1_1_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-(piperazin-1-ylmethyl)phenoxy)methyl)benzonitrile (<b>NC10</b>)</h5><div class="NLM_p last"><b>NC10</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with piperazine replacing 2-amino-2-methylpropanoic acid. White solid (7 mg, yield 15%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.45 (s, 2H), 7.96 (s, 1H), 7.88–7.77 (m, 2H), 7.65 (t, <i>J</i> = 7.8 Hz, 1H), 7.46 (d, <i>J</i> = 6.5 Hz, 1H), 7.36 (s, 1H), 7.26 (t, <i>J</i> = 7.4 Hz, 1H), 7.19 (d, <i>J</i> = 6.4 Hz, 1H), 7.13 (s, 1H), 6.94 (d, <i>J</i> = 8.2 Hz, 1H), 6.78 (d, <i>J</i> = 2.0 Hz, 1H), 6.77–6.71 (m, 1H), 5.29 (s, 2H), 5.24 (s, 2H), 4.29 (s, 4H), 3.53 (s, 2H), 3.08 (s, 4H), 2.57 (s, 4H), 2.25 (s, 3H). MS: <i>m</i>/<i>z</i> = 596.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.875 min, purity 98.2%.</div></div><div id="sec4_1_1_1_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> <i>tert</i>-Butyl (2-((5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)amino)ethyl)carbamate (<b>NC11</b>)</h5><div class="NLM_p last"><b>NC11</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with <i>tert</i>-butyl (2-aminoethyl)carbamate replacing 2-amino-2-methylpropanoic acid. White solid (13 mg, yield 18.5%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.95 (s, 1H), 7.83 (d, <i>J</i> = 7.8 Hz, 2H), 7.64 (t, <i>J</i> = 7.7 Hz, 1H), 7.44 (d, <i>J</i> = 7.3 Hz, 1H), 7.37 (s, 1H), 7.25 (t, <i>J</i> = 7.4 Hz, 1H), 7.18 (d, <i>J</i> = 7.4 Hz, 1H), 7.07 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.86–6.75 (m, 2H), 6.71 (s, 1H), 5.28 (s, 2H), 5.22 (s, 2H), 4.29 (s, 4H), 3.65 (s, 2H), 3.02 (d, <i>J</i> = 5.9 Hz, 2H), 2.38 (d, <i>J</i> = 5.4 Hz, 2H), 2.25 (s, 3H), 2.16 (s, 1H), 1.36 (s, 9H). MS: <i>m</i>/<i>z</i> = 670.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.948 min, purity 96.3%.</div></div><div id="sec4_1_1_1_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> <i>tert</i>-Butyl 4-(5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)piperazine-1-carboxylate (<b>NC12</b>)</h5><div class="NLM_p last"><b>NC12</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with <i>tert</i>-butyl piperazine-1-carboxylate replacing 2-amino-2-methylpropanoic acid. White solid (12 mg, yield 19%). <sup>1</sup>H NMR (600 MHz, DMSO) δ 7.95 (s, 1H), 7.83 (t, <i>J</i> = 7.8 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.45 (d, <i>J</i> = 7.0 Hz, 1H), 7.31 (s, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 6.7 Hz, 1H), 7.09 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.78 (d, <i>J</i> = 2.1 Hz, 1H), 6.75 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 5.29 (s, 2H), 5.22 (s, 2H), 4.28 (s, 4H), 3.44 (s, 2H), 3.30 (s, 4H), 2.40–2.27 (m, 4H), 2.24 (s, 3H), 1.38 (s, 9H). MS: <i>m</i>/<i>z</i> = 696.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.962 min, purity 95.9%.</div></div><div id="sec4_1_1_1_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> (5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)glycine (<b>NP1</b>)</h5><div class="NLM_p last"><b>NP1</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with glycine replacing 2-amino-2-methylpropanoic acid. Colorless oil (10 mg, yield 15.5%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.89 (s, 1H), 7.81–7.72 (m, 2H), 7.56 (t, <i>J</i> = 7.8 Hz, 1H), 7.42 (d, <i>J</i> = 7.4 Hz, 1H), 7.37 (s, 1H), 7.22 (d, <i>J</i> = 7.6 Hz, 1H), 7.17 (d, <i>J</i> = 7.7 Hz, 1H), 7.02 (s, 1H), 6.92 (d, <i>J</i> = 8.1 Hz, 1H), 6.77 (s, 1H), 6.75 (d, <i>J</i> = 7.9 Hz, 1H), 5.24 (s, 2H), 5.18 (s, 2H), 4.29 (s, 4H), 3.77 (s, 2H), 3.51 (s, 2H), 2.22 (s, 3H). MS: <i>m</i>/<i>z</i> = 585.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 1.103 min, purity 95.4%.</div></div><div id="sec4_1_1_1_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> (<i>S</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)pyrrolidine-3-carboxylic Acid (<b>NP2</b>)</h5><div class="NLM_p last"><b>NP2</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with (<i>S</i>)-pyrrolidine-3-carboxylic acid replacing 2-amino-2-methylpropanoic acid. Colorless oil (11 mg, yield 16%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (s, 1H), 7.83 (dd, <i>J</i> = 7.8, 4.3 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.46 (d, <i>J</i> = 6.6 Hz, 1H), 7.33 (s, 1H), 7.24 (d, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 6.5 Hz, 1H), 7.09 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.79 (d, <i>J</i> = 2.0 Hz, 1H), 6.77–6.70 (m, 1H), 5.29 (s, 2H), 5.22 (s, 2H), 4.29 (s, 4H), 3.56 (s, 2H), 3.00–2.86 (m, 2H), 2.68 (s, 2H), 2.25 (s, 3H), 2.05–1.91 (m, 3H). MS: <i>m</i>/<i>z</i> = 625.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.907 min, purity 95.1%.</div></div><div id="sec4_1_1_1_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> (<i>R</i>)-3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-((3-hydroxypyrrolidin-1-yl)methyl)phenoxy)methyl)benzonitrile (<b>NP3</b>)</h5><div class="NLM_p last"><b>NP3</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with (<i>R</i>)-pyrrolidin-3-ol replacing 2-amino-2-methylpropanoic acid. Colorless oil (8 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (s, 1H), 7.84 (t, <i>J</i> = 7.2 Hz, 2H), 7.64 (t, <i>J</i> = 7.8 Hz, 1H), 7.46 (d, <i>J</i> = 7.3 Hz, 1H), 7.33 (s, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 7.3 Hz, 1H), 7.08 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.79 (d, <i>J</i> = 1.9 Hz, 1H), 6.76 (dd, <i>J</i> = 8.2, 2.0 Hz, 1H), 5.29 (s, 2H), 5.22 (s, 2H), 4.70 (s, 1H), 4.29 (s, 4H), 4.20 (s, 1H), 3.60–3.50 (m, 2H), 2.68 (s, 1H), 2.58 (s, 1H), 2.42 (s, 1H), 2.34 (s, 1H), 2.25 (s, 3H), 2.01–1.96 (m, 1H), 1.55 (s, 1H). MS: <i>m</i>/<i>z</i> = 597.4 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.892 min, purity 96.7%.</div></div><div id="sec4_1_1_1_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> (<i>R</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)pyrrolidine-3-carboxylic Acid (<b>NP4</b>)</h5><div class="NLM_p last"><b>NP4</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with (<i>R</i>)- pyrrolidine-3-carboxylic acid replacing 2-amino-2-methylpropanoic acid. Colorless oil (6 mg, yield 16%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (s, 1H), 7.83 (s, 2H), 7.63 (t, <i>J</i> = 7.7 Hz, 1H), 7.46 (d, <i>J</i> = 7.3 Hz, 1H), 7.33 (s, 1H), 7.24 (d, <i>J</i> = 7.5 Hz, 1H), 7.18 (d, <i>J</i> = 6.5 Hz, 1H), 7.09 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.79 (d, <i>J</i> = 2.0 Hz, 1H), 6.76 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 5.29 (s, 2H), 5.22 (s, 2H), 4.29 (s, 4H), 3.56 (s, 2H), 2.92 (d, <i>J</i> = 7.7 Hz, 2H), 2.68 (s, 2H), 2.24 (s, 3H), 2.02–1.92 (m, 3H). MS: <i>m</i>/<i>z</i> = 625.4 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.899 min, purity 95.9%.</div></div><div id="sec4_1_1_1_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> (<i>S</i>)-3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-((3-hydroxypyrrolidin-1-yl)methyl)phenoxy)methyl)benzonitrile (<b>NP5</b>)</h5><div class="NLM_p last"><b>NP5</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with (<i>S</i>)-pyrrolidin-3-ol replacing 2-amino-2-methylpropanoic acid. Yellow oil (13 mg, yield 18%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (s, 1H), 7.84 (t, <i>J</i> = 7.1 Hz, 2H), 7.64 (t, <i>J</i> = 7.7 Hz, 1H), 7.46 (d, <i>J</i> = 7.3 Hz, 1H), 7.33 (s, 1H), 7.25 (t, <i>J</i> = 7.4 Hz, 1H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 7.08 (s, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.79 (s, 1H), 6.76 (d, <i>J</i> = 8.2 Hz, 1H), 5.28 (s, 2H), 5.22 (s, 2H), 4.68 (s, 1H), 4.29 (s, 4H), 4.20 (s, 1H), 3.58–3.50 (m, 2H), 2.68 (s, 1H), 2.59 (s, 1H), 2.43 (s, 1H), 2.34 (s, 1H), 2.25 (s, 3H), 2.02–1.97 (m, 1H), 1.54 (s, 1H). MS: <i>m</i>/<i>z</i> = 597.4 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.895 min, purity 96.6%.</div></div><div id="sec4_1_1_1_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)azetidine-3-carboxylic Acid (<b>NP6</b>)</h5><div class="NLM_p last"><b>NP6</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with azetidine-3-carboxylic acid replacing 2-amino-2-methylpropanoic acid. Colorless oil (10 mg, yield 19%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.98 (s, 1H), 7.91–7.79 (m, 2H), 7.64 (t, <i>J</i> = 7.7 Hz, 1H), 7.44 (d, <i>J</i> = 7.1 Hz, 1H), 7.25 (d, <i>J</i> = 4.7 Hz, 1H), 7.23 (s, 1H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 7.07 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.78 (s, 1H), 6.76 (d, <i>J</i> = 7.9 Hz, 1H), 5.29 (s, 2H), 5.21 (s, 2H), 4.29 (s, 4H), 3.51 (s, 4H), 3.39 (s, 2H), 3.20 (s, 1H), 2.24 (s, 3H). MS: <i>m</i>/<i>z</i> = 611.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.894 min, purity 98.2%.</div></div><div id="sec4_1_1_1_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 3-((2-(((2-Aminoethyl)amino)methyl)-4-chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)phenoxy)methyl)benzonitrile (<b>NP7</b>)</h5><div class="NLM_p last"><b>NP7</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with ethane-1,2-diamine replacing 2-amino-2-methylpropanoic acid. Yellow oil (10 mg, yield 15%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (d, <i>J</i> = 14.1 Hz, 1H), 7.85 (d, <i>J</i> = 7.4 Hz, 2H), 7.63 (s, 1H), 7.44 (d, <i>J</i> = 7.1 Hz, 1H), 7.36 (s, 1H), 7.27–7.21 (m, 1H), 7.18 (d, <i>J</i> = 7.5 Hz, 1H), 7.12 (s, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.77 (s, 1H), 6.75 (d, <i>J</i> = 8.1 Hz, 1H), 5.30 (d, <i>J</i> = 8.3 Hz, 2H), 5.24 (s, 2H), 4.29 (s, 4H), 3.51 (s, 2H), 3.17 (s, 1H), 2.59 (s, 2H), 2.36 (d, <i>J</i> = 7.9 Hz, 2H), 2.24 (s, 3H). MS: <i>m</i>/<i>z</i> = 570.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.841 min, purity 100%.</div></div><div id="sec4_1_1_1_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-(((2<i>R</i>,4<i>S</i>)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl)methyl)phenoxy)methyl)benzonitrile (<b>NP8</b>)</h5><div class="NLM_p last"><b>NP8</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with (3<i>S</i>,5<i>R</i>)-5-(hydroxymethyl)pyrrolidin-3-ol replacing 2-amino-2-methylpropanoic acid. Yellow oil (10 mg, yield 16%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.97 (s, 1H), 7.83 (d, <i>J</i> = 6.3 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.45 (d, <i>J</i> = 6.8 Hz, 1H), 7.34 (s, 1H), 7.25 (t, <i>J</i> = 7.5 Hz, 1H), 7.18 (d, <i>J</i> = 6.7 Hz, 1H), 7.07 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.79 (d, <i>J</i> = 2.0 Hz, 1H), 6.76 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 5.77 (s, 1H), 5.28 (d, <i>J</i> = 6.5 Hz, 2H), 5.22 (s, 2H), 4.67 (s, 1H), 4.33 (s, 1H), 4.29 (s, 4H), 4.10 (s, 1H), 3.92 (d, <i>J</i> = 13.5 Hz, 1H), 3.42 (s, 1H), 3.26 (s, 1H), 3.01 (dd, <i>J</i> = 9.1, 5.6 Hz, 1H), 2.80 (d, <i>J</i> = 4.9 Hz, 1H), 2.24 (s, 3H), 2.16–2.08 (m, 1H), 1.72 (dd, <i>J</i> = 15.8, 9.2 Hz, 2H). MS: <i>m</i>/<i>z</i> = 627.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.878 min, purity 99.4%.</div></div><div id="sec4_1_1_1_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-(((3<i>S</i>,4<i>S</i>)-3-fluoro-4-hydroxypyrrolidin-1-yl)methyl)phenoxy)methyl)benzonitrile (<b>NP9</b>)</h5><div class="NLM_p last"><b>NP9</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with (3<i>S</i>,4<i>S</i>)-4-fluoropyrrolidin-3-ol replacing 2-amino-2-methylpropanoic acid. Colorless oil (13 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.95 (s, 1H), 7.84 (t, <i>J</i> = 7.8 Hz, 2H), 7.63 (t, <i>J</i> = 7.7 Hz, 1H), 7.46 (d, <i>J</i> = 7.3 Hz, 1H), 7.32 (s, 1H), 7.26 (t, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 7.8 Hz, 1H), 7.10 (s, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.79 (s, 1H), 6.76 (d, <i>J</i> = 8.2 Hz, 1H), 5.29 (d, <i>J</i> = 6.1 Hz, 2H), 5.23 (s, 2H), 4.87–4.73 (dd, <i>J</i> = 53.2, 5.4 Hz, 1H), 4.29 (s, 4H), 4.16 (dd, <i>J</i> = 24.4, 5.4 Hz, 1H), 3.58 (d, <i>J</i> = 10.0 Hz, 1H), 3.52 (d, <i>J</i> = 6.3 Hz, 2H), 3.07–3.01 (m, 1H), 2.85–2.76 (m, 1H), 2.64 (dd, <i>J</i> = 11.5, 5.4 Hz, 1H), 2.29 (d, <i>J</i> = 35.2 Hz, 3H), 2.18 (dd, <i>J</i> = 9.4, 5.5 Hz, 1H). <sup>19</sup>F NMR (565 MHz, DMSO) δ −176.34 (s). MS: <i>m</i>/<i>z</i> = 615.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.902 min, purity 98.9%.</div></div><div id="sec4_1_1_1_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-((3-hydroxy-3-methylazetidin-1-yl)methyl)phenoxy)methyl)benzonitrile (<b>NP10</b>)</h5><div class="NLM_p last"><b>NP10</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with 3-methylazetidin-3-ol replacing 2-amino-2-methylpropanoic acid. Colorless oil (10 mg, yield 15%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.97 (s, 1H), 7.84 (d, <i>J</i> = 8.0 Hz, 2H), 7.64 (t, <i>J</i> = 7.8 Hz, 1H), 7.44 (d, <i>J</i> = 6.8 Hz, 1H), 7.25 (s, 1H), 7.18 (d, <i>J</i> = 6.6 Hz, 1H), 7.07 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.78 (d, <i>J</i> = 2.0 Hz, 1H), 6.76 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 5.28 (s, 2H), 5.22 (s, 2H), 4.29 (s, 4H), 3.53 (d, <i>J</i> = 14.7 Hz, 2H), 3.25–3.11 (m, 2H), 2.90 (s, 2H), 2.24 (s, 3H), 1.37 (s, 3H). MS: <i>m</i>/<i>z</i> = 597.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.896 min, purity 98.6%.</div></div><div id="sec4_1_1_1_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-((3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl)methyl)phenoxy)methyl)benzonitrile (<b>NP11</b>)</h5><div class="NLM_p last"><b>NP11</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with 4-(hydroxymethyl)pyrrolidin-3-ol replacing 2-amino-2-methylpropanoic acid. Colorless oil (13 mg, yield 18%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.95 (d, <i>J</i> = 6.6 Hz, 1H), 7.84 (t, <i>J</i> = 7.6 Hz, 2H), 7.64 (t, <i>J</i> = 7.7 Hz, 1H), 7.46 (d, <i>J</i> = 7.4 Hz, 1H), 7.33 (s, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 6.5 Hz, 1H), 7.08 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.79 (d, <i>J</i> = 2.0 Hz, 1H), 6.76 (dd, <i>J</i> = 8.2, 2.1 Hz, 1H), 5.28 (s, 2H), 5.22 (s, 2H), 4.73 (s, 1H), 4.54 (s, 1H), 4.29 (s, 4H), 4.21 (s, 1H), 3.82 (s, 1H), 3.60 (d, <i>J</i> = 6.0 Hz, 1H), 3.51 (s, 2H), 3.45 (dd, <i>J</i> = 10.5, 5.8 Hz, 1H), 3.26 (s, 1H), 2.68 (s, 1H), 2.34 (s, 1H), 2.25 (s, 3H), 2.03–1.96 (m, 1H). MS: <i>m</i>/<i>z</i> = 627.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.881 min, purity 99.1%.</div></div><div id="sec4_1_1_1_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-((3-hydroxypyrrolidin-1-yl)methyl)phenoxy)methyl)benzonitrile (<b>NP12</b>)</h5><div class="NLM_p last"><b>NP12</b> was prepared from <b>8a</b> in a similar manner as described for <b>NC1</b>, with pyrrolidin-3-ol replacing 2-amino-2-methylpropanoic acid. White solid (10 mg, yield 15%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (s, 1H), 7.84 (t, <i>J</i> = 7.2 Hz, 2H), 7.64 (t, <i>J</i> = 7.8 Hz, 1H), 7.46 (d, <i>J</i> = 7.3 Hz, 1H), 7.33 (s, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 7.4 Hz, 1H), 7.08 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.79 (d, <i>J</i> = 1.9 Hz, 1H), 6.76 (dd, <i>J</i> = 8.2, 1.9 Hz, 1H), 5.28 (s, 2H), 5.22 (s, 2H), 4.69 (s, 1H), 4.29 (s, 4H), 4.20 (s, 1H), 3.61–3.51 (m, 2H), 2.68 (s, 1H), 2.59 (s, 1H), 2.43 (s, 1H), 2.33 (s, 1H), 2.25 (s, 3H), 2.01–1.97 (m, 1H), 1.55 (s, 1H). MS: <i>m</i>/<i>z</i> = 597.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.900 min, purity 96.9%.</div></div><div id="sec4_1_1_1_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)glycine (<b>NP13</b>)</h5><div class="NLM_p last"><b>NP13</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with glycine replacing 2-amino-2-methylpropanoic acid. Colorless oil (11 mg, yield 15.8%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.03 (s, 1H), 7.89 (d, <i>J</i> = 7.5 Hz, 1H), 7.84 (d, <i>J</i> = 8.1 Hz, 1H), 7.66–7.61 (m, 1H), 7.48 (dd, <i>J</i> = 13.9, 6.7 Hz, 3H), 7.40 (d, <i>J</i> = 7.2 Hz, 1H), 7.30 (dd, <i>J</i> = 16.0, 7.2 Hz, 3H), 7.25–7.19 (m, 2H), 7.13 (s, 1H), 5.33 (s, 2H), 5.28 (s, 2H), 3.96 (s, 2H), 3.51 (s, 2H), 2.24 (s, 3H). MS: <i>m</i>/<i>z</i> = 527.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.926 min, purity 95.1%.</div></div><div id="sec4_1_1_1_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> (<i>R</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)pyrrolidine-3-carboxylic Acid (<b>NP14</b>)</h5><div class="NLM_p last"><b>NP14</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with (<i>R</i>)- pyrrolidine-3-carboxylic acid replacing 2-amino-2-methylpropanoic acid. Colorless oil (10 mg, yield 16%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (s, 1H), 7.87–7.81 (m, 2H), 7.64 (d, <i>J</i> = 7.9 Hz, 1H), 7.48 (dd, <i>J</i> = 14.0, 7.3 Hz, 3H), 7.40 (d, <i>J</i> = 7.1 Hz, 1H), 7.31 (dd, <i>J</i> = 16.0, 7.9 Hz, 4H), 7.22 (d, <i>J</i> = 7.7 Hz, 1H), 7.10 (s, 1H), 5.29 (s, 2H), 5.25 (s, 2H), 3.57 (s, 2H), 2.98–2.86 (m, 2H), 2.68 (s, 2H), 2.36–2.29 (m, 1H), 2.24 (s, 3H), 1.99 (d, <i>J</i> = 5.8 Hz, 2H). MS: <i>m</i>/<i>z</i> = 567.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.923 min, purity 95.3%.</div></div><div id="sec4_1_1_1_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> (<i>R</i>)-3-((4-Chloro-2-((3-hydroxypyrrolidin-1-yl)methyl)-5-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)phenoxy)methyl)benzonitrile (<b>NP15</b>)</h5><div class="NLM_p last"><b>NP15</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with (<i>R</i>)-pyrrolidin-3-ol replacing 2-amino-2-methylpropanoic acid. Colorless oil (14 mg, yield 15.7%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (s, 1H), 7.84 (t, <i>J</i> = 7.5 Hz, 2H), 7.64 (t, <i>J</i> = 7.8 Hz, 1H), 7.48 (dd, <i>J</i> = 13.9, 7.2 Hz, 3H), 7.40 (d, <i>J</i> = 7.2 Hz, 1H), 7.31 (dd, <i>J</i> = 15.4, 7.3 Hz, 4H), 7.22 (d, <i>J</i> = 7.6 Hz, 1H), 7.10 (s, 1H), 5.29 (s, 2H), 5.25 (s, 2H), 4.69 (s, 1H), 4.20 (s, 1H), 3.55 (d, <i>J</i> = 10.3 Hz, 2H), 2.68 (s, 1H), 2.59 (s, 1H), 2.43 (s, 1H), 2.34 (s, 1H), 2.24 (s, 3H), 2.00 (d, <i>J</i> = 7.1 Hz, 1H), 1.55 (s, 1H). MS: <i>m</i>/<i>z</i> = 539.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.915 min, purity 95.8%.</div></div><div id="sec4_1_1_1_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> (<i>S</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)pyrrolidine-3-carboxylic Acid (<b>NP16</b>)</h5><div class="NLM_p last"><b>NP16</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with (<i>S</i>)-pyrrolidine-3-carboxylic acid replacing 2-amino-2-methylpropanoic acid. Colorless oil (6 mg, yield 18%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.97 (s, 1H), 7.83 (d, <i>J</i> = 5.8 Hz, 2H), 7.64 (d, <i>J</i> = 8.0 Hz, 1H), 7.48 (dd, <i>J</i> = 13.7, 7.0 Hz, 3H), 7.40 (d, <i>J</i> = 6.9 Hz, 1H), 7.31 (dd, <i>J</i> = 15.7, 7.8 Hz, 4H), 7.21 (s, 1H), 7.11 (s, 1H), 5.30 (s, 2H), 5.25 (s, 2H), 3.59 (s, 2H), 2.93 (s, 2H), 2.68 (s, 2H), 2.34 (s, 1H), 2.24 (s, 3H), 1.99 (d, <i>J</i> = 4.6 Hz, 2H). MS: <i>m</i>/<i>z</i> = 567.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.922 min, purity 95.3%.</div></div><div id="sec4_1_1_1_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> (<i>S</i>)-3-((4-Chloro-2-((3-hydroxypyrrolidin-1-yl)methyl)-5-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)phenoxy)methyl)benzonitrile (<b>NP17</b>)</h5><div class="NLM_p last"><b>NP17</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with (<i>S</i>)-pyrrolidin-3-ol replacing 2-amino-2-methylpropanoic acid. Colorless oil (5 mg, yield 16.5%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (s, 1H), 7.84 (t, <i>J</i> = 7.6 Hz, 2H), 7.65 (d, <i>J</i> = 7.8 Hz, 1H), 7.48 (dd, <i>J</i> = 13.9, 7.2 Hz, 3H), 7.40 (d, <i>J</i> = 7.2 Hz, 1H), 7.31 (dd, <i>J</i> = 15.7, 7.8 Hz, 4H), 7.22 (d, <i>J</i> = 7.5 Hz, 1H), 7.10 (s, 1H), 5.29 (s, 2H), 5.25 (s, 2H), 4.70 (s, 1H), 4.20 (s, 1H), 3.56 (d, <i>J</i> = 9.2 Hz, 2H), 2.68 (s, 1H), 2.60 (s, 1H), 2.43 (s, 1H), 2.33 (s, 1H), 2.24 (s, 3H), 2.00 (d, <i>J</i> = 7.3 Hz, 1H), 1.55 (s, 1H). MS: <i>m</i>/<i>z</i> = 539.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.915 min, purity 95%.</div></div><div id="sec4_1_1_1_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)azetidine-3-carboxylic Acid (<b>NP18</b>)</h5><div class="NLM_p last"><b>NP18</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with azetidine-3-carboxylic acid replacing 2-amino-2-methylpropanoic acid. Colorless oil (5 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.99 (s, 1H), 7.84 (t, <i>J</i> = 7.0 Hz, 2H), 7.64 (t, <i>J</i> = 7.7 Hz, 1H), 7.47 (t, <i>J</i> = 7.7 Hz, 3H), 7.38 (d, <i>J</i> = 7.5 Hz, 1H), 7.30 (dd, <i>J</i> = 17.7, 8.0 Hz, 4H), 7.22 (d, <i>J</i> = 7.5 Hz, 1H), 7.09 (s, 1H), 5.29 (s, 2H), 5.24 (s, 2H), 3.52 (s, 2H), 3.40 (s, 2H), 3.21 (s, 2H), 3.17 (s, 1H), 2.23 (s, 3H). MS: <i>m</i>/<i>z</i> = 553.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.937 min, purity 95.2%.</div></div><div id="sec4_1_1_1_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 2-((5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)amino)-2-methylpropanoic Acid (<b>NP19</b>)</h5><div class="NLM_p last"><b>NP19</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with 2-amino-2-methylpropanoic acid replacing 2-amino-2-methylpropanoic acid. The product was convert into the corresponding hydrochloride salt as white solid (1 g, yield 25%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.04 (s, 1H), 7.90 (d, <i>J</i> = 7.8 Hz, 1H), 7.84 (d, <i>J</i> = 7.8 Hz, 1H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.57 (s, 1H), 7.47 (t, <i>J</i> = 7.4 Hz, 3H), 7.39 (t, <i>J</i> = 7.3 Hz, 1H), 7.36–7.24 (m, 3H), 7.22 (d, <i>J</i> = 6.6 Hz, 1H), 7.12 (s, 1H), 5.30 (s, 4H), 3.87 (s, 2H), 2.24 (s, 3H), 1.27 (s, 6H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 173.39, 156.42, 154.72, 142.64, 141.66, 138.70, 135.36, 134.39, 132.97, 132.19, 131.65, 130.23, 130.11, 129.57, 128.68, 128.26, 127.40, 125.98, 119.05, 113.16, 111.87, 100.64, 99.93, 70.03, 69.52, 62.03, 23.27, 16.26. MS: <i>m</i>/<i>z</i> = 555.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.913 min, purity 100%.</div></div><div id="sec4_1_1_1_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 3-((4-Chloro-2-(((2-(dimethylamino)ethyl)amino)methyl)-5-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)phenoxy)methyl)benzonitrile (<b>NP20</b>)</h5><div class="NLM_p last"><b>NP20</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with <i>N</i><sup>1</sup>,<i>N</i><sup>1</sup>-dimethylethane-1,2-diamine replacing 2-amino-2-methylpropanoic acid. Colorless oil (5 mg, yield 15.4%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.99 (s, 1H), 7.83 (d, <i>J</i> = 7.7 Hz, 2H), 7.64 (s, 1H), 7.48 (dd, <i>J</i> = 15.0, 7.8 Hz, 3H), 7.40 (d, <i>J</i> = 7.3 Hz, 1H), 7.31 (dd, <i>J</i> = 14.8, 7.2 Hz, 4H), 7.22 (d, <i>J</i> = 7.4 Hz, 1H), 7.11 (s, 1H), 5.29 (s, 2H), 5.26 (s, 2H), 3.51 (s, 2H), 2.48 (d, <i>J</i> = 4.1 Hz, 2H), 2.37 (d, <i>J</i> = 5.4 Hz, 2H), 2.24 (s, 3H), 2.17 (s, 6H). MS: <i>m</i>/<i>z</i> = 540.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.904 min, purity 95.6%.</div></div><div id="sec4_1_1_1_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 3-((4-Chloro-2-(((2<i>R</i>,4<i>S</i>)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl)methyl)-5-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)phenoxy)methyl)benzonitrile (<b>NP21</b>)</h5><div class="NLM_p last"><b>NP21</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with (3<i>S</i>,5<i>R</i>)-5-(hydroxymethyl)pyrrolidin-3-ol replacing 2-amino-2-methylpropanoic acid. Colorless oil (8 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.97 (s, 1H), 7.83 (d, <i>J</i> = 6.8 Hz, 2H), 7.64 (d, <i>J</i> = 7.8 Hz, 1H), 7.48 (dd, <i>J</i> = 12.8, 5.7 Hz, 3H), 7.40 (d, <i>J</i> = 7.3 Hz, 1H), 7.37–7.26 (m, 4H), 7.22 (d, <i>J</i> = 7.2 Hz, 1H), 7.08 (s, 1H), 5.28 (d, <i>J</i> = 6.6 Hz, 2H), 5.24 (s, 2H), 4.67 (s, 1H), 4.34 (s, 1H), 4.09 (s, 1H), 3.92 (d, <i>J</i> = 13.8 Hz, 1H), 3.51 (s, 2H), 3.26 (s, 1H), 3.00 (s, 1H), 2.81 (s, 1H), 2.24 (s, 3H), 2.11 (s, 1H), 1.71 (s, 1H), 1.45 (s, 1H). MS: <i>m</i>/<i>z</i> = 569.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.888 min, purity 100%.</div></div><div id="sec4_1_1_1_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> 3-((4-Chloro-2-(((3<i>S</i>,4<i>S</i>)-3-fluoro-4-hydroxypyrrolidin-1-yl)methyl)-5-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)phenoxy)methyl)benzonitrile (<b>NP22</b>)</h5><div class="NLM_p last"><b>NP22</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with (3<i>S</i>,4<i>S</i>)-4-fluoropyrrolidin-3-ol replacing 2-amino-2-methylpropanoic acid. Colorless oil (11 mg, yield 16%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (s, 1H), 7.84 (t, <i>J</i> = 8.0 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.48 (dd, <i>J</i> = 14.7, 7.4 Hz, 3H), 7.40 (d, <i>J</i> = 7.2 Hz, 1H), 7.36–7.27 (m, 4H), 7.22 (d, <i>J</i> = 7.4 Hz, 1H), 7.11 (s, 1H), 5.29 (s, 2H), 5.25 (s, 2H), 4.87–4.72 (m, 1H), 4.16 (dd, <i>J</i> = 24.3, 5.5 Hz, 1H), 3.58 (d, <i>J</i> = 10.1 Hz, 2H), 3.08–3.02 (m, 1H), 2.85–2.76 (m, 1H), 2.75–2.68 (m, 1H), 2.24 (s, 3H), 2.18 (dd, <i>J</i> = 9.5, 5.5 Hz, 1H). <sup>19</sup>F NMR (565 MHz, DMSO) δ −176.32 (s). MS: <i>m</i>/<i>z</i> = 557.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.902 min, purity 97.8%.</div></div><div id="sec4_1_1_1_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> 3-((4-Chloro-2-((3-hydroxy-3-methylazetidin-1-yl)methyl)-5-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)phenoxy)methyl)benzonitrile (<b>NP23</b>)</h5><div class="NLM_p last"><b>NP23</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with 3-methylazetidin-3-ol replacing 2-amino-2-methylpropanoic acid. Colorless oil (6 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.97 (s, 1H), 7.84 (d, <i>J</i> = 7.7 Hz, 2H), 7.64 (t, <i>J</i> = 7.7 Hz, 1H), 7.47 (t, <i>J</i> = 7.9 Hz, 3H), 7.39 (t, <i>J</i> = 7.4 Hz, 1H), 7.32 (d, <i>J</i> = 8.1 Hz, 2H), 7.28 (d, <i>J</i> = 7.6 Hz, 2H), 7.22 (d, <i>J</i> = 7.4 Hz, 1H), 7.09 (s, 1H), 5.29 (s, 2H), 5.24 (s, 2H), 5.16 (s, 1H), 3.55 (s, 2H), 3.20 (s, 2H), 2.91 (s, 2H), 2.24 (s, 3H), 1.37 (s, 3H). MS: <i>m</i>/<i>z</i> = 539.0 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.913 min, purity 95.9%.</div></div><div id="sec4_1_1_1_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 3-((4-Chloro-2-((3-hydroxyazetidin-1-yl)methyl)-5-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)phenoxy)methyl)benzonitrile (<b>NP24</b>)</h5><div class="NLM_p last"><b>NP24</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with azetidin-3-ol replacing 2-amino-2-methylpropanoic acid. Yellow oil (6 mg, yield 17.6%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.99 (s, 1H), 7.85 (s, 1H), 7.83 (s, 1H), 7.64 (t, <i>J</i> = 7.8 Hz, 1H), 7.47 (t, <i>J</i> = 7.8 Hz, 3H), 7.40 (d, <i>J</i> = 7.2 Hz, 1H), 7.33 (s, 1H), 7.31 (s, 1H), 7.30–7.23 (m, 2H), 7.22 (d, <i>J</i> = 7.6 Hz, 1H), 7.09 (s, 1H), 5.29 (s, 2H), 5.24 (s, 2H), 4.21 (d, <i>J</i> = 6.5 Hz, 1H), 3.51 (s, 4H), 2.80 (s, 2H), 2.24 (s, 3H). MS: <i>m</i>/<i>z</i> = 525.0 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.903 min, purity 95.2%.</div></div><div id="sec4_1_1_1_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> 3-((4-Chloro-2-((3-hydroxypyrrolidin-1-yl)methyl)-5-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)phenoxy)methyl)benzonitrile (<b>NP25</b>)</h5><div class="NLM_p last"><b>NP25</b> was prepared from <b>8b</b> in a similar manner as described for <b>NC1</b>, with pyrrolidin-3-ol replacing 2-amino-2-methylpropanoic acid. Colorless oil (8 mg, yield 16%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.96 (s, 1H), 7.84 (t, <i>J</i> = 7.4 Hz, 2H), 7.64 (t, <i>J</i> = 7.8 Hz, 1H), 7.48 (dd, <i>J</i> = 13.7, 7.1 Hz, 3H), 7.39 (t, <i>J</i> = 7.2 Hz, 1H), 7.31 (dd, <i>J</i> = 15.3, 7.3 Hz, 4H), 7.22 (d, <i>J</i> = 7.5 Hz, 1H), 7.10 (s, 1H), 5.29 (s, 2H), 5.25 (s, 2H), 4.68 (s, 1H), 4.20 (s, 1H), 3.55 (d, <i>J</i> = 9.9 Hz, 2H), 2.68 (t, <i>J</i> = 8.2 Hz, 1H), 2.59 (d, <i>J</i> = 5.5 Hz, 1H), 2.42 (d, <i>J</i> = 5.8 Hz, 1H), 2.34 (s, 1H), 2.24 (s, 3H), 2.01–1.98 (m, 1H), 1.54 (s, 1H). MS: <i>m</i>/<i>z</i> = 539.0 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.902 min, purity 95.9%.</div></div><div id="sec4_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> Synthesis of Compounds <b>NT1–22</b></h5></div><div id="sec4_1_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> (<i>S</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-3-yl)benzyl)oxy)benzyl)piperidine-2-carboxylic Acid (<b>NT1</b>)</h5><div class="NLM_p last">A solution of <b>12a</b> (10 mg, 21.32 μmol), (<i>S</i>)-piperidine-2-carboxylic acid (11 mg, 85.3 μmol), sodium cyanoborohydride (6.7 mg, 106.6 μmol), and AcOH (2 drops) in DMF (3 mL) was stirred at 80 °C for 1 h. The mixture was concentrated under reduce pressure. Purification by Prep-TLC provided the <b>NC1</b> (2 mg, 16%) as yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.61 (s, 1H), 8.56 (s, 1H), 7.96 (s, 1H), 7.83 (s, 2H), 7.78 (s, 1H), 7.63 (s, 1H), 7.55 (d, <i>J</i> = 7.1 Hz, 1H), 7.51 (s, 1H), 7.43 (s, 1H), 7.33 (d, <i>J</i> = 7.3 Hz, 1H), 7.27 (d, <i>J</i> = 7.5 Hz, 1H), 7.10 (s, 1H), 5.28 (d, <i>J</i> = 12.7 Hz, 4H), 3.75 (s, 1H), 3.62 (s, 1H), 3.17 (s, 1H), 2.91 (s, 1H), 2.33 (s, 1H), 2.25 (s, 3H), 1.77 (d, <i>J</i> = 20.8 Hz, 2H), 1.49 (s, 3H), 1.39 (s, 1H). MS: <i>m</i>/<i>z</i> = 582.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.768 min, purity 95.7%.</div></div><div id="sec4_1_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> (2<i>S</i>,4<i>S</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-3-yl)benzyl)oxy)benzyl)-4-hydroxypyrrolidine-2-carboxylic Acid (<b>NT2</b>)</h5><div class="NLM_p last"><b>NT2</b> was prepared from <b>12a</b> in a similar manner as described for <b>NT1</b>, with (2<i>S</i>,4<i>S</i>)-4-hydroxypyrrolidine-2-carboxylic acid replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (5 mg, yield 16%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.76 (d, <i>J</i> = 6.9 Hz, 1H), 8.61 (d, <i>J</i> = 5.1 Hz, 1H), 8.55 (s, 1H), 8.40 (d, <i>J</i> = 7.3 Hz, 1H), 7.98 (s, 1H), 7.89 (d, <i>J</i> = 7.7 Hz, 1H), 7.81 (d, <i>J</i> = 13.0 Hz, 1H), 7.64 (d, <i>J</i> = 6.4 Hz, 1H), 7.53 (d, <i>J</i> = 10.5 Hz, 1H), 7.39–7.33 (m, 1H), 7.28 (d, <i>J</i> = 3.7 Hz, 1H), 7.20 (s, 1H), 6.65 (s, 1H), 5.31 (d, <i>J</i> = 25.6 Hz, 4H), 4.90 (s, 1H), 4.22 (s, 1H), 3.96 (d, <i>J</i> = 12.0 Hz, 1H), 3.81 (d, <i>J</i> = 11.3 Hz, 1H), 3.51 (s, 2H), 2.95 (d, <i>J</i> = 15.4 Hz, 1H), 2.75 (s, 1H), 2.25 (s, 3H), 1.87 (s, 1H), 1.45 (s, 1H). MS: <i>m</i>/<i>z</i> = 584.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.754 min, purity 95.5%.</div></div><div id="sec4_1_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> (5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-3-yl)benzyl)oxy)benzyl)-<i>D</i>-serine (<b>NT3</b>)</h5><div class="NLM_p last"><b>NT3</b> was prepared from <b>12a</b> in a similar manner as described for <b>NT1</b>, with <i>D</i>-serine replacing (<i>S</i>)-piperidine-2-carboxylic acid. Colorless oil (5 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.76 (s, 1H), 8.63 (d, <i>J</i> = 20.1 Hz, 1H), 8.55 (s, 1H), 8.39 (s, 1H), 8.02 (s, 1H), 7.91 (d, <i>J</i> = 7.5 Hz, 1H), 7.84 (d, <i>J</i> = 7.6 Hz, 1H), 7.63 (s, 1H), 7.52 (s, 1H), 7.34 (s, 1H), 7.28 (s, 1H), 7.13 (s, 1H), 6.66 (s, 1H), 5.30 (d, <i>J</i> = 11.3 Hz, 4H), 3.97 (s, 2H), 3.70 (s, 1H), 3.63 (s, 1H), 3.51 (s, 1H), 2.25 (s, 3H). MS: <i>m</i>/<i>z</i> = 558.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.780 min, purity 95.1%.</div></div><div id="sec4_1_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> 2-((5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-3-yl)benzyl)oxy)benzyl)amino)-2-methylpropanoic Acid (<b>NT4</b>)</h5><div class="NLM_p last"><b>NT4</b> was prepared from <b>12a</b> in a similar manner as described for <b>NT1</b>, with 2-amino-2-methylpropanoic acid replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (6 mg, yield 16%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.76 (s, 1H), 8.63 (d, <i>J</i> = 11.9 Hz, 1H), 8.55 (s, 1H), 8.38 (s, 1H), 8.03 (s, 1H), 7.90 (d, <i>J</i> = 8.3 Hz, 1H), 7.83 (d, <i>J</i> = 7.6 Hz, 1H), 7.64 (d, <i>J</i> = 8.2 Hz, 1H), 7.55 (d, <i>J</i> = 13.8 Hz, 1H), 7.36 (d, <i>J</i> = 17.8 Hz, 1H), 7.27 (d, <i>J</i> = 7.0 Hz, 1H), 7.13 (s, 1H), 6.66 (s, 1H), 5.31 (d, <i>J</i> = 10.4 Hz, 4H), 3.87 (s, 2H), 2.25 (s, 3H), 1.24 (s, 6H). MS: <i>m</i>/<i>z</i> = 556.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.790 min, purity 96.3%.</div></div><div id="sec4_1_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> (<i>S</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyrimidin-5-yl)benzyl)oxy)benzyl)piperidine-2-carboxylic Acid (<b>NT5</b>)</h5><div class="NLM_p last"><b>NT5</b> was prepared from <b>12b</b> in a similar manner as described for <b>NT1</b>. Yellow oil (7 mg, yield 15%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.21 (s, 1H), 8.07 (s, 1H), 7.85 (d, <i>J</i> = 7.4 Hz, 1H), 7.62 (d, <i>J</i> = 8.3 Hz, 2H), 7.49 (d, <i>J</i> = 7.5 Hz, 2H), 7.45 (s, 1H), 7.37 (s, 1H), 7.18 (s, 1H), 7.11 (s, 1H), 6.66 (s, 1H), 5.33 (s, 1H), 5.26 (s, 3H), 3.85 (d, <i>J</i> = 10.9 Hz, 1H), 3.74 (s, 1H), 3.51 (s, 1H), 3.17 (s, 1H), 2.92 (d, <i>J</i> = 5.7 Hz, 1H), 2.42 (s, 3H), 2.36 (s, 1H), 1.83 (d, <i>J</i> = 11.5 Hz, 1H), 1.71 (d, <i>J</i> = 6.0 Hz, 1H), 1.49 (s, 3H), 1.34 (s, 1H). MS: <i>m</i>/<i>z</i> = 583.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.885 min, purity 95.0%.</div></div><div id="sec4_1_1_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> (2<i>S</i>,4<i>S</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyrimidin-5-yl)benzyl)oxy)benzyl)-4-hydroxypyrrolidine-2-carboxylic Acid (<b>NT6</b>)</h5><div class="NLM_p last"><b>NT6</b> was prepared from <b>12b</b> in a similar manner as described for <b>NT1</b>, with (2<i>S</i>,4<i>S</i>)-4-hydroxypyrrolidine-2-carboxylic acid replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (8 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.38 (d, <i>J</i> = 4.4 Hz, 1H), 8.11 (s, 1H), 7.86 (d, <i>J</i> = 9.8 Hz, 1H), 7.66–7.60 (m, 1H), 7.49 (s, 1H), 7.39 (d, <i>J</i> = 7.7 Hz, 1H), 7.34 (s, 1H), 7.27 (d, <i>J</i> = 7.8 Hz, 1H), 7.18 (s, 2H), 7.12 (s, 1H), 6.64 (s, 1H), 5.30 (d, <i>J</i> = 26.4 Hz, 4H), 4.92 (s, 1H), 4.21 (s, 1H), 4.03 (d, <i>J</i> = 6.3 Hz, 1H), 3.87 (d, <i>J</i> = 15.4 Hz, 1H), 3.52 (s, 1H), 3.49–3.44 (m, 1H), 3.01 (s, 1H), 2.82 (s, 1H), 2.42 (s, 3H), 2.33 (s, 1H), 1.87 (s, 1H). MS: <i>m</i>/<i>z</i> = 585.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.809 min, purity 95.6%.</div></div><div id="sec4_1_1_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> (<i>E</i>)-2-((5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzylidene)amino)-3-mercaptopropanoic Acid (<b>NT7</b>)</h5><div class="NLM_p last"><b>NT7</b> was prepared from <b>12c</b> in a similar manner as described for <b>NT1</b>, with <i>D</i>-cysteine replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (8 mg, yield 16.5%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 7.98 (s, 1H), 7.85 (dd, <i>J</i> = 14.9, 7.7 Hz, 2H), 7.66 (s, 1H), 7.47 (t, <i>J</i> = 7.7 Hz, 4H), 7.41–7.37 (m, 1H), 7.32 (d, <i>J</i> = 7.3 Hz, 2H), 7.29 (s, 1H), 7.22 (d, <i>J</i> = 7.5 Hz, 1H), 7.12 (d, <i>J</i> = 13.8 Hz, 1H), 5.33 (s, 2H), 5.27 (d, <i>J</i> = 9.6 Hz, 2H), 4.12 (s, 1H), 3.84 (s, 1H), 3.51 (s, 1H), 3.22 (s, 1H), 2.94 (d, <i>J</i> = 8.4 Hz, 1H), 2.24 (s, 3H). HRMS (ESI) for C<sub>32</sub>H<sub>27</sub>ClN<sub>2</sub>O<sub>4</sub>S [M + H]<sup>+</sup>, calcd: 571.1458, found: 571.1445. [M - H]<sup>−</sup>, calcd: 569.1302, found: 569.1293. MS: <i>m</i>/<i>z</i> = 571.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 1.037 min, purity 95%.</div></div><div id="sec4_1_1_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> (5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)-<i>D</i>-serine (<b>NT8</b>)</h5><div class="NLM_p last"><b>NT8</b> was prepared from <b>12c</b> in a similar manner as described for <b>NT1</b>, with <i>D</i>-serine replacing (<i>S</i>)-piperidine-2-carboxylic acid. Colorless oil (6 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.02 (s, 1H), 7.91 (d, <i>J</i> = 7.9 Hz, 1H), 7.82 (s, 1H), 7.62 (t, <i>J</i> = 7.7 Hz, 1H), 7.47 (t, <i>J</i> = 7.9 Hz, 4H), 7.40 (d, <i>J</i> = 7.9 Hz, 1H), 7.32 (d, <i>J</i> = 7.4 Hz, 2H), 7.28 (d, <i>J</i> = 7.1 Hz, 1H), 7.22 (d, <i>J</i> = 7.5 Hz, 1H), 7.13 (s, 1H), 5.31 (s, 2H), 5.27 (s, 2H), 3.97 (s, 2H), 3.70 (s, 1H), 3.63 (s, 1H), 3.17 (s, 1H), 2.24 (s, 3H). MS: <i>m</i>/<i>z</i> = 557.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.930 min, purity 98.3%.</div></div><div id="sec4_1_1_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> (5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)-<i>D</i>-threonine (<b>NT9</b>)</h5><div class="NLM_p last"><b>NT9</b> was prepared from <b>12c</b> in a similar manner as described for <b>NT1</b>, with <i>D</i>-threonine replacing (<i>S</i>)-piperidine-2-carboxylic acid. Colorless oil (6 mg, yield 18%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.01 (s, 1H), 7.88 (s, 1H), 7.83 (s, 1H), 7.63 (s, 1H), 7.51–7.44 (m, 3H), 7.39 (s, 1H), 7.32 (d, <i>J</i> = 6.7 Hz, 2H), 7.29 (s, 1H), 7.22 (d, <i>J</i> = 7.8 Hz, 1H), 7.12 (s, 1H), 6.65 (s, 1H), 5.29 (d, <i>J</i> = 15.1 Hz, 4H), 3.92 (s, 1H), 3.88 (s, 2H), 3.51 (s, 1H), 2.24 (s, 3H), 1.13 (s, 3H). MS: <i>m</i>/<i>z</i> = 571.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.940 min, purity 96.5%.</div></div><div id="sec4_1_1_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> (5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)-<i>L</i>-allothreonine (<b>NT10</b>)</h5><div class="NLM_p last"><b>NT10</b> was prepared from <b>12c</b> in a similar manner as described for <b>NT1</b>, with <i>L</i>-allothreonine replacing (<i>S</i>)-piperidine-2-carboxylic acid. Colorless oil (4 mg, yield 18%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.01 (s, 1H), 7.88 (s, 1H), 7.83 (s, 1H), 7.62 (s, 1H), 7.52–7.43 (m, 3H), 7.40 (d, <i>J</i> = 7.4 Hz, 1H), 7.32 (d, <i>J</i> = 8.2 Hz, 2H), 7.29 (s, 1H), 7.22 (d, <i>J</i> = 7.6 Hz, 1H), 7.12 (s, 1H), 6.65 (s, 1H), 5.76 (s, 1H), 5.29 (d, <i>J</i> = 15.9 Hz, 4H), 3.91 (d, <i>J</i> = 13.3 Hz, 3H), 3.52 (s, 1H), 2.24 (s, 3H), 1.07 (d, <i>J</i> = 6.7 Hz, 3H). MS: <i>m</i>/<i>z</i> = 571.3 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.929 min, purity100%.</div></div><div id="sec4_1_1_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> (5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)-<i>L</i>-threonine (<b>NT11</b>)</h5><div class="NLM_p last"><b>NT11</b> was prepared from <b>12c</b> in a similar manner as described for <b>NT1</b>, with <i>L</i>- threonine replacing (<i>S</i>)-piperidine-2-carboxylic acid. Colorless oil (5 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.01 (s, 1H), 7.88 (s, 1H), 7.83 (s, 1H), 7.63 (d, <i>J</i> = 7.6 Hz, 1H), 7.51–7.44 (m, 3H), 7.40 (d, <i>J</i> = 7.2 Hz, 1H), 7.32 (d, <i>J</i> = 7.3 Hz, 2H), 7.28 (d, <i>J</i> = 7.0 Hz, 1H), 7.22 (d, <i>J</i> = 7.8 Hz, 1H), 7.12 (s, 1H), 6.65 (s, 1H), 5.28 (d, <i>J</i> = 13.7 Hz, 4H), 3.88 (s, 3H), 3.52 (s, 1H), 2.24 (s, 3H), 1.13 (d, <i>J</i> = 4.7 Hz, 3H). MS: <i>m</i>/<i>z</i> = 571.2 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.943 min, purity 98.5%.</div></div><div id="sec4_1_1_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> (<i>S</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-4-yl)benzyl)oxy)benzyl)piperidine-2-carboxylic Acid (<b>NT14</b>)</h5><div class="NLM_p last"><b>NT14</b> was prepared from <b>12d</b> in a similar manner as described for <b>NT1</b>. Yellow oil (8 mg, yield 17.5%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.75 (d, <i>J</i> = 6.2 Hz, 1H), 8.66 (d, <i>J</i> = 4.8 Hz, 1H), 7.96 (s, 1H), 7.91 (d, <i>J</i> = 6.2 Hz, 1H), 7.83 (s, 2H), 7.64 (d, <i>J</i> = 7.8 Hz, 1H), 7.56 (d, <i>J</i> = 7.3 Hz, 1H), 7.43 (s, 1H), 7.40–7.35 (m, 2H), 7.28 (t, <i>J</i> = 15.3 Hz, 1H), 7.10 (s, 1H), 5.28 (d, <i>J</i> = 11.9 Hz, 4H), 3.76 (d, <i>J</i> = 13.8 Hz, 1H), 3.62 (d, <i>J</i> = 14.1 Hz, 1H), 3.16 (s, 1H), 2.90 (s, 1H), 2.28 (d, <i>J</i> = 21.4 Hz, 4H), 1.77 (d, <i>J</i> = 18.4 Hz, 2H), 1.49 (s, 3H), 1.38 (s, 1H). MS: <i>m</i>/<i>z</i> = 582.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.766 min, purity 98.3%.</div></div><div id="sec4_1_1_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> (2<i>S</i>,4<i>S</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-4-yl)benzyl)oxy)benzyl)-4-hydroxypyrrolidine-2-carboxylic Acid (<b>NT15</b>)</h5><div class="NLM_p last"><b>NT15</b> was prepared from <b>12d</b> in a similar manner as described for <b>NT1</b>, with (2<i>S</i>,4<i>S</i>)-4-hydroxypyrrolidine-2-carboxylic acid replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (6 mg, yield 16%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.74 (s, 1H), 8.66 (s, 1H), 7.98 (s, 1H), 7.91 (d, <i>J</i> = 4.9 Hz, 1H), 7.83 (d, <i>J</i> = 7.3 Hz, 1H), 7.63 (d, <i>J</i> = 6.2 Hz, 1H), 7.47 (s, 1H), 7.39 (s, 2H), 7.27 (s, 1H), 7.19 (s, 1H), 7.12 (s, 1H), 6.65 (s, 1H), 5.30 (d, <i>J</i> = 16.8 Hz, 4H), 4.88 (s, 1H), 4.21 (s, 1H), 3.94 (d, <i>J</i> = 12.4 Hz, 1H), 3.80 (d, <i>J</i> = 12.9 Hz, 1H), 3.52 (s, 2H), 2.92 (s, 1H), 2.68 (s, 1H), 2.31 (s, 3H), 1.85 (s, 1H), 0.86 (s, 1H). MS: <i>m</i>/<i>z</i> = 584.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.757 min, purity 96.1%.</div></div><div id="sec4_1_1_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> (5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-4-yl)benzyl)oxy)benzyl)-<i>D</i>-serine (<b>NT16</b>)</h5><div class="NLM_p last"><b>NT16</b> was prepared from <b>12d</b> in a similar manner as described for <b>NT1</b>, with <i>D</i>-serine replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (6 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.74 (s, 1H), 8.67 (s, 1H), 8.01 (s, 1H), 7.91 (s, 1H), 7.83 (s, 1H), 7.63 (s, 1H), 7.53 (d, <i>J</i> = 12.8 Hz, 1H), 7.39 (s, 2H), 7.31 (d, <i>J</i> = 29.6 Hz, 1H), 7.19 (s, 1H), 7.13 (s, 1H), 6.65 (s, 1H), 5.30 (d, <i>J</i> = 12.0 Hz, 4H), 3.96 (s, 2H), 3.69 (s, 1H), 3.63 (s, 1H), 3.52 (s, 1H), 3.17 (s, 1H), 2.31 (s, 3H). MS: <i>m</i>/<i>z</i> = 558.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.739 min, purity 98.2%.</div></div><div id="sec4_1_1_2_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> (5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-4-yl)benzyl)oxy)benzyl)-<i>D</i>-threonine (<b>NT17</b>)</h5><div class="NLM_p last"><b>NT17</b> was prepared from <b>12d</b> in a similar manner as described for <b>NT1</b>, with <i>D</i>- threonine replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (8 mg, yield 16%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.75 (s, 1H), 8.67 (s, 1H), 8.00 (s, 1H), 7.90 (s, 1H), 7.83 (s, 1H), 7.63 (s, 1H), 7.55 (s, 1H), 7.50 (s, 1H), 7.38 (s, 1H), 7.27 (s, 1H), 7.19 (s, 1H), 7.12 (s, 1H), 6.65 (s, 1H), 5.31 (s, 4H), 3.87 (s, 3H), 3.52 (s, 1H), 2.31 (s, 3H), 1.13 (d, J = 6.5 Hz, 3H). MS: <i>m</i>/<i>z</i> = 572.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.754 min, purity 95.8%.</div></div><div id="sec4_1_1_2_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> (<i>R</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-4-yl)benzyl)oxy)benzyl)piperidine-2-carboxylic Acid (<b>NT18</b>)</h5><div class="NLM_p last"><b>NT18</b> was prepared from <b>12d</b> in a similar manner as described for <b>NT1</b>, with (<i>R</i>)-piperidine-2-carboxylic acid replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (7 mg, yield 15%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.75 (d, <i>J</i> = 5.9 Hz, 1H), 8.66 (d, <i>J</i> = 3.6 Hz, 1H), 7.96 (s, 1H), 7.91 (d, <i>J</i> = 6.1 Hz, 1H), 7.83 (s, 2H), 7.64 (d, <i>J</i> = 7.8 Hz, 1H), 7.61–7.51 (m, 1H), 7.43 (s, 1H), 7.39–7.33 (m, 2H), 7.26 (d, <i>J</i> = 7.8 Hz, 1H), 7.10 (s, 1H), 5.28 (d, <i>J</i> = 12.0 Hz, 4H), 3.76 (d, <i>J</i> = 13.7 Hz, 1H), 3.63 (d, <i>J</i> = 13.8 Hz, 1H), 3.51 (s, 1H), 3.17 (s, 1H), 2.89 (s, 1H), 2.28 (d, <i>J</i> = 21.4 Hz, 4H), 1.77 (d, <i>J</i> = 18.7 Hz, 2H), 1.49 (s, 3H), 1.38 (s, 1H). HRMS (ESI) for C<sub>34</sub>H<sub>32</sub>ClN<sub>3</sub>O<sub>4</sub> [M + H]<sup>+</sup>, calcd: 582.2154, found: 582.2153. [M - H]<sup>−</sup>, calcd: 580.1998, found: 580.1995. MS: <i>m</i>/<i>z</i> = 582.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.764 min, purity 98.2%.</div></div><div id="sec4_1_1_2_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> (5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-4-yl)benzyl)oxy)benzyl)-<i>L</i>-serine (<b>NT19</b>)</h5><div class="NLM_p last"><b>NT19</b> was prepared from <b>12d</b> in a similar manner as described for <b>NT1</b>, with <i>L</i>-serine replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (8 mg, yield 18%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.74 (s, 1H), 8.67 (s, 1H), 8.01 (s, 1H), 7.91 (s, 1H), 7.84 (d, <i>J</i> = 7.5 Hz, 1H), 7.63 (s, 1H), 7.51 (s, 1H), 7.37 (d, <i>J</i> = 21.4 Hz, 2H), 7.27 (s, 1H), 7.19 (s, 1H), 7.14 (s, 1H), 6.65 (s, 1H), 5.30 (d, <i>J</i> = 12.8 Hz, 4H), 3.96 (s, 2H), 3.70 (d, <i>J</i> = 4.2 Hz, 1H), 3.63 (s, 1H), 3.17 (s, 1H), 2.31 (s, 3H). MS: <i>m</i>/<i>z</i> = 558.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.748 min, purity 95.5%.</div></div><div id="sec4_1_1_2_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> 2-((5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-4-yl)benzyl)oxy)benzyl)amino)-2-methylpropanoic Acid (<b>NT20</b>)</h5><div class="NLM_p last"><b>NT20</b> was prepared from <b>12d</b> in a similar manner as described for <b>NT1</b>, with 2-amino-2-methylpropanoic acid replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (9 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.75 (s, 1H), 8.67 (s, 1H), 8.02 (s, 1H), 7.90 (s, 1H), 7.84 (d, <i>J</i> = 8.9 Hz, 1H), 7.64 (d, <i>J</i> = 7.7 Hz, 1H), 7.56 (s, 1H), 7.38 (s, 1H), 7.34 (s, 1H), 7.27 (s, 1H), 7.20 (s, 1H), 7.12 (s, 1H), 6.66 (s, 1H), 5.34 (s, 2H), 5.30 (s, 2H), 3.86 (s, 2H), 2.26 (s, 3H), 1.26 (s, 6H). MS: <i>m</i>/<i>z</i> = 556.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.755 min, purity 96.6%.</div></div><div id="sec4_1_1_2_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> 1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-3-(pyridin-4-yl)benzyl)oxy)benzyl)piperidine-2-carboxylic Acid (<b>NT21</b>)</h5><div class="NLM_p last"><b>NT21</b> was prepared from <b>12d</b> in a similar manner as described for <b>NT1</b>, with piperidine-2-carboxylic acid replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (6 mg, yield 15%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.75 (d, <i>J</i> = 5.4 Hz, 1H), 8.66 (d, <i>J</i> = 4.6 Hz, 1H), 7.96 (s, 1H), 7.91 (d, <i>J</i> = 6.1 Hz, 1H), 7.83 (s, 2H), 7.65 (s, 1H), 7.56 (d, <i>J</i> = 7.9 Hz, 1H), 7.43 (s, 1H), 7.38 (d, <i>J</i> = 5.4 Hz, 1H), 7.35 (s, 1H), 7.26 (d, <i>J</i> = 7.5 Hz, 1H), 7.10 (s, 1H), 5.28 (d, <i>J</i> = 12.0 Hz, 4H), 3.78 (s, 1H), 3.61 (s, 1H), 3.51 (s, 1H), 3.17 (s, 1H), 2.91 (s, 1H), 2.31 (s, 1H), 2.26 (s, 3H), 1.76 (d, <i>J</i> = 18.0 Hz, 2H), 1.49 (s, 3H), 1.38 (d, <i>J</i> = 3.0 Hz, 1H). MS: <i>m</i>/<i>z</i> = 582.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.763 min, purity 97.4%.</div></div><div id="sec4_1_1_2_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> 3-((4-Chloro-2-(((2-hydroxyethyl)amino)methyl)-5-((2-methyl-3-(pyridin-4-yl)benzyl)oxy)phenoxy)methyl)benzonitrile (<b>NT22</b>)</h5><div class="NLM_p last"><b>NT22</b> was prepared from <b>12d</b> in a similar manner as described for <b>NT1</b>, with 2-aminoethan-1-ol replacing (<i>S</i>)-piperidine-2-carboxylic acid. Yellow oil (8 mg, yield 17%). <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.67 (s, 2H), 7.96 (s, 1H), 7.84 (d, <i>J</i> = 7.8 Hz, 2H), 7.67–7.60 (m, 1H), 7.56 (d, <i>J</i> = 7.1 Hz, 1H), 7.39 (s, 2H), 7.26 (d, <i>J</i> = 7.4 Hz, 1H), 7.19 (s, 1H), 7.10 (s, 1H), 6.66 (s, 1H), 5.28 (d, <i>J</i> = 9.7 Hz, 4H), 3.71 (s, 2H), 3.47 (s, 2H), 2.58 (s, 2H), 2.26 (s, 3H). MS: <i>m</i>/<i>z</i> = 514.1 [M+1]<sup>+</sup>. LCMS: <i>t</i><sub>R</sub> 0.735 min, purity 96.2%.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> <i>In Vitro</i> PD-1/PD-L1 Binding Assay</h3><div class="NLM_p last">The ability of compounds in inhibition of PD-1/PD-L1 interaction was investigated using a PD-1/PD-L1 homogenous time-resolved fluorescence (HTRF) binding assay. The PD-1/PD-L1 binding assay kits (64ICP01PEG&64ICP01PEH) were purchased from <i>Cisbio</i>. The experiments were performed according to the instruction manual which could be downloaded at <a href="https://www.cisbio.com/usa/drug-discovery/human-pd1pd-l1-biochemical-interaction-assay" class="extLink">https://www.cisbio.com/usa/drug-discovery/human-pd1pd-l1-biochemical-interaction-assay</a>.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Determination of IFN-γ Release</h3><div class="NLM_p last">The Tumor/T cell coculture assay was conducted by ChemPartner. Briefly, Hep3B cells were engineered to stably express OS-8 (anti-CD3 single chain variable fragment) and human PD-L1 (hPD-L1). Fresh PBMCs were isolated from healthy donor by density gradient centrifugation. CD3 T cells were isolated from fresh PBMCs by EasySep Human T Cell Isolation Kit (negative selection, STEMCELL Technologies). Hep3B-OS8-hPDL1 cells were harvested and treated with 10 μg/mL mitomycin C at 37 °C for 1.5 h and washed 4 times with PBS. Hep3B-OS8-hPDL1 and T cells (2.5 × 10<sup>4</sup> in 50 μL and 5 × 10<sup>4</sup> in 100 μL complete media, respectively) were added to the 96-well plates, followed by the addition of 4× final concentration of test compound in 50 μL complete media according to the plate map, and coculture at 37 °C, 5% CO<sub>2</sub> incubator for 72 h. The supernatants (150 μL) were harvested after 72 h of coculture to determine IFN-γ levels by ELISA.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> Pharmacokinetic Study in Male Sprague–Dawley Rats</h3><div class="NLM_p last">All experimental procedures and protocols were reviewed and approved by the National Institutional Animal Care and Ethical Committee of Southern Medical University and were in accordance with the Guide for the Care and Use of Laboratory Animals. Male Sprague–Dawley rats (200–220 g) were obtained from SPF (Beijing) Biotechnology Co., Ltd. to study the pharmacokinetics of compound <b>NP19</b>. Diet was prohibited for 12 h before the experiment, but water was freely available. Blood samples (0.3 mL) were collected from the tail vein into heparinized 1.5 mL polythene tubes at 0.0833, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, and 24 h after oral (10 mg/kg) or intravenous (1 mg/kg) administration of compound <b>NP19</b>. The compound was dissolved in 5% DMSO and 95% PEG-300 for intravenous administration or suspended in 0.5% sodium carboxymethyl cellulose (CMC-Na) for oral administration. The samples were immediately centrifuged at 3000<i>g</i> for 10 min. The plasma as-obtained (100 μL) was stored at −20 °C until analysis. PK parameters were determined from individual animal data using noncompartmental analysis in DAS (Drug and statistics) software. Instruments and analytical conditions for PK studies: A UPLC-MS/MS system with ACQUITY I-Class UPLC and a XEVO TQD triple quadrupole mass spectrometer (Waters Corp., Milford, MA, USA), equipped with an electrospray ionization (ESI) interface, was used to analyze the blood samples. The UPLC system was comprised of a Binary Solvent Manager (BSM) and a Sample Manager with Flow-Through Needle (SM-FTN). Masslynx 4.1 software (Waters Corp.) was used for data acquisition and instrument control. Multiple reaction monitoring (MRM) modes of <i>m</i>/<i>z</i> 555.35 → 181.03 for NP19 and <i>m</i>/<i>z</i> 237 → 194.1 for carbamazepine were utilized to conduct quantitative analysis.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> <i>In Vivo</i> Efficacy Study in Mouse B16F10 Melanoma Model</h3><div class="NLM_p last">The animal procedures were carried out with the approval of the National Institutional Animal Care and Ethical Committee of Southern Medical University. BALB/c mice from SPF (Beijing) Biotechnology Co., Ltd., aged 6–8 weeks old, were used to study the inhibition effect of <b>NP19</b> on subcutaneous transplanted model of melanoma cells. Murine B16F10 melanoma cells growing in a logarithmic growth phase were suspended in PBS at a density of 2 × 10<sup>6</sup> per mL. Each mouse was inoculated subcutaneously with 200 μL containing 4 × 10<sup>5</sup> cells. After tumors reached approximately 100 mm<sup>3</sup> in volume, mice were divided into four groups randomly (<i>n</i> = 10) and treated with <b>NP19</b> (25, 50, 100 mg/kg) and vehicle, respectively. The drugs were administered via intragastric gavage once a day for 15 days. The vehicle group was administered with 0.5% sodium carboxymethyl cellulose (CMC-Na). Animal activity and body weight were monitored during the entire experiment period to assess acute toxicity. Mice were sacrificed 16 days after the initiation of the treatment, and the tumor tissue and major organ (liver, spleen, thymus, and kidney) samples were collected. The harvested tumor tissue and organs (liver, kidney) were fixed in 4% paraformaldehyde, processed into paraffin routinely, stained with hematoxylin and eosin (H&E), and captured by microscope. Tumor growth inhibition value (TGI) was calculated using the formula: TGI(%) = [1 – Wt/Wv] × 100%, where Wt and Wv are the mean tumor weight of treatment group and vehicle control.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> <i>In Vivo</i> Efficacy Study in Mouse H22 Hepatoma Tumor Model</h3><div class="NLM_p last">6–8 weeks old male BALB/c mice were purchased from SPF (Beijing) Biotechnology Co., Ltd. A total of 8 × 10<sup>5</sup> H22 cells were inoculated into the right flank of each mouse according to protocols of tumor transplant research. NP19 was dissolved in 5% DMSO, 40% PEG-200 and 55% saline solution to produce desired concentrations. Mice in control groups were injected intraperitoneally with 200 μL of vehicle solution only. Tumor volume was measured every 2 days with a traceable electronic digital caliper and calculated using the formula <i>a</i> × <i>b</i><sup>2</sup> × 0.5, where <i>a</i> and <i>b</i> represented the larger and smaller diameters, respectively. The mice were sacrificed after the treatments and tumors were excised and weighed.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> <i>In Vitro</i> Antiproliferative Assay</h3><div class="NLM_p last">The cytotoxicity of the test compounds was determined using the MTT assay. Briefly, the cell lines were incubated at 37 °C in a humidified 5% CO<sub>2</sub> incubator for 24 h in 96-microwell plates. Then, 100 μL of culture medium with 0.1% DMSO containing the test compounds at different concentrations was added to each well and incubated at 37 °C for another 48 h. The MTT (5 mg/10 mL in PBS) was added and incubated for another 4 h, and the optical density was detected with a microplate reader at 570 nm. The IC<sub>50</sub> values were calculated according to the dose-dependent curves.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> Mouse PD-1:PD-L1 ELISA Assay</h3><div class="NLM_p last">The mouse PD-1:PD-L1 ELISA assay was conducted by BPS Bioscience Inc. (San Diego, CA). Ten μL of compound solutions were preincubated with 20 μL of 1X mouse PD-1 assay buffer in assay wells before starting the reaction by the addition of 20 μL of 5 ng/μL mouse PD-1[Biotin]. Reaction was progressed for 2 h at room temperature. Then, wells were washed three times with 1X mouse PD-1 assay buffer and blocked with blocking buffer for 10 min. 100 μL of streptavidin-HRP was added to all wells and incubated for 1 h. Lastly, the plate was emptied, washed three times, and blocked before the addition of 100 μL of freshly prepared HRP chemiluminescent substrates to every well. Immediately, the luminescence of the samples was measured in a BioTek Synergy 2 microplate reader.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> Flow Cytometry</h3><div class="NLM_p last">Organs of mice were harvested and cells were isolated by mechanical dissociation using 40 μm cell strainers. Red blood cells were lysed by ACK lysis buffer (Beyotime). Cells were stained for 30 min at 4 °C for flow cytometry using antibodies against following targets and isotype controls, both obtained from BioLegend if not otherwise specified: FITC antimouse CD3 Antibody (Cat No: 100204, LOT: B249620), APC antimouse CD8a antibody (Cat No: 100711, LOT: B280032), PE antimouse CD4 Antibody (Cat No: 100407, LOT: B266389), PD-L1 (D5 V3B) Rabbit mAb (Mouse Specific, 64988T, TS-201904-388, CST), Anti-Rabbit-IgG H&L (Alexa Fluor488) Antibody (ab150077, Lot: GR3225145-2, Abcam). Flow cytometry for murine cells was performed on a BD AccuriC6 and data was analyzed using FlowJo (Tree Star v7.6.1).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> Statistical Analysis</h3><div class="NLM_p last">Data was analyzed using Prism Software 5.0. Data was provided as mean ± SD unless otherwise indicated. The statistical significance (<i>P</i> < 0.05) was calculated by one-way analysis of variance (ANOVA).</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> Molecular Docking</h3><div class="NLM_p last">Molecular graphic manipulations and visualizations were performed using Glide 7.4. X-ray structures of three different PD-L1 cocrystals were retrieved from the PDB (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89">5J89</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIX">5NIX</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIU">5NIU</a>) and prepared using the Protein Preparation Wizard from the Schrödinger suite. Ligands were created, as appropriate, with multiple protonation and tautomeric states.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i105"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00574" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00574?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00574</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H NMR, <sup>13</sup>C NMR, and LCMS spectra, as well as figures generated from pharmacokinetic studies (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">(<a href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_002.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_001.pdf">jm0c00574_si_001.pdf (14.54 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_002.pdb">jm0c00574_si_002.pdb (727.34 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_003.csv">jm0c00574_si_003.csv (9.38 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00574" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86278" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86278" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianjun Chen</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of
New Drug Screening, Southern Medical University, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5668-6572" title="Orcid link">http://orcid.org/0000-0001-5668-6572</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2248414a474c101362514f570c4746570c414c"><span class="__cf_email__" data-cfemail="214b4249444f131061524c540f4445540f424f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Binbin Cheng</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of
New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yichang Ren</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of
New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoge Niu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of
New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Wang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of
New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuanghu Wang</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of
New Drug Screening, Southern Medical University, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0057-267X" title="Orcid link">http://orcid.org/0000-0002-0057-267X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingfeng Tu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of
New Drug Screening, Southern Medical University, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2605-0172" title="Orcid link">http://orcid.org/0000-0003-2605-0172</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuwen Liu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of
New Drug Screening, Southern Medical University, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6346-5006" title="Orcid link">http://orcid.org/0000-0001-6346-5006</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jin Wang</span> - <span class="hlFld-Affiliation affiliation">AbbVie
Inc., North Chicago, Illinois 60064, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deying Yang</span> - <span class="hlFld-Affiliation affiliation">Joint
Laboratory for Translational Cancer Research of Chinese Medicine of
the Ministry of Education of the People’s Republic of China,
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guochao Liao</span> - <span class="hlFld-Affiliation affiliation">Joint
Laboratory for Translational Cancer Research of Chinese Medicine of
the Ministry of Education of the People’s Republic of China,
International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i106">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26035" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26035" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by scientific research project of high level talents (No. C1051008) in Southern Medical University of China; Thousand Youth Talents Program (No. C1080092) from the Organization Department of the CPC Central Committee, China; and International Science and Technology Cooperation Projects of Guangdong Province (No. G819310411).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed cell death-1</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed cell death-ligand 1</p></td></tr><tr><td class="NLM_term">PD-L2</td><td class="NLM_def"><p class="first last">programmed cell death-ligand 2</p></td></tr><tr><td class="NLM_term">mAbs</td><td class="NLM_def"><p class="first last">monoclonal antibodies</p></td></tr><tr><td class="NLM_term">FCM</td><td class="NLM_def"><p class="first last">flow cytometry</p></td></tr><tr><td class="NLM_term">H&E</td><td class="NLM_def"><p class="first last">hematoxylin and eosin</p></td></tr><tr><td class="NLM_term">SARs</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">TILs</td><td class="NLM_def"><p class="first last">tumor-infiltrating lymphocytes</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i108">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11227" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11227" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 48 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giroux
Leprieur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumenil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumoulin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinet, T.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2016.12.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.ejca.2016.12.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28407528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1WitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2017&pages=16-23&author=E.+Giroux%0ALeprieurauthor=C.+Dumenilauthor=C.+Julieauthor=V.+Giraudauthor=J.+Dumoulinauthor=S.+Labruneauthor=T.+Chinet&title=Immunotherapy+revolutionises+non-small-cell+lung+cancer+therapy%3A+results%2C+perspectives+and+new+challenges&doi=10.1016%2Fj.ejca.2016.12.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges</span></div><div class="casAuthors">Giroux Leprieur, Etienne; Dumenil, Coraline; Julie, Catherine; Giraud, Violaine; Dumoulin, Jennifer; Labrune, Sylvie; Chinet, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16-23</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors (ICIs) are antibodies that target key signalling pathways such as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to improve anti-tumor immune responses.  Until recently, nivolumab was the only ICI validated for advanced non-small-cell lung cancer (NSCLC) in a second-line treatment setting.  Results from recent phase II and phase III randomised trials testing other ICIs have been presented.  In Keynote-024, pembrolizumab, an anti-PD1 antibody, was reported to have great efficacy in the first-line treatment of PDL1 ≥ 50% tumors (30% of screened tumors), with a progression-free survival (PFS, median) of 10.4 mo vs. 6.0 mo with chemotherapy (CT; hazard ratio [HR] = 0.50; 95% confidence interval [95% CI] 0.37-0.68, P < 0.001), overall response rate (ORR) of 45% vs. 28% with CT (P = 0.0011), and a 1-yr overall survival (OS) of around 70%.  In contrast, Checkmate-026 reported that nivolumab failed to show any benefit compared with std. platinum-based CT, with a PFS (median) in the PDL1 ≥ 5% NSCLC group of 4.2 mo (nivolumab) vs. 5.9 mo (CT; HR = 1.15: 95% CI 0.91-1.45, P = 0.25).  No benefit was obsd. in the PDL1 ≥ 50% subgroup.  An encouraging report of the efficacy of pembrolizumab in addn. to CT in first-line treatment in unselected NSCLC was also presented (Keynote-021) with an ORR of 55% vs. 29% with CT alone (P = 0.0016).  Atezolizumab, an anti-PDL1 antibody, showed efficacy for second-line treatment compared with docetaxel (OAK phase III study) with an OS (median) of 13.8 mo vs. 9.6 mo with docetaxel.  These results suggest a new paradigm for the treatment of advanced NSCLC using pembrolizumab for the first-line treatment of PDL1 ≥ 50% tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBggcFpUUyMrVg90H21EOLACvtfcHk0lgIiiuJ_UUyHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1WitL0%253D&md5=579dfdb1eac14da9a8504517986df41c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2016.12.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2016.12.041%26sid%3Dliteratum%253Aachs%26aulast%3DGiroux%2BLeprieur%26aufirst%3DE.%26aulast%3DDumenil%26aufirst%3DC.%26aulast%3DJulie%26aufirst%3DC.%26aulast%3DGiraud%26aufirst%3DV.%26aulast%3DDumoulin%26aufirst%3DJ.%26aulast%3DLabrune%26aufirst%3DS.%26aulast%3DChinet%26aufirst%3DT.%26atitle%3DImmunotherapy%2520revolutionises%2520non-small-cell%2520lung%2520cancer%2520therapy%253A%2520results%252C%2520perspectives%2520and%2520new%2520challenges%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2017%26volume%3D78%26spage%3D16%26epage%3D23%26doi%3D10.1016%2Fj.ejca.2016.12.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, W.</span></span> <span> </span><span class="NLM_article-title">The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge</span>. <i>Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=185-191&author=W.+Alexander&title=The+checkpoint+immunotherapy+revolution%3A+what+started+as+a+trickle+has+become+a+flood%2C+despite+some+daunting+adverse+effects%3B+new+drugs%2C+indications%2C+and+combinations+continue+to+emerge"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DW.%26atitle%3DThe%2520checkpoint%2520immunotherapy%2520revolution%253A%2520what%2520started%2520as%2520a%2520trickle%2520has%2520become%2520a%2520flood%252C%2520despite%2520some%2520daunting%2520adverse%2520effects%253B%2520new%2520drugs%252C%2520indications%252C%2520and%2520combinations%2520continue%2520to%2520emerge%26jtitle%3DPharm.%2520Ther.%26date%3D2016%26volume%3D41%26spage%3D185%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy: harnessing the immune system to battle cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3335</span>– <span class="NLM_lpage">3337</span>, <span class="refDoi"> DOI: 10.1172/JCI83871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1172%2FJCI83871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=26325031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A280%3ADC%252BC287otVersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3335-3337&author=Y.+Yang&title=Cancer+immunotherapy%3A+harnessing+the+immune+system+to+battle+cancer&doi=10.1172%2FJCI83871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy: harnessing the immune system to battle cancer</span></div><div class="casAuthors">Yang Yiping</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3335-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer immunotherapy.  These successes also underscore the importance of understanding basic tumor immunology for successful clinical translation in treating patients with cancer.  The Reviews in this Review Series focus on current developments in cancer immunotherapy, highlight recent advances in our understanding of basic aspects of tumor immunology, and suggest how these insights can lead to the development of new immunotherapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCDsEQcCnxNc25P7XSLhESfW6udTcc2ea_FjRdUJQI-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287otVersw%253D%253D&md5=5a53437eb397adb28804ede24b04c8cf</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1172%2FJCI83871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI83871%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26atitle%3DCancer%2520immunotherapy%253A%2520harnessing%2520the%2520immune%2520system%2520to%2520battle%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D3335%26epage%3D3337%26doi%3D10.1172%2FJCI83871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span> <span> </span><span class="NLM_article-title">Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2014.174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnrclinonc.2014.174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=25311350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A280%3ADC%252BC2M7pvFOrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=630-632&author=S.+A.+Rosenberg&title=Decade+in+review-cancer+immunotherapy%3A+entering+the+mainstream+of+cancer+treatment&doi=10.1038%2Fnrclinonc.2014.174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment</span></div><div class="casAuthors">Rosenberg Steven A</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">630-2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTqtYSUle6TmBAiYWy6n3SfW6udTcc2ea_FjRdUJQI-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7pvFOrug%253D%253D&md5=f28ea9cae64fbddd396fecbcaf063276</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.174%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DDecade%2520in%2520review-cancer%2520immunotherapy%253A%2520entering%2520the%2520mainstream%2520of%2520cancer%2520treatment%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D630%26epage%3D632%26doi%3D10.1038%2Fnrclinonc.2014.174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span> <span> </span><span class="NLM_article-title">Small-molecule targets in immuno-oncology</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1148</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.chembiol.2017.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28938090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1148-1160&author=D.+Dhanakauthor=J.+P.+Edwardsauthor=A.+Nguyenauthor=P.+J.+Tummino&title=Small-molecule+targets+in+immuno-oncology&doi=10.1016%2Fj.chembiol.2017.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Targets in Immuno-Oncology</span></div><div class="casAuthors">Dhanak, Dashyant; Edwards, James P.; Nguyen, Ancho; Tummino, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1148-1160</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advances in understanding the role and mol. mechanisms underlying immune surveillance and control of (pre)malignancies is revolutionizing clin. practice in the treatment of cancer.  Presently, multiple biol. drugs targeting the immune checkpoint proteins PD(L)1 or CTLA4 have been approved and/or are in advanced stages of clin. development for many cancers.  In addn., combination therapy with these agents and other immunomodulators is being intensively explored with the aim of improving primary response rates or prolonging overall survival.  The effectiveness of cancer immunotherapy with biologics is spurring research in alternate approaches including small-mol.-mediated targeting of intracellular pathways modulating the innate and adaptive immune response.  This focus of this review is on some of the key intracellular pathways where the development of a small-mol. therapeutic is attractive, tractable, and potentially synergistic with extracellular biol.-mediated immune checkpoint blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSIXjWBbl9wbVg90H21EOLACvtfcHk0lir2WYP4bopIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurnL&md5=7f0f2368bec10000a87a3234bb82c035</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DNguyen%26aufirst%3DA.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26atitle%3DSmall-molecule%2520targets%2520in%2520immuno-oncology%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D1148%26epage%3D1160%26doi%3D10.1016%2Fj.chembiol.2017.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Transcriptional activation of PD-L1 by sox2 contributes to the proliferation of hepatocellular carcinoma cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3061</span>– <span class="NLM_lpage">3067</span>, <span class="refDoi"> DOI: 10.3892/or.2017.5523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.3892%2For.2017.5523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28339084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVOhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=3061-3067&author=F.+Zhongauthor=X.+Chengauthor=S.+Sunauthor=J.+Zhou&title=Transcriptional+activation+of+PD-L1+by+sox2+contributes+to+the+proliferation+of+hepatocellular+carcinoma+cells&doi=10.3892%2For.2017.5523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells</span></div><div class="casAuthors">Zhong, Feng; Cheng, Xinsheng; Sun, Shibo; Zhou, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3061-3067</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies in the world.  Sox2 is a potential oncogene in the pathogenesis of HCC, however, the actual mechanisms of Sox2 functions in HCC has not emerged yet.  In this study, we explored the expression, function and the relationship between Sox2 and PD-L1 in HCC.  We found that both Sox2 and PD-L1 were expressed at a markedly higher level in HCC tissues in comparison to adjacent non-tumor tissues.  Moreover, the expression levels of both genes were correlated with each other.  Knockdown of Sox2 reduced the cell proliferation ability and induces apoptosis of HCC cells, suggesting the function of Sox2 in regulating both the cell proliferation and apoptosis.  Noteworthy, the depletion of Sox2 also reduced the expression of PD-L1.  Further anal. showed that there is a consensus Sox2 binding site in the promoter region of PD-L1.  Through in vitro EMSA assay and in vivo chromatin immunopptn. assays, we demonstrated that Sox2 directly bound to the PD-L1 promoter through the consensus Sox2 motif.  Further evidence by luciferase reporter assays revealed that Sox2 promoted the transcription activity of PD-L1 promoter region through the Sox2 motif.  Collectively, our data provide a novel insight into the function and the interplay of Sox2 and PD-L1 in HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPyoVYfudBKLVg90H21EOLACvtfcHk0lir2WYP4bopIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVOhsLk%253D&md5=9f3b11a3e650a52c402cb66bd8e4e7c9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3892%2For.2017.5523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2017.5523%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DTranscriptional%2520activation%2520of%2520PD-L1%2520by%2520sox2%2520contributes%2520to%2520the%2520proliferation%2520of%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DOncol.%2520Rep.%26date%3D2017%26volume%3D37%26spage%3D3061%26epage%3D3067%26doi%3D10.3892%2For.2017.5523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.07.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.canlet.2017.07.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28797844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlWks7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2017&pages=27-35&author=X.+Shiauthor=X.+Zhangauthor=J.+Liauthor=H.+Zhaoauthor=L.+Moauthor=X.+Shiauthor=Z.+Huauthor=J.+Gaoauthor=W.+Tan&title=PD-1%2FPD-L1+blockade+enhances+the+efficacy+of+SA-GM-CSF+surface-modified+tumor+vaccine+in+prostate+cancer&doi=10.1016%2Fj.canlet.2017.07.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer</span></div><div class="casAuthors">Shi, Xiaojun; Zhang, Xinji; Li, Jinlong; Zhao, Hongfan; Mo, Lijun; Shi, Xianghua; Hu, Zhiming; Gao, Jimin; Tan, Wanlong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-35</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Program death receptor-1 (PD-1)/program death ligand 1 (PD-L1) signaling plays an important role in tumor adaptive immune resistance.  The streptavidin-granulocyte-macrophage colony stimulating factor (SA-GM-CSF) surface-modified tumor cells vaccine developed through our novel protein-anchor technol. could significantly promote the activation of dendritic cells.  Although GM-CSF vaccine could significantly increase the no. of tumor-specific CD8+T-cells, the majority of these CD8+T-cells expressed PD-1.  Moreover, GM-CSF vaccine up-regulated the PD-L1 expression of tumor cells, resulting in immune resistance.  Adding PD-1/PD-L1 blockade to GM-CSF vaccine therapy could significantly increase the population of CD4+ T, CD8+ T and CD8+ IFN-γ+ T but not CD4+ Foxp3+ T-cells and induced the highest prodn. of IFN-γ.  PD-1/PD-L1 blockade could effectively rescue the tumor-specific T lymphocytes generated by the GM-CSF vaccine, resulting in consistent tumor rejection.  Taken together, PD-1/PD-L1 blockade combined with SA-GM-CSF-modified vaccine could effectively induce a strong specific antitumor immune response against prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow34npepjP1rVg90H21EOLACvtfcHk0lir2WYP4bopIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlWks7%252FF&md5=4d35b9568bae551a53cdb4792de551e1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.07.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.07.029%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMo%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DPD-1%252FPD-L1%2520blockade%2520enhances%2520the%2520efficacy%2520of%2520SA-GM-CSF%2520surface-modified%2520tumor%2520vaccine%2520in%2520prostate%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D406%26spage%3D27%26epage%3D35%26doi%3D10.1016%2Fj.canlet.2017.07.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span> <span> </span><span class="NLM_article-title">Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1753</span>– <span class="NLM_lpage">1763</span>, <span class="refDoi"> DOI: 10.1111/cas.13618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1111%2Fcas.13618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=29675979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvFWmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=1753-1763&author=Z.+Chenauthor=K.+Huauthor=L.+Fengauthor=R.+Suauthor=N.+Laiauthor=Z.+Yangauthor=S.+Kang&title=Senescent+cells+re-engineered+to+express+soluble+programmed+death+receptor-1+for+inhibiting+programmed+death+receptor-1%2Fprogrammed+death+ligand-1+as+a+vaccination+approach+against+breast+cancer&doi=10.1111%2Fcas.13618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer</span></div><div class="casAuthors">Chen, Zehong; Hu, Kang; Feng, Lieting; Su, Ruxiong; Lai, Nan; Yang, Zike; Kang, Shijun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1753-1763</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Various types of vaccines have been proposed as approaches for prevention or delay of the onset of cancer by boosting the endogenous immune system.  We previously developed a senescent-cell-based vaccine, induced by radiation and veliparib, as a preventive and therapeutic tool against triple-neg. breast cancer.  However, the programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) pathway was found to play an important role in vaccine failure.  Hence, we further developed sol. programmed death receptor-1 (sPD1)-expressing senescent cells to overcome PD-L1/PD-1-mediated immune suppression while vaccinating to promote dendritic cell (DC) maturity, thereby amplifying T-cell activation.  In the present study, sPD1-expressing senescent cells showed a particularly active status characterized by growth arrest and modified immunostimulatory cytokine secretion in vitro.  As expected, sPD1-expressing senescent tumor cell vaccine (STCV/sPD-1) treatment attracted more mature DC and fewer exhausted-PD1+ T cells in vivo.  During the course of the vaccine studies, we obsd. greater safety and efficacy for STCV/sPD-1 than for control treatments.  STCV/sPD-1 pre-injections provided complete protection from 4T1 tumor challenge in mice.  Addnl., the in vivo therapeutic study of mice with s.c. 4T1 tumor showed that STCV/sPD-1 vaccination delayed tumorigenesis and suppressed tumor progression at early stages.  These results showed that STCV/sPD-1 effectively induced a strong antitumor immune response against cancer and suggested that it might be a potential strategy for TNBC prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1aoZrIsOQ_7Vg90H21EOLACvtfcHk0liftP1mfbrjDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvFWmuro%253D&md5=dc9f8ab8a29bf8f8c8ca330ecdc2a6a9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fcas.13618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13618%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DKang%26aufirst%3DS.%26atitle%3DSenescent%2520cells%2520re-engineered%2520to%2520express%2520soluble%2520programmed%2520death%2520receptor-1%2520for%2520inhibiting%2520programmed%2520death%2520receptor-1%252Fprogrammed%2520death%2520ligand-1%2520as%2520a%2520vaccination%2520approach%2520against%2520breast%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2018%26volume%3D109%26spage%3D1753%26epage%3D1763%26doi%3D10.1111%2Fcas.13618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardhan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anagnostou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussiotis, V. A.</span></span> <span> </span><span class="NLM_article-title">The PD-1:PD-L1/2 pathway from discovery to clinical implementation</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">Article 550</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2016.00550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.3389%2Ffimmu.2016.00550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=26834743" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1-17&issue=Article+550&author=K.+Bardhanauthor=T.+Anagnostouauthor=V.+A.+Boussiotis&title=The+PD-1%3APD-L1%2F2+pathway+from+discovery+to+clinical+implementation&doi=10.3389%2Ffimmu.2016.00550"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2016.00550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2016.00550%26sid%3Dliteratum%253Aachs%26aulast%3DBardhan%26aufirst%3DK.%26aulast%3DAnagnostou%26aufirst%3DT.%26aulast%3DBoussiotis%26aufirst%3DV.%2BA.%26atitle%3DThe%2520PD-1%253APD-L1%252F2%2520pathway%2520from%2520discovery%2520to%2520clinical%2520implementation%26jtitle%3DFront.%2520Immunol.%26date%3D2016%26volume%3D7%26issue%3DArticle%2520550%26spage%3D1%26epage%3D17%26doi%3D10.3389%2Ffimmu.2016.00550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2286</span>– <span class="NLM_lpage">2288</span>, <span class="refDoi"> DOI: 10.1002/anie.201307906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1002%2Fanie.201307906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A280%3ADC%252BC2czpvVOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=2286-2288&author=A.+Domlingauthor=T.+A.+Holak&title=Programmed+death-1%3A+therapeutic+success+after+more+than+100+years+of+cancer+immunotherapy&doi=10.1002%2Fanie.201307906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy</span></div><div class="casAuthors">Domling Alexander; Holak Tad A</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2286-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related.  Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies.  Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8kC5nL6VwzPcsfMJQC1ZdfW6udTcc2ea6oNqZTK4cTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czpvVOhuw%253D%253D&md5=907c71bc856c102a3d93600aac71a2ea</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307906%26sid%3Dliteratum%253Aachs%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DProgrammed%2520death-1%253A%2520therapeutic%2520success%2520after%2520more%2520than%2520100%2520years%2520of%2520cancer%2520immunotherapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D2286%26epage%3D2288%26doi%3D10.1002%2Fanie.201307906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint blockade: a common denominator approach to cancer therapy</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.ccell.2015.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=25858804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVaku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=450-461&author=S.+L.+Topalianauthor=C.+G.+Drakeauthor=D.+M.+Pardoll&title=Immune+checkpoint+blockade%3A+a+common+denominator+approach+to+cancer+therapy&doi=10.1016%2Fj.ccell.2015.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy</span></div><div class="casAuthors">Topalian, Suzanne L.; Drake, Charles G.; Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">450-461</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands.  These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction.  Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions.  The complex biol. of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb0YUggJYBrLVg90H21EOLACvtfcHk0liftP1mfbrjDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVaku7k%253D&md5=e42c02d50881184b78630e5dd23f7f2e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DImmune%2520checkpoint%2520blockade%253A%2520a%2520common%2520denominator%2520approach%2520to%2520cancer%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D450%26epage%3D461%26doi%3D10.1016%2Fj.ccell.2015.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassady, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span> <span> </span><span class="NLM_article-title">PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8<sup>+</sup> T cells</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1960</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1172/JCI91138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1172%2FJCI91138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28414296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A280%3ADC%252BC1cvotlShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=1960-1977&author=X.+Niauthor=Q.+Songauthor=K.+Cassadyauthor=R.+Dengauthor=H.+Jinauthor=M.+Zhangauthor=H.+Dongauthor=S.+Formanauthor=P.+J.+Martinauthor=Y.+Z.+Chenauthor=J.+Wangauthor=D.+Zeng&title=PD-L1+interacts+with+CD80+to+regulate+graft-versus-leukemia+activity+of+donor+CD8%2B+T+cells&doi=10.1172%2FJCI91138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells</span></div><div class="casAuthors">Ni Xiong; Song Qingxiao; Cassady Kaniel; Deng Ruishu; Jin Hua; Zhang Mingfeng; Dong Haidong; Forman Stephen; Martin Paul J; Chen Yuan-Zhong; Wang Jianmin; Zeng Defu</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1960-1977</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Programmed death ligand-1 (PD-L1) interacts with programmed death-1 (PD-1) and the immunostimulatory molecule CD80 and functions as a checkpoint to regulate immune responses.  The interaction of PD-L1 with CD80 alone has been shown to exacerbate the severity of graft-versus-host disease (GVHD), whereas costimulation of CD80 and PD-1 ameliorates GVHD.  Here we have demonstrated that temporary depletion of donor CD4+ T cells early after hematopoietic cell transplantation effectively prevents GVHD while preserving strong graft-versus-leukemia (GVL) effects in allogeneic and xenogeneic murine GVHD models.  Depletion of donor CD4+ T cells increased serum IFN-γ but reduced IL-2 concentrations, leading to upregulation of PD-L1 expression by recipient tissues and donor CD8+ T cells.  In GVHD target tissues, the interactions of PD-L1 with PD-1 on donor CD8+ T cells cause anergy, exhaustion, and apoptosis, thereby preventing GVHD.  In lymphoid tissues, the interactions of PD-L1 with CD80 augment CD8+ T cell expansion without increasing anergy, exhaustion, or apoptosis, resulting in strong GVL effects.  These results indicate that the outcome of PD-L1-mediated signaling in CD8+ T cells depends on the presence or absence of CD4+ T cells, the nature of the interacting receptor expressed by CD8+ T cells, and the tissue environment in which the signaling occurs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRj4Yk771GSWjDnmmyUf5qOfW6udTcc2eZl64As_XHws7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvotlShtQ%253D%253D&md5=39c5a3f1375dafd766a0ad4952f27dca</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1172%2FJCI91138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI91138%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DCassady%26aufirst%3DK.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DForman%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DD.%26atitle%3DPD-L1%2520interacts%2520with%2520CD80%2520to%2520regulate%2520graft-versus-leukemia%2520activity%2520of%2520donor%2520CD8%252B%2520T%2520cells%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D1960%26epage%3D1977%26doi%3D10.1172%2FJCI91138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span> <span> </span><span class="NLM_article-title">The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from nephritis</span>. <i>Am. J. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">379</span>, <span class="refDoi"> DOI: 10.1159/000480641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1159%2F000480641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=29069649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=371-379&author=W.+Liaoauthor=H.+Zhengauthor=S.+Wuauthor=Y.+Zhangauthor=W.+Wangauthor=Z.+Zhangauthor=C.+Zhouauthor=H.+Wuauthor=J.+Min&title=The+systemic+activation+of+programmed+death+1-PD-L1+axis+protects+systemic+lupus+erythematosus+model+from+nephritis&doi=10.1159%2F000480641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis</span></div><div class="casAuthors">Liao, Wenjun; Zheng, Hua; Wu, Sha; Zhang, Yanmei; Wang, Wei; Zhang, Zili; Zhou, Chenfei; Wu, Hongjun; Min, Jie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Nephrology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">371-379</span>CODEN:
                <span class="NLM_cas:coden">AJNED9</span>;
        ISSN:<span class="NLM_cas:issn">0250-8095</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Systemic lupus erythematosus (SLE) is characterized by abnormal activated T cells, autoreactive B cells, and massive cytokines.  The CD4+ T cells detd. B-cells differentiation and cytokines prodn.  The programmed death 1 (PD-1) is the checkpoint immunoinhibitory receptor of activated T cells, and its engagement could exhaust T cells.  In this study, we investigated the role of PD-1 systemic engagement with PD-L1-Ig in lupus-like nephritis in SLE mice.  Methods: The murine PD-L1-Ig was injected into SLE-prone mice.  The proteinuria and survival ratio were monitored.  The prodn. of anti-dsDNA autoantibodies and cytokines in serum were measured by ELISA.  The cytokine-producing T cells (interferon-γ, IFN-γ and IL-17α) in kidney and spleen were detected with flowcytometry.  The pathol. evaluation of the Ig deposition in the glomeruliand was detd. with immunofluorescence.  Lymphocytes in 24-h urine were detected with flowcytometry.  Results: The systemic administration of PD-L1-Ig activated PD-1-PD-L1 axis of CD4+ T lymphocytes, suppressed Th17 formation in many organs, including the spleen and the kidney, demolished abnormal prodn. of cytokines (IFN-γ, IL-17, and IL-10) and anti-dsDNA autoantibodies in serum, inhibited IgG deposition in the glomeruli with the decrease of proteinuria, and activated T cells in urine.  Accordingly, the systemic conjugation of PD-L1-PD-1 impaired renal autoimmune injure and prolonged survival time.  Conclusion: Our research demonstrated that the protective function of systemic activation of PD-1-PD-L1 axis with PD-L1-Ig attenuates the nephritis in SLE-prone mice, which facilitates us to understand the suppressive function of PD-1-PD-L1 axis in the pathogenesis and progress of the lupus nephritis, and to explore a possible effective therapeutic strategy to SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow--p2nB5yobVg90H21EOLACvtfcHk0lgGBAyieL9Y2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbvO&md5=c555ef6c1df4bfdf86d582877e357d98</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1159%2F000480641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000480641%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DMin%26aufirst%3DJ.%26atitle%3DThe%2520systemic%2520activation%2520of%2520programmed%2520death%25201-PD-L1%2520axis%2520protects%2520systemic%2520lupus%2520erythematosus%2520model%2520from%2520nephritis%26jtitle%3DAm.%2520J.%2520Nephrol.%26date%3D2017%26volume%3D46%26spage%3D371%26epage%3D379%26doi%3D10.1159%2F000480641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy: anti-PD-1 therapies-a new first-line option in advanced melanoma</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnrclinonc.2015.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=26416151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A280%3ADC%252BC283ms1Wmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=625-626&author=R.+J.+Sullivanauthor=K.+T.+Flaherty&title=Immunotherapy%3A+anti-PD-1+therapies-a+new+first-line+option+in+advanced+melanoma&doi=10.1038%2Fnrclinonc.2015.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma</span></div><div class="casAuthors">Sullivan Ryan J; Flaherty Keith T</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">625-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkbwjUIJOh8YUSrryheKE6fW6udTcc2eZl64As_XHws7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ms1Wmsg%253D%253D&md5=015a1194cf584003c341b1315faa8669</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.170%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DImmunotherapy%253A%2520anti-PD-1%2520therapies-a%2520new%2520first-line%2520option%2520in%2520advanced%2520melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26spage%3D625%26epage%3D626%26doi%3D10.1038%2Fnrclinonc.2015.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudreau, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrales-Rodriguez, L.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy comes of age in lung cancer</span>. <i>Clin. Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.cllc.2016.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.cllc.2016.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=27461776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKmtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=13-22&author=P.+Khannaauthor=N.+Blaisauthor=P.+O.+Gaudreauauthor=L.+Corrales-Rodriguez&title=Immunotherapy+comes+of+age+in+lung+cancer&doi=10.1016%2Fj.cllc.2016.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy Comes of Age in Lung Cancer</span></div><div class="casAuthors">Khanna, Priyanka; Blais, Normand; Gaudreau, Pierre-Olivier; Corrales-Rodriguez, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-22</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Lung carcinoma is the leading cause of death by cancer worldwide.  When possible, surgery is the best treatment strategy for patients with non-small-cell lung cancer.  However, even with curative-intent therapy, most patients will develop local or systemic recurrence and, ultimately, succumb to their disease.  In recent years, evidence on the role of the antitumor activity of the immune system and the understanding of tumor immunosurveillance have resulted in the emergence of immunotherapy as a promising therapeutic approach in lung cancer.  The main approaches are immune checkpoint inhibition, such as blockade of the cytotoxic T-lymphocyte antigen-4 and programmed cell death-1 receptors and the programmed cell death-1 ligand, and vaccine therapy, which elicits specific antitumor immunity against relevant tumor-assocd. antigens.  We have reviewed recently reported results from clin. trials and the possible future role of vaccine therapy and immune checkpoint inhibition in the treatment of small cell lung cancer and non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGY02iVifEhLVg90H21EOLACvtfcHk0lggGJwyeuCVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKmtb7O&md5=c8e8688a720f582a30a7ef0601c18187</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2016.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2016.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DKhanna%26aufirst%3DP.%26aulast%3DBlais%26aufirst%3DN.%26aulast%3DGaudreau%26aufirst%3DP.%2BO.%26aulast%3DCorrales-Rodriguez%26aufirst%3DL.%26atitle%3DImmunotherapy%2520comes%2520of%2520age%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2017%26volume%3D18%26spage%3D13%26epage%3D22%26doi%3D10.1016%2Fj.cllc.2016.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanghavi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, M.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacology considerations for the development of immune checkpoint inhibitors</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57 Suppl 10</i></span>,  <span class="NLM_fpage">S26</span>– <span class="NLM_lpage">S42</span>, <span class="refDoi"> DOI: 10.1002/jcph.990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1002%2Fjcph.990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28921644" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57+Suppl+10&publication_year=2017&pages=S26-S42&author=J.+Shengauthor=S.+Srivastavaauthor=K.+Sanghaviauthor=Z.+Luauthor=B.+J.+Schmidtauthor=A.+Belloauthor=M.+Gupta&title=Clinical+pharmacology+considerations+for+the+development+of+immune+checkpoint+inhibitors&doi=10.1002%2Fjcph.990"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fjcph.990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.990%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DJ.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DSanghavi%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DSchmidt%26aufirst%3DB.%2BJ.%26aulast%3DBello%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DM.%26atitle%3DClinical%2520pharmacology%2520considerations%2520for%2520the%2520development%2520of%2520immune%2520checkpoint%2520inhibitors%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D57%2520Suppl%252010%26spage%3DS26%26epage%3DS42%26doi%3D10.1002%2Fjcph.990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnrc.2016.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=27079802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVOrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=275-287&author=S.+L.+Topalianauthor=J.+M.+Taubeauthor=R.+A.+Andersauthor=D.+M.+Pardoll&title=Mechanism-driven+biomarkers+to+guide+immune+checkpoint+blockade+in+cancer+therapy&doi=10.1038%2Fnrc.2016.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy</span></div><div class="casAuthors">Topalian, Suzanne L.; Taube, Janis M.; Anders, Robert A.; Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">275-287</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte assocd. antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and addnl. immune checkpoints being targeted clin., many questions still remain regarding the optimal use of drugs that block these checkpoint pathways.  Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests.  Here, we discuss biomarkers for anti-PD1 therapy based on immunol., genetic and virol. criteria.  The unique biol. of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development.  Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzuy2z2GgvObVg90H21EOLACvtfcHk0lggGJwyeuCVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVOrurc%253D&md5=781c5a772910be415334b1ef2e247671</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.36%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DMechanism-driven%2520biomarkers%2520to%2520guide%2520immune%2520checkpoint%2520blockade%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D275%26epage%3D287%26doi%3D10.1038%2Fnrc.2016.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Small-molecule targets in tumor immunotherapy</span>. <i>Nat. Prod. Bioprospect.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1007/s13659-018-0177-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1007%2Fs13659-018-0177-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=29974338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12lsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=297-301&author=H.+F.+Zhuauthor=Y.+Li&title=Small-molecule+targets+in+tumor+immunotherapy&doi=10.1007%2Fs13659-018-0177-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Targets in Tumor Immunotherapy</span></div><div class="casAuthors">Zhu, Hui-Fang; Li, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Natural Products and Bioprospecting</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-301</span>CODEN:
                <span class="NLM_cas:coden">NPBAAH</span>;
        ISSN:<span class="NLM_cas:issn">2192-2209</span>.
    
            (<span class="NLM_cas:orgname">Kunming Institute of Botany, Chinese Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  Cancer immunotherapy has been widely recognized as a powerful approach to fight cancers.  To date, over 50 phase III trials in cancer immunotherapy are in progress.  Among the many immunotherapy approaches, immune checkpoint therapy has attracted considerable attention.  The reported clin. success of targeting the T cell immune checkpoint receptors PD-1 or CTLA4 by antibodies blockade in advanced stages of cancers has demonstrated the importance of immune modulation.  But antibodies-based immunotherapy confronted with some disadvantages, such as immunogenicity, stability, membrane permeability, and prodn. cost.  Therefore, alternative approaches including small-mol.-regulated immune response are being introduced.  In this review, we focused on some of the key intracellular pathways where small-mol. therapeutic is potential and attractive, which highlights the great potential of natural products in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrit8YB3mZAwLVg90H21EOLACvtfcHk0lggGJwyeuCVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12lsrvI&md5=1ce40d184a3dea755c98c949e851e929</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs13659-018-0177-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13659-018-0177-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%2BF.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DSmall-molecule%2520targets%2520in%2520tumor%2520immunotherapy%26jtitle%3DNat.%2520Prod.%2520Bioprospect.%26date%3D2018%26volume%3D8%26spage%3D297%26epage%3D301%26doi%3D10.1007%2Fs13659-018-0177-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vladimer, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigenzahn, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardeau, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Fuente, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knobl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Global survey of the immunomodulatory potential of common drugs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnchembio.2360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28437395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=681-690&author=G.+I.+Vladimerauthor=B.+Snijderauthor=N.+Krallauthor=J.+W.+Bigenzahnauthor=K.+V.+M.+Huberauthor=C.+H.+Lardeauauthor=K.+Sanjivauthor=A.+Ringlerauthor=U.+W.+Berglundauthor=M.+Sablerauthor=O.+L.+de+la+Fuenteauthor=P.+Knoblauthor=S.+Kubicekauthor=T.+Helledayauthor=U.+Jagerauthor=G.+Superti-Furga&title=Global+survey+of+the+immunomodulatory+potential+of+common+drugs&doi=10.1038%2Fnchembio.2360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Global survey of the immunomodulatory potential of common drugs</span></div><div class="casAuthors">Vladimer, Gregory I.; Snijder, Berend; Krall, Nikolaus; Bigenzahn, Johannes W.; Huber, Kilian V. M.; Lardeau, Charles-Hugues; Sanjiv, Kumar; Ringler, Anna; Berglund, Ulrika Warpman; Sabler, Monika; de la Fuente, Oscar Lopez; Knoebl, Paul; Kubicek, Stefan; Helleday, Thomas; Jaeger, Ulrich; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">681-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drugs may complement antibody-based therapies in an immune-oncol. setting, yet systematic methods for the identification and characterization of the immunomodulatory properties of these entities are lacking.  We surveyed the immumomodulatory potential of 1,402 small chem. mols., as defined by their ability to alter the cell-cell interactions among peripheral mononuclear leukocytes ex vivo, using automated microscopy and population-wide single-cell image anal.  Unexpectedly, ∼10% of the agents tested affected these cell-cell interactions differentially.  The results accurately recapitulated known immunomodulatory drug classes and revealed several clin. approved drugs that unexpectedly harbor the ability to modulate the immune system, which could potentially contribute to their physiol. mechanism of action.  For instance, the kinase inhibitor crizotinib promoted T cell interactions with monocytes, as well as with cancer cells, through inhibition of the receptor tyrosine kinase MSTR1 and subsequent upregulation of the expression of major histocompatibility complex mols.  The approach offers an attractive platform for the personalized identification and characterization of immunomodulatory therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXf0_7KFGbY7Vg90H21EOLACvtfcHk0lhjwn_LcAxb8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D&md5=c177974d4daf99d7a40b5c2a73c6504a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2360%26sid%3Dliteratum%253Aachs%26aulast%3DVladimer%26aufirst%3DG.%2BI.%26aulast%3DSnijder%26aufirst%3DB.%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DBigenzahn%26aufirst%3DJ.%2BW.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DLardeau%26aufirst%3DC.%2BH.%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DRingler%26aufirst%3DA.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DSabler%26aufirst%3DM.%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DO.%2BL.%26aulast%3DKnobl%26aufirst%3DP.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DJager%26aufirst%3DU.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520survey%2520of%2520the%2520immunomodulatory%2520potential%2520of%2520common%2520drugs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D681%26epage%3D690%26doi%3D10.1038%2Fnchembio.2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smothers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, A.</span></span> <span> </span><span class="NLM_article-title">Big opportunities for small molecules in immuno-oncology</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">622</span>, <span class="refDoi"> DOI: 10.1038/nrd4596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnrd4596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=26228631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KiurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=603-622&author=J.+L.+Adamsauthor=J.+Smothersauthor=R.+Srinivasanauthor=A.+Hoos&title=Big+opportunities+for+small+molecules+in+immuno-oncology&doi=10.1038%2Fnrd4596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Big opportunities for small molecules in immuno-oncology</span></div><div class="casAuthors">Adams, Jerry L.; Smothers, James; Srinivasan, Roopa; Hoos, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">603-622</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The regulatory approval of ipilimumab (Yervoy) in 2011 ushered in a new era of cancer immunotherapies with durable clin. effects.  Most of these breakthrough medicines are monoclonal antibodies that block protein-protein interactions between T cell checkpoint receptors and their cognate ligands.  In addn., genetically engineered autologous T cell therapies have also recently demonstrated significant clin. responses in haematol. cancers.  Conspicuously missing from this class of therapies are traditional small-mol. drugs, which have previously served as the backbone of targeted cancer therapies.  Modulating the immune system through a small-mol. approach offers several unique advantages that are complementary to, and potentially synergistic with, biol. modalities.  This Review highlights immuno-oncol. pathways and mechanisms that can be best or solely targeted by small-mol. medicines.  Agents aimed at these mechanisms - modulation of the immune response, trafficking to the tumor microenvironment and cellular infiltration - are poised to significantly extend the scope of immuno-oncol. applications and enhance the opportunities for combination with tumor-targeted agents and biol. immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBZyGzN4ec8bVg90H21EOLACvtfcHk0lhjwn_LcAxb8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KiurvE&md5=b6c9d41ae81a8c504ee6aac209ea0509</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd4596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4596%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DSmothers%26aufirst%3DJ.%26aulast%3DSrinivasan%26aufirst%3DR.%26aulast%3DHoos%26aufirst%3DA.%26atitle%3DBig%2520opportunities%2520for%2520small%2520molecules%2520in%2520immuno-oncology%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D603%26epage%3D622%26doi%3D10.1038%2Fnrd4596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Recent advances in small molecule based cancer immunotherapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">582</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.ejmech.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=30125720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=582-598&author=B.+Chengauthor=W.+E.+Yuanauthor=J.+Suauthor=Y.+Liuauthor=J.+Chen&title=Recent+advances+in+small+molecule+based+cancer+immunotherapy&doi=10.1016%2Fj.ejmech.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in small molecule based cancer immunotherapy</span></div><div class="casAuthors">Cheng, Binbin; Yuan, Wei-En; Su, Jing; Liu, Yao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">582-598</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Immunotherapy has been increasingly utilized for the treatment of cancer.  Currently available cancer immunotherapies mainly involve the use of antibodies, which have advantages in terms of pharmacodynamics such as efficacy and specificity, however, they exhibit disadvantages in regard to the pharmacokinetics including but not limited to poor tissue and tumor penetration, very long half-life, and the lack of oral bioavailability.  Also they are immunogenic and may cause undesired side effects.  In addn., they are difficult and expensive to produce.  In contrast to therapeutic antibodies, small mol. immuno-oncol. agents generally have favorable pharmacokinetics, for example, better oral bioavailability, higher tissue and tumor penetration, reasonable half-lives etc.  Furthermore, some small mols. are highly selective and efficacious with benign toxicity profiles.  Therefore, small mol. immuno-oncol. agents have the potential to overcome the drawbacks of therapeutic antibodies, and they can complement existing therapeutic antibodies and may also be used in combination with antibodies to achieve synergistic effects.  In this article, we summarize the current advances in the field of small mol. approaches in tumor immunol. which include the small mols. in clin. trials and preclin. studies, and the reported crystal structures of small mols. and their target proteins as well as the binding interactions between small mols. and the targets.  The tumorigenesis mechanism of different targets (the programmed cell death 1/programmed cell death ligand 1(PD1/PD-L1), retinoic acid-related orphan receptor-gamma t (RORγt), Chemokine receptor, Stimulator of Interferon Genes (Sting), Indoleamine 2,3-dioxygenase (IDO), toll-like receptors (TLR) etc.) are also elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvYDM1Fp9HUbVg90H21EOLACvtfcHk0lhVRF7B2WjTVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FP&md5=e15fa8048cf9b12ecd494d9ff8db8be5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DW.%2BE.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DRecent%2520advances%2520in%2520small%2520molecule%2520based%2520cancer%2520immunotherapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D582%26epage%3D598%26doi%3D10.1016%2Fj.ejmech.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">Immunomodulating peptidomimetic derivatives</span>. <span class="NLM_patent">WO2015036927</span>, 19 March, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=Immunomodulating+peptidomimetic+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunomodulating%2520peptidomimetic%2520derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L.</span>; <span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Compounds useful as immunomodulators</span>. <span class="NLM_patent">WO2015034820</span>, March 12, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+Chupak&author=X.+Zheng&title=Compounds+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%26atitle%3DCompounds%2520useful%2520as%2520immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span>; <span class="NLM_string-name">Xiao, J.</span>; <span class="NLM_string-name">Liu, A.</span>; <span class="NLM_string-name">Wei, X.</span>; <span class="NLM_string-name">Zhong, W.</span>; <span class="NLM_string-name">Zheng, Z.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Xie, Y.</span>; <span class="NLM_string-name">Zhao, G.</span>; <span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Resorcinol compound and medicinal use thereof</span>. <span class="NLM_patent">CN107286057</span>, October 24, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Li&author=J.+Xiao&author=A.+Liu&author=X.+Wei&author=W.+Zhong&author=Z.+Zheng&author=X.+Wang&author=Y.+Xie&author=G.+Zhao&author=H.+Li&title=Resorcinol+compound+and+medicinal+use+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26atitle%3DResorcinol%2520compound%2520and%2520medicinal%2520use%2520thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00990</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00990" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1715-1730&author=T.+Wangauthor=X.+Wuauthor=C.+Guoauthor=K.+Zhangauthor=J.+Xuauthor=Z.+Liauthor=S.+Jiang&title=Development+of+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+signaling+pathway&doi=10.1021%2Facs.jmedchem.8b00990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway</span></div><div class="casAuthors">Wang, Tianyu; Wu, Xiaoxing; Guo, Changying; Zhang, Kuojun; Xu, Jinyi; Li, Zheng; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1715-1730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The clin. success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy.  Currently, most drugs targeting this pathway are monoclonal antibodies.  Small-mol. inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include prodn. difficulties and their long half-life.  Recently, progress has been reported on anti-PD-1/PD-L1 small-mol. inhibitors.  In this paper, we review the development of inhibitors targeting the PD-1/PD-L1 pathway, focusing mainly on peptide-based and nonpeptidic small-mol. inhibitors.  The structures and the preclin. and clin. studies of several peptide-based small-mol. candidate compds. in clin. trials are discussed.  We also illustrate the design strategies underlying reported nonpeptidic small-mol. inhibitors and provide insight into possible future exploration.  Development of small-mol. drugs for anti-PD-1/PD-L1 activity with specific cancer applications is a promising and challenging prospect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonItidshja8LVg90H21EOLACvtfcHk0lhVRF7B2WjTVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL&md5=2fc7ee8e9bb8d37c7569913a4529d753</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00990%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520signaling%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1715%26epage%3D1730%26doi%3D10.1021%2Facs.jmedchem.8b00990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blevins, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolduc, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gignac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hof, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulff, J. E.</span></span> <span> </span><span class="NLM_article-title">In vitro assessment of putative PD-1/PD-L1 inhibitors: suggestions of an alternative mode of action</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1192</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00221</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00221" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1187-1192&author=D.+J.+Blevinsauthor=R.+Hanleyauthor=T.+Bolducauthor=D.+A.+Powellauthor=M.+Gignacauthor=K.+Walkerauthor=M.+D.+Carrauthor=F.+Hofauthor=J.+E.+Wulff&title=In+vitro+assessment+of+putative+PD-1%2FPD-L1+inhibitors%3A+suggestions+of+an+alternative+mode+of+action&doi=10.1021%2Facsmedchemlett.9b00221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action</span></div><div class="casAuthors">Blevins, Derek J.; Hanley, Ronan; Bolduc, Trevor; Powell, David A.; Gignac, Michael; Walker, Kayleigh; Carr, Mark D.; Hof, Fraser; Wulff, Jeremy E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1187-1192</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The programmed cell death protein 1 (PD-1) signaling axis is among the most important therapeutic targets in modern oncol.  Aurigene Discovery Technologies Ltd. (Aurigene) has patented a series of peptidomimetic small mols. derived from the PD-1 protein sequence for use in targeting the interaction between PD-1 and its ligand, PD-L1.  We evaluated three of Aurigene's most potent compds. in SPR binding assays.  Our results showed that these compds. each of which is known to be potently effective in a splenocyte recovery assay-do not directly inhibit the PD-1/PD-L1 interaction nor do they appear to bind to either of the constituent proteins, indicating that another mechanism is at play.  As a result of these studies and upon consideration of structural features within the PD-1/PD-L1 complex, we hypothesize that the Aurigene mols. may interact with a currently unknown protein capable of regulating the PD-1 axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrekmaz9w_0ZrVg90H21EOLACvtfcHk0lhmN1CY68fthA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsrbF&md5=a7d8471006f1fc6f7736be28c5ce8557</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00221%26sid%3Dliteratum%253Aachs%26aulast%3DBlevins%26aufirst%3DD.%2BJ.%26aulast%3DHanley%26aufirst%3DR.%26aulast%3DBolduc%26aufirst%3DT.%26aulast%3DPowell%26aufirst%3DD.%2BA.%26aulast%3DGignac%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DK.%26aulast%3DCarr%26aufirst%3DM.%2BD.%26aulast%3DHof%26aufirst%3DF.%26aulast%3DWulff%26aufirst%3DJ.%2BE.%26atitle%3DIn%2520vitro%2520assessment%2520of%2520putative%2520PD-1%252FPD-L1%2520inhibitors%253A%2520suggestions%2520of%2520an%2520alternative%2520mode%2520of%2520action%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1187%26epage%3D1192%26doi%3D10.1021%2Facsmedchemlett.9b00221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czub, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plewka, J.</span></span> <span> </span><span class="NLM_article-title">CA-170 - a potent small-molecule PD-L1 inhibitor or not?</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">Article 2804</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.3390/molecules24152804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.3390%2Fmolecules24152804" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1-13&issue=Article+2804&author=B.+Musielakauthor=J.+Kocikauthor=L.+Skalniakauthor=K.+Magiera-Mularzauthor=D.+Salaauthor=M.+Czubauthor=M.+Stecauthor=M.+Siedlarauthor=T.+A.+Holakauthor=J.+Plewka&title=CA-170+-+a+potent+small-molecule+PD-L1+inhibitor+or+not%3F&doi=10.3390%2Fmolecules24152804"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24152804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24152804%26sid%3Dliteratum%253Aachs%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DCzub%26aufirst%3DM.%26aulast%3DStec%26aufirst%3DM.%26aulast%3DSiedlar%26aufirst%3DM.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DPlewka%26aufirst%3DJ.%26atitle%3DCA-170%2520-%2520a%2520potent%2520small-molecule%2520PD-L1%2520inhibitor%2520or%2520not%253F%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26issue%3DArticle%25202804%26spage%3D1%26epage%3D13%26doi%3D10.3390%2Fmolecules24152804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of phospholipase A2 inhibitory biflavonoids</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2373</span>– <span class="NLM_lpage">2375</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.01.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.bmcl.2006.01.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=16504502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BD28XislChurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=2373-2375&author=J.+Chenauthor=H.+W.+Changauthor=H.+P.+Kimauthor=H.+Park&title=Synthesis+of+phospholipase+A2+inhibitory+biflavonoids&doi=10.1016%2Fj.bmcl.2006.01.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of phospholipase A2 inhibitory biflavonoids</span></div><div class="casAuthors">Chen, Jianjun; Chang, Hyeun Wook; Kim, Hyun Pyo; Park, Haeil</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2373-2375</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of C-C biflavones was designed to investigate the relationship between structural array of different flavone-flavone subunit linkage and the inhibitory activity against phospholipase A2 (PLA2).  Among six classes of C-C biflavones designed, four classes of C-C biflavones, which have flavone-flavone subunit linkages at A ring-A ring, A ring-B ring, B ring-B ring, and B ring-C ring, were synthesized.  The synthetic biflavones exhibited somewhat different inhibitory activities against sPLA2-IIA.  Among them, biflavone I a having a C-C 4'-4' linkage showed comparable inhibitory activity with that of the natural biflavonoid, ochnaflavone, and 7-fold stronger activity than that of amentoflavone.  Further chem. modification is being carried out in order to obtain the chem. optimized biflavonoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_3Q_1TIV67Vg90H21EOLACvtfcHk0lhmN1CY68fthA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XislChurk%253D&md5=c08d5a23d6f0a5c8f2c33ed8d865a199</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.01.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.01.117%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DH.%2BW.%26aulast%3DKim%26aufirst%3DH.%2BP.%26aulast%3DPark%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520phospholipase%2520A2%2520inhibitory%2520biflavonoids%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D2373%26epage%3D2375%26doi%3D10.1016%2Fj.bmcl.2006.01.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5857</span>– <span class="NLM_lpage">5867</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5857-5867&author=K.+Guzikauthor=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Magieraauthor=B.+Musielakauthor=R.+Tornerauthor=L.+Skalniakauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+death-ligand+1+%28PD-1%2FPD-L1%29+interaction+via+transiently+induced+protein+states+and+dimerization+of+PD-L1&doi=10.1021%2Facs.jmedchem.7b00293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1</span></div><div class="casAuthors">Guzik, Katarzyna; Zak, Krzysztof M.; Grudnik, Przemyslaw; Magiera, Katarzyna; Musielak, Bogdan; Torner, Ricarda; Skalniak, Lukasz; Domling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5857-5867</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances in cancer treatment.  The antibody-based immunotherapies carry a no. of disadvantages such as the high cost of the antibodies, their limited half-life, and immunogenicity.  Development of small-mol. PD-1/PD-L1 inhibitors that could overcome these drawbacks is slow because of the incomplete structural information for this pathway.  The first chem. PD-1/PD-L1 inhibitors have been recently disclosed by Bristol-Myers Squibb.  Here we present NMR and X-ray characterization for the two classes of these inhibitors.  The X-ray structures of the PD-L1/inhibitor complexes reveal one inhibitor mol. located at the center of the PD-L1 homodimer, filling a deep hydrophobic channel-like pocket between two PD-L1 mols.  Derivs. of (2-methyl-3-biphenylyl)methanol exhibit the structures capped on one side of the channel, whereas the compds. based on [3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methanol induce an enlarged interaction interface that results in the open "face-back" tunnel through the PD-L1 dimer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppmfSesG1M6rVg90H21EOLACvtfcHk0lhEJCFFS0cLzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D&md5=c039796cda3b9ef92a0ed3b10b11932b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DTorner%26aufirst%3DR.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520%2528PD-1%252FPD-L1%2529%2520interaction%2520via%2520transiently%2520induced%2520protein%2520states%2520and%2520dimerization%2520of%2520PD-L1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5857%26epage%3D5867%26doi%3D10.1021%2Facs.jmedchem.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of [1,2,4]triazolo[4,3- a]pyridines as potent inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4703</span>– <span class="NLM_lpage">4715</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4703-4715&author=M.+Qinauthor=Q.+Caoauthor=S.+Zhengauthor=Y.+Tianauthor=H.+Zhangauthor=J.+Xieauthor=H.+Xieauthor=Y.+Liuauthor=Y.+Zhaoauthor=P.+Gong&title=Discovery+of+%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-+a%5Dpyridines+as+potent+inhibitors+targeting+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction&doi=10.1021%2Facs.jmedchem.9b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Zheng, Shuaishuai; Tian, Ye; Zhang, Haotian; Xie, Jun; Xie, Hongbo; Liu, Yajing; Zhao, Yanfang; Gong, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4703-4715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction using small-mol. inhibitors is an emerging immunotherapeutic approach.  A novel series of [1,2,4]triazolo[4,3-a]pyridines were designed and found to be potent inhibitors of the PD-1/PD-L1 interaction.  Among them, compd. I exhibited the most potent activity, as assessed by homogeneous time-resolved fluorescence assay, with an IC50 of 92.3 nM.  Furthermore, I dose-dependent elevated interferon-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  The authors concluded that I is a promising lead compd. for the development of inhibitors of the PD-1/PD-L1 interaction.  In addn., the authors explored the structure-activity relationships of the newly synthesized [1,2,4]triazolo[4,3-a]pyridines and demonstrated that a ring fusion strategy can be employed for designing analogs of the Bristol-Myers Squibb chem. series.  These studies pave the way for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCgkEJ5SqGXLVg90H21EOLACvtfcHk0lhEJCFFS0cLzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D&md5=44d4ee689be577a86c16cc4da3edec71</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00312%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-%2520a%255Dpyridines%2520as%2520potent%2520inhibitors%2520targeting%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4703%26epage%3D4715%26doi%3D10.1021%2Facs.jmedchem.9b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Shen, B.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic compounds as immunomodulators</span>. <span class="NLM_patent">WO2017070089</span>, April 27, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Wu&author=B.+Shen&author=J.+Li&author=K.+Liu&author=F.+Zhang&author=W.+Yao&title=Heterocyclic+compounds+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DHeterocyclic%2520compounds%2520as%2520immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lajkiewicz, N.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic compounds as immunomodulators</span>. <span class="NLM_patent">US20170174679</span>, June 22, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=N.+Lajkiewicz&author=L.+Wu&author=W.+Yao&title=Heterocyclic+compounds+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLajkiewicz%26aufirst%3DN.%26atitle%3DHeterocyclic%2520compounds%2520as%2520immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yu, Z.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-phenyl-pyridine-2-carboxamide derivatives and their use as PD-1/PD-L1 protein/protein interaction modulators</span>. <span class="NLM_patent">WO2017106634</span>, June 22, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Wu&author=Z.+Yu&author=F.+Zhang&author=W.+Yao&title=N-phenyl-pyridine-2-carboxamide+derivatives+and+their+use+as+PD-1%2FPD-L1+protein%2Fprotein+interaction+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DN-phenyl-pyridine-2-carboxamide%2520derivatives%2520and%2520their%2520use%2520as%2520PD-1%252FPD-L1%2520protein%252Fprotein%2520interaction%2520modulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K.-S.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Saulnier, M. G.</span>; <span class="NLM_string-name">Frennesson, D. B.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Hewawasam, P.</span>; <span class="NLM_string-name">Wang, T.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Meng, Z.</span>; <span class="NLM_string-name">Sun, L.-Q.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Biaryl compounds useful as immunomodulators</span>. <span class="NLM_patent">WO2018044963</span>, March 08, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=K.-S.+Yeung&author=K.+A.+Grant-Young&author=J.+Zhu&author=M.+G.+Saulnier&author=D.+B.+Frennesson&author=D.+R.+Langley&author=P.+Hewawasam&author=T.+Wang&author=Z.+Zhang&author=Z.+Meng&author=L.-Q.+Sun&author=E.+Mull&author=P.+M.+Scola&title=Biaryl+compounds+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.-S.%26atitle%3DBiaryl%2520compounds%2520useful%2520as%2520immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Saulnier, M. G.</span>; <span class="NLM_string-name">Frennesson, D. B.</span>; <span class="NLM_string-name">Meng, Z. X.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">1,3-dihydroxy-phenyl derivatives useful as immunomodulators</span>. <span class="NLM_patent">WO2018009505</span>, January 11, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=K.+S.+Yeung&author=K.+A.+Grant-Young&author=J.+Zhu&author=M.+G.+Saulnier&author=D.+B.+Frennesson&author=Z.+X.+Meng&author=P.+M.+Scola&title=1%2C3-dihydroxy-phenyl+derivatives+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.%2BS.%26atitle%3D1%252C3-dihydroxy-phenyl%2520derivatives%2520useful%2520as%2520immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K.-S.</span>; <span class="NLM_string-name">Connolly, T. P.</span>; <span class="NLM_string-name">Frennesson, D. B.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Hewawasam, P.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Meng, Z.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Parcella, K. E.</span>; <span class="NLM_string-name">Saulnier, M. G.</span>; <span class="NLM_string-name">Sun, L.-Q.</span>; <span class="NLM_string-name">Wang, A. X.</span>; <span class="NLM_string-name">Xu, N.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Compounds useful as immunomodulators</span>. <span class="NLM_patent">WO2017066227</span>, April 20, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.-S.+Yeung&author=T.+P.+Connolly&author=D.+B.+Frennesson&author=K.+A.+Grant-Young&author=P.+Hewawasam&author=D.+R.+Langley&author=Z.+Meng&author=E.+Mull&author=K.+E.+Parcella&author=M.+G.+Saulnier&author=L.-Q.+Sun&author=A.+X.+Wang&author=N.+Xu&author=J.+Zhu&author=P.+M.+Scola&title=Compounds+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.-S.%26atitle%3DCompounds%2520useful%2520as%2520immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krupka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kischel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugmaier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenegger, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohnke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeremias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzeler, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauerle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riethmuller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subklewe, M.</span></span> <span> </span><span class="NLM_article-title">Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fleu.2015.214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=26239198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=484-491&author=C.+Krupkaauthor=P.+Kuferauthor=R.+Kischelauthor=G.+Zugmaierauthor=F.+S.+Lichteneggerauthor=T.+Kohnkeauthor=B.+Vickauthor=I.+Jeremiasauthor=K.+H.+Metzelerauthor=T.+Altmannauthor=S.+Schneiderauthor=M.+Fieglauthor=K.+Spiekermannauthor=P.+A.+Bauerleauthor=W.+Hiddemannauthor=G.+Riethmullerauthor=M.+Subklewe&title=Blockade+of+the+PD-1%2FPD-L1+axis+augments+lysis+of+AML+cells+by+the+CD33%2FCD3+BiTE+antibody+construct+AMG+330%3A+reversing+a+T-cell-induced+immune+escape+mechanism&doi=10.1038%2Fleu.2015.214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism</span></div><div class="casAuthors">Krupka, C.; Kufer, P.; Kischel, R.; Zugmaier, G.; Lichtenegger, F. S.; Koehnke, T.; Vick, B.; Jeremias, I.; Metzeler, K. H.; Altmann, T.; Schneider, S.; Fiegl, M.; Spiekermann, K.; Bauerle, P. A.; Hiddemann, W.; Riethmueller, G.; Subklewe, M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">484-491</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bispecific T-cell engagers (BiTEs) are very effective in recruiting and activating T cells.  We tested the cytotoxicity of the CD33/CD3 BiTE antibody construct AMG 330 on primary acute myeloid leukemia (AML) cells ex vivo and characterized parameters contributing to antileukemic cytolytic activity.  The E:T ratio and the CD33 expression level significantly influenced lysis kinetics in long-term cultures of primary AML cells (n=38).  AMG 330 induced T-cell-mediated proinflammatory conditions, favoring the upregulation of immune checkpoints on target and effector cells.  Although not constitutively expressed at the time of primary diagnosis (n=123), PD-L1 was strongly upregulated on primary AML cells upon AMG 330 addn. to ex vivo cultures (n=27, P<0.0001).  This phenomenon was cytokine-driven as the sole addn. of interferon (IFN)-γ and tumor necrosis factor-α also induced expression.  Through blockade of the PD-1/PD-L1 interaction, AMG 330-mediated lysis (n=9, P=0.03), T-cell proliferation (n=9, P=0.01) and IFN-γ secretion (n=8, P=0.008) were significantly enhanced.  The combinatorial approach was most beneficial in settings of protracted AML cell lysis.  Taken together, we have characterized a crit. resistance mechanism employed by primary AML cells under AMG 330-mediated proinflammatory conditions.  Our results support the evaluation of checkpoint mols. in upcoming clin. trials with AMG 330 to enhance BiTE antibody construct-mediated cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY6o4l8H8hXbVg90H21EOLACvtfcHk0lgRS3th1nb65A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr%252FF&md5=c7cdddb37f2e034cdfde250a0aaf6ed0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.214%26sid%3Dliteratum%253Aachs%26aulast%3DKrupka%26aufirst%3DC.%26aulast%3DKufer%26aufirst%3DP.%26aulast%3DKischel%26aufirst%3DR.%26aulast%3DZugmaier%26aufirst%3DG.%26aulast%3DLichtenegger%26aufirst%3DF.%2BS.%26aulast%3DKohnke%26aufirst%3DT.%26aulast%3DVick%26aufirst%3DB.%26aulast%3DJeremias%26aufirst%3DI.%26aulast%3DMetzeler%26aufirst%3DK.%2BH.%26aulast%3DAltmann%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DFiegl%26aufirst%3DM.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DBauerle%26aufirst%3DP.%2BA.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DRiethmuller%26aufirst%3DG.%26aulast%3DSubklewe%26aufirst%3DM.%26atitle%3DBlockade%2520of%2520the%2520PD-1%252FPD-L1%2520axis%2520augments%2520lysis%2520of%2520AML%2520cells%2520by%2520the%2520CD33%252FCD3%2520BiTE%2520antibody%2520construct%2520AMG%2520330%253A%2520reversing%2520a%2520T-cell-induced%2520immune%2520escape%2520mechanism%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D484%26epage%3D491%26doi%3D10.1038%2Fleu.2015.214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">The IFN-gamma/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">UNSP 290</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1186/s12974-018-1330-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1186%2Fs12974-018-1330-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=29301548" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=1-13&issue=UNSP+290&author=J.+Qianauthor=C.+Wangauthor=B.+Wangauthor=J.+Yangauthor=Y.+Wangauthor=F.+Luoauthor=J.+Xuauthor=C.+Zhaoauthor=R.+Liuauthor=Y.+Chu&title=The+IFN-gamma%2FPD-L1+axis+between+T+cells+and+tumor+microenvironment%3A+hints+for+glioma+anti-PD-1%2FPD-L1+therapy&doi=10.1186%2Fs12974-018-1330-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2Fs12974-018-1330-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-018-1330-2%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DChu%26aufirst%3DY.%26atitle%3DThe%2520IFN-gamma%252FPD-L1%2520axis%2520between%2520T%2520cells%2520and%2520tumor%2520microenvironment%253A%2520hints%2520for%2520glioma%2520anti-PD-1%252FPD-L1%2520therapy%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2018%26volume%3D15%26issue%3DUNSP%2520290%26spage%3D1%26epage%3D13%26doi%3D10.1186%2Fs12974-018-1330-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0lgRS3th1nb65A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">International
Transporter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Membrane transporters in drug development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nrd3028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnrd3028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=20190787" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=215-236&author=C.+International%0ATransporterauthor=K.+M.+Giacominiauthor=S.+M.+Huangauthor=D.+J.+Tweedieauthor=L.+Z.+Benetauthor=K.+L.+Brouwerauthor=X.+Chuauthor=A.+Dahlinauthor=R.+Eversauthor=V.+Fischerauthor=K.+M.+Hillgrenauthor=K.+A.+Hoffmasterauthor=T.+Ishikawaauthor=D.+Kepplerauthor=R.+B.+Kimauthor=C.+A.+Leeauthor=M.+Niemiauthor=J.+W.+Polliauthor=Y.+Sugiyamaauthor=P.+W.+Swaanauthor=J.+A.+Wareauthor=S.+H.+Wrightauthor=S.+W.+Yeeauthor=M.+J.+Zamek-Gliszczynskiauthor=L.+Zhang&title=Membrane+transporters+in+drug+development&doi=10.1038%2Fnrd3028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd3028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3028%26sid%3Dliteratum%253Aachs%26aulast%3DInternational%2BTransporter%26aufirst%3DC.%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%26aulast%3DChu%26aufirst%3DX.%26aulast%3DDahlin%26aufirst%3DA.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DV.%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DHoffmaster%26aufirst%3DK.%2BA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DWright%26aufirst%3DS.%2BH.%26aulast%3DYee%26aufirst%3DS.%2BW.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DMembrane%2520transporters%2520in%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D215%26epage%3D236%26doi%3D10.1038%2Fnrd3028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lounkine, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhailov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doak, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, L.</span></span> <span> </span><span class="NLM_article-title">Large-scale prediction and testing of drug activity on side-effect targets</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>486</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1038/nature11159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnature11159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=22722194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=361-367&author=E.+Lounkineauthor=M.+J.+Keiserauthor=S.+Whitebreadauthor=D.+Mikhailovauthor=J.+Hamonauthor=J.+L.+Jenkinsauthor=P.+Lavanauthor=E.+Weberauthor=A.+K.+Doakauthor=S.+Coteauthor=B.+K.+Shoichetauthor=L.+Urban&title=Large-scale+prediction+and+testing+of+drug+activity+on+side-effect+targets&doi=10.1038%2Fnature11159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale prediction and testing of drug activity on side-effect targets</span></div><div class="casAuthors">Lounkine, Eugen; Keiser, Michael J.; Whitebread, Steven; Mikhailov, Dmitri; Hamon, Jacques; Jenkins, Jeremy L.; Lavan, Paul; Weber, Eckhard; Doak, Allison K.; Cote, Serge; Shoichet, Brian K.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7403</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Discovering the unintended off-targets' that predict adverse drug reactions is daunting by empirical methods alone.  Drugs can act on several protein targets, some of which can be unrelated by conventional mol. metrics, and hundreds of proteins have been implicated in side effects.  Here we use a computational strategy to predict the activity of 656 marketed drugs on 73 unintended side-effect' targets.  Approx. half of the predictions were confirmed, either from proprietary databases unknown to the method or by new exptl. assays.  Affinities for these new off-targets ranged from 1 nM to 30 μM.  To explore relevance, we developed an assocn. metric to prioritize those new off-targets that explained side effects better than any known target of a given drug, creating a drug-target-adverse drug reaction network.  Among these new assocns. was the prediction that the abdominal pain side effect of the synthetic estrogen chlorotrianisene was mediated through its newly discovered inhibition of the enzyme cyclooxygenase-1.  The clin. relevance of this inhibition was borne out in whole human blood platelet aggregation assays.  This approach may have wide application to de-risking toxicol. liabilities in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5sVjfn4mgLLVg90H21EOLACvtfcHk0ljuDxaBtdWf8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D&md5=9c133b839d9527818a27a5834e4dfe11</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnature11159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11159%26sid%3Dliteratum%253Aachs%26aulast%3DLounkine%26aufirst%3DE.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DMikhailov%26aufirst%3DD.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DLavan%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DCote%26aufirst%3DS.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DLarge-scale%2520prediction%2520and%2520testing%2520of%2520drug%2520activity%2520on%2520side-effect%2520targets%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D361%26epage%3D367%26doi%3D10.1038%2Fnature11159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, evaluation, and structural studies of c2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7250</span>– <span class="NLM_lpage">7263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7250-7263&author=S.+Basuauthor=J.+Yangauthor=B.+Xuauthor=K.+Magiera-Mularzauthor=L.+Skalniakauthor=B.+Musielakauthor=V.+Kholodovychauthor=T.+A.+Holakauthor=L.+Hu&title=Design%2C+synthesis%2C+evaluation%2C+and+structural+studies+of+c2-symmetric+small+molecule+inhibitors+of+programmed+cell+death-1%2Fprogrammed+death-ligand+1+protein-protein+interaction&doi=10.1021%2Facs.jmedchem.9b00795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction</span></div><div class="casAuthors">Basu, Subhadwip; Yang, Jeffrey; Xu, Bin; Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Musielak, Bogdan; Kholodovych, Vladyslav; Holak, Tad A.; Hu, Longqin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7250-7263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of C2-sym. inhibitors was designed and evaluated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (PPI) in a homogeneous time-resolved fluorescence (HTRF) assay and PD-1 signaling in cell-based coculture assays.  C2-sym. inhibitors 2a (LH1306) and 2b (LH1307) exhibited IC50 values of 25 and 3.0 nM, resp., in the HTRF assay.  While 2a was ∼3.8-fold more potent than previously reported inhibitor 1a, 2b could not be differentiated from 1b due to their high potency and the limit of our HTRF assay conditions.  In one cell-based coculture PD-1 signaling assay, 2a and 2b were 8.2- and 2.8-fold more potent in inhibiting PD-1 signaling than 1a and 1b, resp.  NMR and X-ray cocrystal structural studies provided more structural insights into the interaction between 2b and PD-L1; 2b binds to PD-L1 at the PD-1 binding site and induces the formation of a more sym. arranged PD-L1 homodimer than that previously reported for other inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9fdh7FbNLLVg90H21EOLACvtfcHk0ljuDxaBtdWf8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ&md5=0dae949116a4157a281802aea6d21b6c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00795%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DHu%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520structural%2520studies%2520of%2520c2-symmetric%2520small%2520molecule%2520inhibitors%2520of%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7250%26epage%3D7263%26doi%3D10.1021%2Facs.jmedchem.9b00795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S. D.</span></span> <span> </span><span class="NLM_article-title">Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats</span>. <i>Drug Dev. Ind. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">876</span>, <span class="refDoi"> DOI: 10.1081/DDC-200034577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1081%2FDDC-200034577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=15521332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotVektL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2004&pages=869-876&author=B.+S.+Shinauthor=C.+H.+Kimauthor=Y.+S.+Junauthor=C.+H.+Yoonauthor=J.+I.+Rhoauthor=K.+C.+Leeauthor=H.+S.+Hanauthor=S.+D.+Yoo&title=Oral+absorption+and+pharmacokinetics+of+rebamipide+and+rebamipide+lysinate+in+rats&doi=10.1081%2FDDC-200034577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Absorption and Pharmacokinetics of Rebamipide and Rebamipide Lysinate in Rats</span></div><div class="casAuthors">Shin, Beom Soo; Kim, Chul Hwan; Jun, Yoon Sik; Yoon, Chi Ho; Rho, Jae Il; Lee, Kang Choon; Han, Hye Seon; Yoo, Sun Dong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Development and Industrial Pharmacy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">869-876</span>CODEN:
                <span class="NLM_cas:coden">DDIPD8</span>;
        ISSN:<span class="NLM_cas:issn">0363-9045</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">Rebamipide is an anti-ulcer agent exhibiting a low aq. soly. and a poor oral bioavailability.  This study was conducted to examine if the rebamipide lysinate salt form would exhibit improved soly. profiles and higher oral bioavailability compared with rebamipide free acid.  Both compds. showed pH-dependent soly. profiles, with the soly. of rebamipide lysinate dramatically improved at a median pH of 5.1 (17-fold increases) over free acid, but the improvement in the soly. was not as pronounced in artificial gastric and intestinal fluids (1.4- and 1.9-fold increases, resp.).  The Cl, Vss and t1/2 in rats after i.v. injection of rebamipide (0.5 mg/kg) averaged 21.0±3.2 mL/min/kg, 0.3±0.0 L/kg, and 0.4±0.1 h, resp.  No significant difference was obsd. in these parameters between rebamipide and rebamipide lysinate.  Despite improved soly. profiles, the abs. oral bioavailability of rebamipide lysinate was not increased (5.1 vs. 4.8%) nor did AUC (407.8 vs. 383.6 ng.hr/mL) and Cmax (87.4 vs.77.0 ng/mL) compared with rebamipide free acid.  Rebamipide lysinate, however, showed a more rapid absorption, and initial serum drug concns. were higher than those found for rebamipide free acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUW1j5qxVyhLVg90H21EOLACvtfcHk0liGsf2IKPaw8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotVektL0%253D&md5=9fc40c2dbc9a997cc5807c13d84091bb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1081%2FDDC-200034577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FDDC-200034577%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DB.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DJun%26aufirst%3DY.%2BS.%26aulast%3DYoon%26aufirst%3DC.%2BH.%26aulast%3DRho%26aufirst%3DJ.%2BI.%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DHan%26aufirst%3DH.%2BS.%26aulast%3DYoo%26aufirst%3DS.%2BD.%26atitle%3DOral%2520absorption%2520and%2520pharmacokinetics%2520of%2520rebamipide%2520and%2520rebamipide%2520lysinate%2520in%2520rats%26jtitle%3DDrug%2520Dev.%2520Ind.%2520Pharm.%26date%3D2004%26volume%3D30%26spage%3D869%26epage%3D876%26doi%3D10.1081%2FDDC-200034577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span> <span> </span><span class="NLM_article-title">Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3053</span>– <span class="NLM_lpage">3063</span>, <span class="refDoi"> DOI: 10.1007/s11095-012-0814-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1007%2Fs11095-012-0814-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=22760659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVSls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=3053-3063&author=C.+M.+Liauthor=Y.+Luauthor=J.+Chenauthor=T.+A.+Costelloauthor=R.+Narayananauthor=M.+N.+Daltonauthor=L.+M.+Snyderauthor=S.+Ahnauthor=W.+Liauthor=D.+D.+Millerauthor=J.+T.+Dalton&title=Orally+bioavailable+tubulin+antagonists+for+paclitaxel-refractory+cancer&doi=10.1007%2Fs11095-012-0814-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Bioavailable Tubulin Antagonists for Paclitaxel-Refractory Cancer</span></div><div class="casAuthors">Li, Chien-Ming; Lu, Yan; Chen, Jianjun; Costello, Terrence A.; Narayanan, Ramesh; Dalton, Mara N.; Snyder, Linda M.; Ahn, Sunjoo; Li, Wei; Miller, Duane D.; Dalton, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3053-3063</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To evaluate the efficacy and oral activity of two promising indoles, (2-(1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone [compd. II] and (2-(1H-indol-5-ylamino)-thiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone [compd. IAT], in paclitaxel- and docetaxel-resistant tumor models in vitro and in vivo.  Methods: The in vitro drug-like properties, including potency, soly., metabolic stability, and drug-drug interactions were examd. for our two active compds.  An in vivo pharmacokinetic study and antitumor efficacy study were also completed to compare their efficacy with docetaxel.  Results: Both compds. bound to the colchicine-binding site on tubulin, and inhibited tubulin polymn., resulting in highly potent cytotoxic activity in vitro.  While the potency of paclitaxel and docetaxel was compromised in a multidrug-resistant cell line that overexpresses P-glycoprotein, the potency of compds. II and IAT was maintained.  Both compds. had favorable drug-like properties, and acceptable oral bioavailability (21-50 %) in mice, rats, and dogs.  Tumor growth inhibition of greater than 100 % was achieved when immunodeficient mice with rapidly growing paclitaxel-resistant prostate cancer cells were treated orally at doses of 3-30 mg/kg of II or IAT.  Conclusions: These studies highlight the potent and broad anticancer activity of two orally bioavailable compds., offering significant pharmacol. advantage over existing drugs of this class for multidrug resistant or taxane-refractory cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA2ZtCfxwTTrVg90H21EOLACvtfcHk0liGsf2IKPaw8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVSls7k%253D&md5=8063cbbcdd9ffaff2e84e4b53b704672</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0814-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0814-5%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCostello%26aufirst%3DT.%2BA.%26aulast%3DNarayanan%26aufirst%3DR.%26aulast%3DDalton%26aufirst%3DM.%2BN.%26aulast%3DSnyder%26aufirst%3DL.%2BM.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26atitle%3DOrally%2520bioavailable%2520tubulin%2520antagonists%2520for%2520paclitaxel-refractory%2520cancer%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D3053%26epage%3D3063%26doi%3D10.1007%2Fs11095-012-0814-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gittis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikami, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garboczi, D. N.</span></span> <span> </span><span class="NLM_article-title">The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">3011</span>– <span class="NLM_lpage">3016</span>, <span class="refDoi"> DOI: 10.1073/pnas.0712278105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1073%2Fpnas.0712278105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=18287011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3011-3016&author=D.+Y.+Linauthor=Y.+Tanakaauthor=M.+Iwasakiauthor=A.+G.+Gittisauthor=H.+P.+Suauthor=B.+Mikamiauthor=T.+Okazakiauthor=T.+Honjoauthor=N.+Minatoauthor=D.+N.+Garboczi&title=The+PD-1%2FPD-L1+complex+resembles+the+antigen-binding+Fv+domains+of+antibodies+and+T+cell+receptors&doi=10.1073%2Fpnas.0712278105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors</span></div><div class="casAuthors">Lin, David Yin-Wei; Tanaka, Yoshimasa; Iwasaki, Masashi; Gittis, Apostolos G.; Su, Hua-Poo; Mikami, Bunzo; Okazaki, Taku; Honjo, Tasuku; Minato, Nagahiro; Garboczi, David N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3011-3016</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Signaling via the programmed death 1 (PD-1) inhibitory receptor upon binding its ligand, PD-L1, suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance.  Release from PD-1 inhibitory signaling revives "exhausted" virus-specific T cells in chronic viral infections.  Here the authors present the crystal structure of murine PD-1 in complex with human PD-L1.  PD-1 and PD-L1 interact through the conserved front and side of their Ig variable (IgV) domains, as do the IgV domains of antibodies and T cell receptors.  This places the loops at the ends of the IgV domains on the same side of the PD-1/PD-L1 complex, forming a surface that is similar to the antigen-binding surface of antibodies and T cell receptors.  Mapping conserved residues allowed the identification of residues that are important in forming the PD-1/PD-L1 interface.  Based on the structure, the authors show that some reported loss-of-binding mutations involve the PD-1/PD-L1 interaction but that others compromise protein folding.  The PD-1/PD-L1 interaction described here may be blocked by antibodies or by designed small-mol. drugs to lower inhibitory signaling that results in a stronger immune response.  The immune receptor-like loops offer a new surface for further study and potentially the design of mols. that would affect PD-1/PD-L1 complex formation and thereby modulate the immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqbP0BPGxxELVg90H21EOLACvtfcHk0liGsf2IKPaw8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitr4%253D&md5=5ea708a1fdb0b926d109ec515c9b81cc</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0712278105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0712278105%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DD.%2BY.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DGittis%26aufirst%3DA.%2BG.%26aulast%3DSu%26aufirst%3DH.%2BP.%26aulast%3DMikami%26aufirst%3DB.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DGarboczi%26aufirst%3DD.%2BN.%26atitle%3DThe%2520PD-1%252FPD-L1%2520complex%2520resembles%2520the%2520antigen-binding%2520Fv%2520domains%2520of%2520antibodies%2520and%2520T%2520cell%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D3011%26epage%3D3016%26doi%3D10.1073%2Fpnas.0712278105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshua, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangadhar, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunceford, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emancipator, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolled-Filhart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebbinghaus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span> <span> </span><span class="NLM_article-title">Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">4102</span>– <span class="NLM_lpage">4109</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.67.2477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1200%2FJCO.2016.67.2477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=27863197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=4102-4109&author=A.+I.+Daudauthor=J.+D.+Wolchokauthor=C.+Robertauthor=W.+J.+Hwuauthor=J.+S.+Weberauthor=A.+Ribasauthor=F.+S.+Hodiauthor=A.+M.+Joshuaauthor=R.+Keffordauthor=P.+Herseyauthor=R.+Josephauthor=T.+C.+Gangadharauthor=R.+Droncaauthor=A.+Patnaikauthor=H.+Zarourauthor=C.+Roachauthor=G.+Tolandauthor=J.+K.+Luncefordauthor=X.+N.+Liauthor=K.+Emancipatorauthor=M.+Dolled-Filhartauthor=S.+P.+Kangauthor=S.+Ebbinghausauthor=O.+Hamid&title=Programmed+death-ligand+1+expression+and+response+to+the+anti-programmed+death+1+antibody+pembrolizumab+in+melanoma&doi=10.1200%2FJCO.2016.67.2477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma</span></div><div class="casAuthors">Daud, Adil I.; Wolchok, Jedd D.; Robert, Caroline; Hwu, Wen-Jen; Weber, Jeffrey S.; Ribas, Antoni; Hodi, F. Stephen; Joshua, Anthony M.; Kefford, Richard; Hersey, Peter; Joseph, Richard; Gangadhar, Tara C.; Dronca, Roxana; Patnaik, Amita; Zarour, Hassane; Roach, Charlotte; Toland, Grant; Lunceford, Jared K.; Li, Xiaoyun Nicole; Emancipator, Kenneth; Dolled-Filhart, Marisa; Kang, S. Peter; Ebbinghaus, Scot; Hamid, Omid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4102-4109</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1).  This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clin. trial information: NCT01295827).  Patients and Methods Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 wk or once every 3 wk, or 2 mg/kg once every 3 wk.  Tumor response was assessed every 12 wk per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review.  Primary outcome was objective response rate.  Secondary outcomes included progression-free survival (PFS) and overall survival (OS).  Membranous PD-L1 expression in tumor and tumor-assocd. immune cells was assessed by a clin. trial immunohistochem. assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clin. outcome; a score ≥ 2 (membranous staining in ≥ 1% of cells) was considered pos.  Results Of 451 patients with evaluable PD-L1 expression, 344 (76%) had PD-L1-pos. tumors.  Demog. and staging variables were equally distributed among PD-L1-pos. and -neg. patients.  An assocn. between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95% CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95% CI, 0.69 to 0.83) was obsd. (P≤ .001 for each).  Objective response rate was 8%, 12%, 22%, 43%, 57%, and 53% for MEL 0, 1, 2, 3, 4, and 5, resp.  Conclusion PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-neg. tumors may also achieve durable responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrICOQPJlNnLbVg90H21EOLACvtfcHk0lhxKHpIy980WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOqt7c%253D&md5=5be54952126630c646743b788c459a87</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.67.2477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.67.2477%26sid%3Dliteratum%253Aachs%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DJoshua%26aufirst%3DA.%2BM.%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DJoseph%26aufirst%3DR.%26aulast%3DGangadhar%26aufirst%3DT.%2BC.%26aulast%3DDronca%26aufirst%3DR.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DZarour%26aufirst%3DH.%26aulast%3DRoach%26aufirst%3DC.%26aulast%3DToland%26aufirst%3DG.%26aulast%3DLunceford%26aufirst%3DJ.%2BK.%26aulast%3DLi%26aufirst%3DX.%2BN.%26aulast%3DEmancipator%26aufirst%3DK.%26aulast%3DDolled-Filhart%26aufirst%3DM.%26aulast%3DKang%26aufirst%3DS.%2BP.%26aulast%3DEbbinghaus%26aufirst%3DS.%26aulast%3DHamid%26aufirst%3DO.%26atitle%3DProgrammed%2520death-ligand%25201%2520expression%2520and%2520response%2520to%2520the%2520anti-programmed%2520death%25201%2520antibody%2520pembrolizumab%2520in%2520melanoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D4102%26epage%3D4109%26doi%3D10.1200%2FJCO.2016.67.2477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowanetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrt, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rost, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leabman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokatrin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span> <span> </span><span class="NLM_article-title">Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>515</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1038/nature14011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnature14011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=25428504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFanurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=515&publication_year=2014&pages=563-567&author=R.+S.+Herbstauthor=J.+C.+Soriaauthor=M.+Kowanetzauthor=G.+D.+Fineauthor=O.+Hamidauthor=M.+S.+Gordonauthor=J.+A.+Sosmanauthor=D.+F.+McDermottauthor=J.+D.+Powderlyauthor=S.+N.+Gettingerauthor=H.+E.+Kohrtauthor=L.+Hornauthor=D.+P.+Lawrenceauthor=S.+Rostauthor=M.+Leabmanauthor=Y.+Xiaoauthor=A.+Mokatrinauthor=H.+Koeppenauthor=P.+S.+Hegdeauthor=I.+Mellmanauthor=D.+S.+Chenauthor=F.+S.+Hodi&title=Predictive+correlates+of+response+to+the+anti-PD-L1+antibody+MPDL3280A+in+cancer+patients&doi=10.1038%2Fnature14011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</span></div><div class="casAuthors">Herbst, Roy S.; Soria, Jean-Charles; Kowanetz, Marcin; Fine, Gregg D.; Hamid, Omid; Gordon, Michael S.; Sosman, Jeffery A.; McDermott, David F.; Powderly, John D.; Gettinger, Scott N.; Kohrt, Holbrook E. K.; Horn, Leora; Lawrence, Donald P.; Rost, Sandra; Leabman, Maya; Xiao, Yuanyuan; Mokatrin, Ahmad; Koeppen, Hartmut; Hegde, Priti S.; Mellman, Ira; Chen, Daniel S.; Hodi, F. Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">515</span>
        (<span class="NLM_cas:issue">7528</span>),
    <span class="NLM_cas:pages">563-567</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumor progression.  These changes distinguish cancer cells from their normal counterparts, allowing tumors to be recognized as foreign by the immune system.  However, tumors are rarely rejected spontaneously, reflecting their ability to maintain an immunosuppressive microenvironment.  Programmed death-ligand 1 (PD-L1; also called B7-H1 or CD274), which is expressed on many cancer and immune cells, plays an important part in blocking the 'cancer immunity cycle' by binding programmed death-1 (PD-1) and B7.1 (CD80), both of which are neg. regulators of T-lymphocyte activation.  Binding of PD-L1 to its receptors suppresses T-cell migration, proliferation and secretion of cytotoxic mediators, and restricts tumor cell killing.  The PD-L1-PD-1 axis protects the host from overactive T-effector cells not only in cancer but also during microbial infections.  Blocking PD-L1 should therefore enhance anticancer immunity, but little is known about predictive factors of efficacy.  This study was designed to evaluate the safety, activity and biomarkers of PD-L1 inhibition using the engineered humanized antibody MPDL3280A.  Here we show that across multiple cancer types, responses (as evaluated by Response Evaluation Criteria in Solid Tumors, version 1.1) were obsd. in patients with tumors expressing high levels of PD-L1, esp. when PD-L1 was expressed by tumor-infiltrating immune cells.  Furthermore, responses were assocd. with T-helper type 1 (TH1) gene expression, CTLA4 expression and the absence of fractalkine (CX3CL1) in baseline tumor specimens.  Together, these data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWwkJV0J8Y_bVg90H21EOLACvtfcHk0lhxKHpIy980WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFanurbM&md5=1a5efa7b5929ca48ed17cb530e4f7916</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnature14011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14011%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DKowanetz%26aufirst%3DM.%26aulast%3DFine%26aufirst%3DG.%2BD.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DKohrt%26aufirst%3DH.%2BE.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DLawrence%26aufirst%3DD.%2BP.%26aulast%3DRost%26aufirst%3DS.%26aulast%3DLeabman%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DMokatrin%26aufirst%3DA.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DHegde%26aufirst%3DP.%2BS.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DD.%2BS.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26atitle%3DPredictive%2520correlates%2520of%2520response%2520to%2520the%2520anti-PD-L1%2520antibody%2520MPDL3280A%2520in%2520cancer%2520patients%26jtitle%3DNature%26date%3D2014%26volume%3D515%26spage%3D563%26epage%3D567%26doi%3D10.1038%2Fnature14011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juneja, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manguso, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFleur, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haining, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1084/jem.20160801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1084%2Fjem.20160801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28302645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2ju7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2017&pages=895-904&author=V.+R.+Junejaauthor=K.+A.+McGuireauthor=R.+T.+Mangusoauthor=M.+W.+LaFleurauthor=N.+Collinsauthor=W.+N.+Hainingauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-L1+on+tumor+cells+is+sufficient+for+immune+evasion+in+immunogenic+tumors+and+inhibits+CD8+T+cell+cytotoxicity&doi=10.1084%2Fjem.20160801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity</span></div><div class="casAuthors">Juneja, Vikram R.; McGuire, Kathleen A.; Manguso, Robert T.; LaFleur, Martin W.; Collins, Natalie; Haining, W. Nicholas; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-904</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">It is unclear whether PD-L1 on tumor cells is sufficient for tumor immune evasion or simply correlates with an inflamed tumor microenvironment.  We used three mouse tumor models sensitive to PD-1 blockade to evaluate the significance of PD-L1 on tumor vs. nontumor cells.  PD-L1 on nontumor cells is crit. for inhibiting antitumor immunity in B16 melanoma and a genetically engineered melanoma.  In contrast, PD-L1 on MC38 colorectal adenocarcinoma cells is sufficient to suppress antitumor immunity, as deletion of PD-L1 on highly immunogenic MC38 tumor cells allows effective antitumor immunity.  MC38-derived PD-L1 potently inhibited CD8+ T cell cytotoxicity.  Wild-type MC38 cells outcompeted PD-L1-deleted MC38 cells in vivo, demonstrating tumor PD-L1 confers a selective advantage.  Thus, both tumor- and host-derived PD-L1 can play crit. roles in immunosuppression.  Differences in tumor immunogenicity appear to underlie their relative importance.  Our findings establish reduced cytotoxicity as a key mechanism by which tumor PD-L1 suppresses antitumor immunity and demonstrate that tumor PD-L1 is not just a marker of suppressed antitumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOvfjGoOhPg7Vg90H21EOLACvtfcHk0lhxKHpIy980WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2ju7nJ&md5=95ceac8e66dd13f327bfc0eb3dab42c1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1084%2Fjem.20160801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20160801%26sid%3Dliteratum%253Aachs%26aulast%3DJuneja%26aufirst%3DV.%2BR.%26aulast%3DMcGuire%26aufirst%3DK.%2BA.%26aulast%3DManguso%26aufirst%3DR.%2BT.%26aulast%3DLaFleur%26aufirst%3DM.%2BW.%26aulast%3DCollins%26aufirst%3DN.%26aulast%3DHaining%26aufirst%3DW.%2BN.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-L1%2520on%2520tumor%2520cells%2520is%2520sufficient%2520for%2520immune%2520evasion%2520in%2520immunogenic%2520tumors%2520and%2520inhibits%2520CD8%2520T%2520cell%2520cytotoxicity%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2017%26volume%3D214%26spage%3D895%26epage%3D904%26doi%3D10.1084%2Fjem.20160801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 11 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Liu Liu, Zhiying Yao, Shijun Wang, Tao Xie, Guoqing Wu, Honghan Zhang, Pu Zhang, Yaojun Wu, Haoliang Yuan, <span class="NLM_string-name hlFld-ContribAuthor">Hongbin Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[c][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with In Vivo Antitumor Activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8391-8409. <a href="https://doi.org/10.1021/acs.jmedchem.1c00392" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00392%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSyntheses%25252C%252BBiological%252BEvaluations%25252C%252Band%252BMechanistic%252BStudies%252Bof%252BBenzo%25255Bc%25255D%25255B1%25252C2%25252C5%25255Doxadiazole%252BDerivatives%252Bas%252BPotent%252BPD-L1%252BInhibitors%252Bwith%252BIn%252BVivo%252BAntitumor%252BActivity%26aulast%3DLiu%26aufirst%3DLiu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04032021%26date%3D11062021%26volume%3D64%26issue%3D12%26spage%3D8391%26epage%3D8409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yiqiang OuYang, Jian Gao, Lei Zhao, Junfeng Lu, Haiqing Zhong, Hua Tang, Shuanglong Jin, Lu Yue, Yuezhen Li, Wenjie Guo, Qiang Xu, <span class="NLM_string-name hlFld-ContribAuthor">Yisheng Lai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7646-7666. <a href="https://doi.org/10.1021/acs.jmedchem.1c00370" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00370%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BEvaluation%252Bof%252Bo-%252528Biphenyl-3-ylmethoxy%252529nitrophenyl%252BDerivatives%252Bas%252BPD-1%25252FPD-L1%252BInhibitors%252Bwith%252BPotent%252BAnticancer%252BEfficacy%252BIn%252BVivo%26aulast%3DOuYang%26aufirst%3DYiqiang%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01032021%26date%3D26052021%26volume%3D64%26issue%3D11%26spage%3D7646%26epage%3D7666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Tianyu Wang, Shi Cai, Mingming Wang, Wanheng Zhang, Kuojun Zhang, Dong Chen, Zheng Li, <span class="NLM_string-name hlFld-ContribAuthor">Sheng Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7390-7403. <a href="https://doi.org/10.1021/acs.jmedchem.1c00010" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00010%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BBiphenyl%252BPyridines%252Bas%252BPotent%252BSmall-Molecule%252BInhibitors%252BTargeting%252Bthe%252BProgrammed%252BCell%252BDeath-1%25252FProgrammed%252BCell%252BDeath-Ligand%252B1%252BInteraction%26aulast%3DWang%26aufirst%3DTianyu%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D04012021%26date%3D31052021%26volume%3D64%26issue%3D11%26spage%3D7390%26epage%3D7403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mingze Qin, Yangyang Meng, Haoshen Yang, Lei Liu, Haotian Zhang, Simeng Wang, Chunyang Liu, Xia Wu, Di Wu, Ye Tian, Yunlei Hou, Yanfang Zhao, Yajing Liu, Congjun Xu, <span class="NLM_string-name hlFld-ContribAuthor">Lihui Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (9)
                                     , 5519-5534. <a href="https://doi.org/10.1021/acs.jmedchem.0c01958" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01958</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01958%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-Arylindolines%252BContaining%252Ba%252BThiazole%252BMoiety%252Bas%252BPotential%252BAntitumor%252BAgents%252BInhibiting%252Bthe%252BProgrammed%252BCell%252BDeath-1%25252FProgrammed%252BCell%252BDeath-Ligand%252B1%252BInteraction%26aulast%3DQin%26aufirst%3DMingze%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D12112020%26date%3D03052021%26volume%3D64%26issue%3D9%26spage%3D5519%26epage%3D5534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Binbin Cheng, Yao Xiao, Mingming Xue, Hao Cao, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15389-15398. <a href="https://doi.org/10.1021/acs.jmedchem.0c01362" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01362</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01362%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BPD-L1%252BModulators%25253A%252BDegraders%25252C%252BDownregulators%25252C%252Band%252BCovalent%252BInhibitors%26aulast%3DCheng%26aufirst%3DBinbin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04082020%26date%3D04122020%26volume%3D63%26issue%3D24%26spage%3D15389%26epage%3D15398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Binbin Cheng, Wei Wang, Xiaoge Niu, Yichang Ren, Ting Liu, Hao Cao, Shuanghu Wang, Yingfeng Tu, Jingxuan Chen, Shuwen Liu, Xuchao Yang, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15946-15959. <a href="https://doi.org/10.1021/acs.jmedchem.0c01684" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01684</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01684%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252Band%252BHighly%252BPotent%252BResorcinol%252BDibenzyl%252BEther-Based%252BPD-1%25252FPD-L1%252BInhibitors%252Bwith%252BImproved%252BDrug-like%252Band%252BPharmacokinetic%252BProperties%252Bfor%252BCancer%252BTreatment%26aulast%3DCheng%26aufirst%3DBinbin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29092020%26date%3D02122020%26volume%3D63%26issue%3D24%26spage%3D15946%26epage%3D15959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinyan  Dai</span>, <span class="hlFld-ContribAuthor ">Ke  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Xupeng  Huang</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105034. <a href="https://doi.org/10.1016/j.bioorg.2021.105034" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105034%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252B1-methyl-1H-pyrazolo%25255B4%25252C3-b%25255Dpyridine%252Bderivatives%252Bas%252Bnovel%252Bsmall-molecule%252Binhibitors%252Btargeting%252Bthe%252BPD-1%25252FPD-L1%252Binteraction%26aulast%3DDai%26aufirst%3DXinyan%26date%3D2021%26volume%3D114%26spage%3D105034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chenglong  Liu</span>, <span class="hlFld-ContribAuthor ">Feilong  Zhou</span>, <span class="hlFld-ContribAuthor ">Ziqin  Yan</span>, <span class="hlFld-ContribAuthor ">Lian  Shen</span>, <span class="hlFld-ContribAuthor ">Xichen  Zhang</span>, <span class="hlFld-ContribAuthor ">Fenglian  He</span>, <span class="hlFld-ContribAuthor ">Heng  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaojie  Lu</span>, <span class="hlFld-ContribAuthor ">Ker  Yu</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>, <span class="hlFld-ContribAuthor ">Di  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a novel, potent and selective small‐molecule inhibitor of PD‐1/PD‐L1 interaction with robust
              in vivo
              anti‐tumour efficacy. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2021,</strong> <em>178 </em>
                                    (13)
                                     , 2651-2670. <a href="https://doi.org/10.1111/bph.15457" title="DOI URL">https://doi.org/10.1111/bph.15457</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.15457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.15457%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DDiscovery%252Bof%252Ba%252Bnovel%25252C%252Bpotent%252Band%252Bselective%252Bsmall%2525E2%252580%252590molecule%252Binhibitor%252Bof%252BPD%2525E2%252580%2525901%25252FPD%2525E2%252580%252590L1%252Binteraction%252Bwith%252Brobust%252Bin%252Bvivo%252Banti%2525E2%252580%252590tumour%252Befficacy%26aulast%3DLiu%26aufirst%3DChenglong%26date%3D2021%26date%3D2021%26volume%3D178%26issue%3D13%26spage%3D2651%26epage%3D2670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Cao</span>, <span class="hlFld-ContribAuthor ">Binbin  Cheng</span>, <span class="hlFld-ContribAuthor ">Ting  Liu</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>188 </em>, 114522. <a href="https://doi.org/10.1016/j.bcp.2021.114522" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114522</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114522%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DSynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252Bnovel%252Bresorcinol%252Bbiphenyl%252Bether%252Banalogs%252Bas%252Bsmall%252Bmolecule%252Binhibitors%252Bof%252BPD-1%25252FPD-L1%252Bwith%252Bbenign%252Btoxicity%252Bprofiles%252Bfor%252Bcancer%252Btreatment%26aulast%3DCao%26aufirst%3DHao%26date%3D2021%26volume%3D188%26spage%3D114522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuchao  Yang</span>, <span class="hlFld-ContribAuthor ">Binbin  Cheng</span>, <span class="hlFld-ContribAuthor ">Yao  Xiao</span>, <span class="hlFld-ContribAuthor ">Mingming  Xue</span>, <span class="hlFld-ContribAuthor ">Ting  Liu</span>, <span class="hlFld-ContribAuthor ">Hao  Cao</span>, <span class="hlFld-ContribAuthor ">Jianjun  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113058. <a href="https://doi.org/10.1016/j.ejmech.2020.113058" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113058%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252BCA-4%252Banalogs%252Bas%252Bdual%252Binhibitors%252Bof%252Btubulin%252Bpolymerization%252Band%252BPD-1%25252FPD-L1%252Binteraction%252Bfor%252Bcancer%252Btreatment%26aulast%3DYang%26aufirst%3DXuchao%26date%3D2021%26volume%3D213%26spage%3D113058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">磊  赵</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Biological Evaluation of Naphthalene Ring PD-1/PD-L1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Hans Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>09 </em>
                                    (02)
                                     , 94-103. <a href="https://doi.org/10.12677/HJMCe.2021.92012" title="DOI URL">https://doi.org/10.12677/HJMCe.2021.92012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.12677/HJMCe.2021.92012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.12677%2FHJMCe.2021.92012%26sid%3Dliteratum%253Aachs%26jtitle%3DHans%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BNaphthalene%252BRing%252BPD-1%25252FPD-L1%252BInhibitors%26aulast%3D%25E8%25B5%25B5%26aufirst%3D%25E7%25A3%258A%26date%3D2021%26volume%3D09%26issue%3D02%26spage%3D94%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of small molecule PD-1/PD-L1 pathway inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Chalcone Compounds <b>CET1–13</b> and Flavonoid Compounds <b>HT1–13</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) paraformaldehyde, concentrated hydrochloric acid, 50 °C, 10 h, 37%; (b) DCM, 40 °C, 2 h, 60%∼70%; (c) KOH, MeOH, 25 °C, 24 h, 40%∼50%; (d) iodine, DMSO, 100 °C, 24 h, 8%∼12%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Naphthalene Compounds <b>N1–17</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PPh<sub>3</sub>, DIAD, THF, 0 °C∼25 °C, 10 h, 36%∼40%; (b) MeOH, AcOH, NaBH<sub>3</sub>CN, 60 °C, 12 h, 15%∼25%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0015.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds NC1–12 and <b>NP1–25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PPh<sub>3</sub>, DIAD, THF, 0 °C∼25 °C, 10 h, 16%∼20%; (b) DMF, Na<sub>2</sub>CO<sub>3</sub>, 80 °C, 30 min, 70%∼80%; (c) DMF, AcOH, NaBH<sub>3</sub>CN, 80 °C, 2 h, 15%∼25%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0016.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>NT1–22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaHCO<sub>3</sub>, DMF, 60 °C, 2 h, 40%; (b) DMF, Na<sub>2</sub>CO<sub>3</sub>, 80 °C, 30 min, 60%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, DMSO, H<sub>2</sub>O, 100 °C, 12 h, 25%∼30%; (d) DMF, AcOH, NaBH<sub>3</sub>CN, 80 °C, 2 h, 15%∼25%.</p></p></figure><figure data-id="fig2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0002.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Docking analysis of <b>Bavachinin</b> with the PD-L1 dimer. (B) Detailed interactions of <b>BMS-202</b> with dimeric PD-L1 protein. (C) Binding overlap of <b>Bavachinin</b> (yellow stick) and <b>BMS-202</b> (light pink stick) in the binding site. The crystal structure of the dimeric PD-L1 protein was taken from the RCSB Protein Data Bank (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89">5J89</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Detailed interactions of <b>BMS-202</b> with the dimeric PD-L1 protein. (B) Docking analysis of <b>CET3</b> with the PD-L1 dimer. (C) Docking analysis of <b>HT11</b> with the PD-L1 dimer. The crystal structure of the dimeric PD-L1 protein was taken from the RCSB Protein Data Bank (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89">5J89</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0004.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. SAR of PD-1/PD-L1 inhibitors. Compounds <b>Incyte-1</b>, <b>A22</b>, <b>Incyte-2</b>, <b>BMS-1016</b>, <b>BMS-1006</b>, and <b>BMS-8</b> were reported by patents or literature.<a onclick="showRef(event, 'ref30 ref31 ref32 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref34 ref35 ref36">(30−32,34−36)</a> Compounds <b>HT11</b>, <b>N8</b>, <b>XA1</b>, <b>NP2</b>, <b>NT20</b>, and <b>NP19</b> were newly synthesized and reported in this paper.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0005.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Effects of compound <b>NP19</b> and Keytruda on IFN-γ secretion from T cells cocultured with tumor cells. Data are shown as mean ± SD, **<i>P</i> < 0.05 compared with vehicle group (<i>n</i> = 3, Dunnett’s multiple comparison test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0006.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. <i>In vivo</i> efficacy study of <b>NP19</b> against B16-F10 melanoma tumors in BALB/c mice. Images of tumor growth in mice treated with vehicle control or <b>NP19</b> (25 mg/kg, 50 mg/kg, 100 mg/kg) are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0007.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Melanoma tumor weight ± SD (<i>n</i> = 10) in vehicle control or <b>NP19</b> treated mice, **<i>P</i> < 0.05 compared with vehicle group (<i>n</i> = 10, Dunnett’s multiple comparison test). (B) Mice body weight ± SD (<i>n</i> = 10) in vehicle control or <b>NP19</b> treated mice. (C) Spleen weight ± SD (<i>n</i> = 10) in vehicle control or <b>NP19</b> treated mice. (D) Thymus weight ± SD (<i>n</i> = 10) in vehicle control or <b>NP19</b> treated mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0008.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <i>In vivo</i> efficacy study of <b>NP19</b> against H22 hepatoma tumor in mice. After intraperitoneal injection with vehicle and compound <b>NP19</b> (25 mg/kg per day) for 14 days, the mice were sacrificed, and the excised tumors were weighed. (A) Images of excised tumors in each group. (B) Weight of the excised tumors of each group. (C) Tumor volume changes during treatment. (D) Body weight changes of mice during treatment. The data were presented as the mean ± SD, **<i>P</i> < 0.05 vs control group, <i>n</i> = 6.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0009.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Expression levels of PD-L1 protein in melanoma tumors. (A) Negative control without adding the primary antibody PD-L1 (D5 V3B) rabbit mAb; (B) mAb-treated group with PD-L1 (D5 V3B) rabbit mAb (primary antibody) and anti-rabbit-IgG H&L (Alexa Fluor488) antibody (second antibody) added.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0010.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Pathological sections of major tissues (kidney, liver) obtained from mice bearing melanoma tumors. (B) Pathological sections of melanoma tumors. Organs were stained with Hematoxylin and Eosin (H&E), and representative images were captured.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0011.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Representative examples for melanoma tumor CD3<sup>+</sup>CD4<sup>+</sup> cells (helper T cells) and CD3<sup>+</sup>CD8<sup>+</sup> cells (activated cytotoxic T cells) in vehicle control or <b>NP19</b> treated mice. (B) Representative image for spleen CD3<sup>+</sup>CD4<sup>+</sup> cells and CD3<sup>+</sup>CD8<sup>+</sup> cells in vehicle control or <b>NP19</b> treated melanoma-bearing mice. The percentages of immune cells were quantified by flow cytometry: (upper left quadrant) CD4<sup>+</sup> or CD8<sup>+</sup> cells; (upper right quadrant) CD3<sup>+</sup>CD4<sup>+</sup> or CD3<sup>+</sup>CD8<sup>+</sup> cells; (bottom left quadrant) spleen or melanoma tumor cells; and (bottom right quadrant) CD3<sup>+</sup> cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/medium/jm0c00574_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0012.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. (A) Melanoma tumor CD3<sup>+</sup>CD4<sup>+</sup> cells ± SD (<i>n</i> = 6) in vehicle control or <b>NP19</b> treated mice, **<i>P</i> < 0.05 compared with vehicle group (<i>n</i> = 6, Dunnett’s multiple comparison test). (B) Melanoma tumor CD3<sup>+</sup>CD8<sup>+</sup> cells ± SD (<i>n</i> = 6) in vehicle control or <b>NP19</b> treated mice. (C) Spleen CD3<sup>+</sup>CD4<sup>+</sup> cells ± SD (<i>n</i> = 6) in vehicle control or <b>NP19</b> treated melanoma bearing mice. (D) Spleen CD3<sup>+</sup>CD8<sup>+</sup> cells ± SD (<i>n</i> = 6) in vehicle control or <b>NP19</b> treated melanoma bearing mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-15/acs.jmedchem.0c00574/20200806/images/large/jm0c00574_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00574&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i108">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86313" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86313" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 48 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giroux
Leprieur, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumenil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julie, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giraud, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumoulin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labrune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinet, T.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2016.12.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.ejca.2016.12.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28407528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1WitL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2017&pages=16-23&author=E.+Giroux%0ALeprieurauthor=C.+Dumenilauthor=C.+Julieauthor=V.+Giraudauthor=J.+Dumoulinauthor=S.+Labruneauthor=T.+Chinet&title=Immunotherapy+revolutionises+non-small-cell+lung+cancer+therapy%3A+results%2C+perspectives+and+new+challenges&doi=10.1016%2Fj.ejca.2016.12.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges</span></div><div class="casAuthors">Giroux Leprieur, Etienne; Dumenil, Coraline; Julie, Catherine; Giraud, Violaine; Dumoulin, Jennifer; Labrune, Sylvie; Chinet, Thierry</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16-23</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Immune checkpoint inhibitors (ICIs) are antibodies that target key signalling pathways such as programmed death 1 (PD1)/programmed death-ligands 1 and 2 (PDL1 and PDL2) to improve anti-tumor immune responses.  Until recently, nivolumab was the only ICI validated for advanced non-small-cell lung cancer (NSCLC) in a second-line treatment setting.  Results from recent phase II and phase III randomised trials testing other ICIs have been presented.  In Keynote-024, pembrolizumab, an anti-PD1 antibody, was reported to have great efficacy in the first-line treatment of PDL1 ≥ 50% tumors (30% of screened tumors), with a progression-free survival (PFS, median) of 10.4 mo vs. 6.0 mo with chemotherapy (CT; hazard ratio [HR] = 0.50; 95% confidence interval [95% CI] 0.37-0.68, P < 0.001), overall response rate (ORR) of 45% vs. 28% with CT (P = 0.0011), and a 1-yr overall survival (OS) of around 70%.  In contrast, Checkmate-026 reported that nivolumab failed to show any benefit compared with std. platinum-based CT, with a PFS (median) in the PDL1 ≥ 5% NSCLC group of 4.2 mo (nivolumab) vs. 5.9 mo (CT; HR = 1.15: 95% CI 0.91-1.45, P = 0.25).  No benefit was obsd. in the PDL1 ≥ 50% subgroup.  An encouraging report of the efficacy of pembrolizumab in addn. to CT in first-line treatment in unselected NSCLC was also presented (Keynote-021) with an ORR of 55% vs. 29% with CT alone (P = 0.0016).  Atezolizumab, an anti-PDL1 antibody, showed efficacy for second-line treatment compared with docetaxel (OAK phase III study) with an OS (median) of 13.8 mo vs. 9.6 mo with docetaxel.  These results suggest a new paradigm for the treatment of advanced NSCLC using pembrolizumab for the first-line treatment of PDL1 ≥ 50% tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBggcFpUUyMrVg90H21EOLACvtfcHk0ljR6gGYeE-YkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1WitL0%253D&md5=579dfdb1eac14da9a8504517986df41c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2016.12.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2016.12.041%26sid%3Dliteratum%253Aachs%26aulast%3DGiroux%2BLeprieur%26aufirst%3DE.%26aulast%3DDumenil%26aufirst%3DC.%26aulast%3DJulie%26aufirst%3DC.%26aulast%3DGiraud%26aufirst%3DV.%26aulast%3DDumoulin%26aufirst%3DJ.%26aulast%3DLabrune%26aufirst%3DS.%26aulast%3DChinet%26aufirst%3DT.%26atitle%3DImmunotherapy%2520revolutionises%2520non-small-cell%2520lung%2520cancer%2520therapy%253A%2520results%252C%2520perspectives%2520and%2520new%2520challenges%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2017%26volume%3D78%26spage%3D16%26epage%3D23%26doi%3D10.1016%2Fj.ejca.2016.12.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, W.</span></span> <span> </span><span class="NLM_article-title">The checkpoint immunotherapy revolution: what started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge</span>. <i>Pharm. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=185-191&author=W.+Alexander&title=The+checkpoint+immunotherapy+revolution%3A+what+started+as+a+trickle+has+become+a+flood%2C+despite+some+daunting+adverse+effects%3B+new+drugs%2C+indications%2C+and+combinations+continue+to+emerge"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlexander%26aufirst%3DW.%26atitle%3DThe%2520checkpoint%2520immunotherapy%2520revolution%253A%2520what%2520started%2520as%2520a%2520trickle%2520has%2520become%2520a%2520flood%252C%2520despite%2520some%2520daunting%2520adverse%2520effects%253B%2520new%2520drugs%252C%2520indications%252C%2520and%2520combinations%2520continue%2520to%2520emerge%26jtitle%3DPharm.%2520Ther.%26date%3D2016%26volume%3D41%26spage%3D185%26epage%3D191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Cancer immunotherapy: harnessing the immune system to battle cancer</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">3335</span>– <span class="NLM_lpage">3337</span>, <span class="refDoi"> DOI: 10.1172/JCI83871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1172%2FJCI83871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=26325031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A280%3ADC%252BC287otVersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3335-3337&author=Y.+Yang&title=Cancer+immunotherapy%3A+harnessing+the+immune+system+to+battle+cancer&doi=10.1172%2FJCI83871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer immunotherapy: harnessing the immune system to battle cancer</span></div><div class="casAuthors">Yang Yiping</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3335-7</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer immunotherapy.  These successes also underscore the importance of understanding basic tumor immunology for successful clinical translation in treating patients with cancer.  The Reviews in this Review Series focus on current developments in cancer immunotherapy, highlight recent advances in our understanding of basic aspects of tumor immunology, and suggest how these insights can lead to the development of new immunotherapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTCDsEQcCnxNc25P7XSLhESfW6udTcc2eaNH1Ee9hfpRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287otVersw%253D%253D&md5=5a53437eb397adb28804ede24b04c8cf</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1172%2FJCI83871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI83871%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26atitle%3DCancer%2520immunotherapy%253A%2520harnessing%2520the%2520immune%2520system%2520to%2520battle%2520cancer%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D3335%26epage%3D3337%26doi%3D10.1172%2FJCI83871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, S. A.</span></span> <span> </span><span class="NLM_article-title">Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">632</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2014.174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnrclinonc.2014.174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=25311350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A280%3ADC%252BC2M7pvFOrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=630-632&author=S.+A.+Rosenberg&title=Decade+in+review-cancer+immunotherapy%3A+entering+the+mainstream+of+cancer+treatment&doi=10.1038%2Fnrclinonc.2014.174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Decade in review-cancer immunotherapy: entering the mainstream of cancer treatment</span></div><div class="casAuthors">Rosenberg Steven A</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">630-2</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTqtYSUle6TmBAiYWy6n3SfW6udTcc2eZpRFZdFReYE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7pvFOrug%253D%253D&md5=f28ea9cae64fbddd396fecbcaf063276</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2014.174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2014.174%26sid%3Dliteratum%253Aachs%26aulast%3DRosenberg%26aufirst%3DS.%2BA.%26atitle%3DDecade%2520in%2520review-cancer%2520immunotherapy%253A%2520entering%2520the%2520mainstream%2520of%2520cancer%2520treatment%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D11%26spage%3D630%26epage%3D632%26doi%3D10.1038%2Fnrclinonc.2014.174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhanak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, P. J.</span></span> <span> </span><span class="NLM_article-title">Small-molecule targets in immuno-oncology</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1148</span>– <span class="NLM_lpage">1160</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.08.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.chembiol.2017.08.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28938090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1148-1160&author=D.+Dhanakauthor=J.+P.+Edwardsauthor=A.+Nguyenauthor=P.+J.+Tummino&title=Small-molecule+targets+in+immuno-oncology&doi=10.1016%2Fj.chembiol.2017.08.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Targets in Immuno-Oncology</span></div><div class="casAuthors">Dhanak, Dashyant; Edwards, James P.; Nguyen, Ancho; Tummino, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1148-1160</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Advances in understanding the role and mol. mechanisms underlying immune surveillance and control of (pre)malignancies is revolutionizing clin. practice in the treatment of cancer.  Presently, multiple biol. drugs targeting the immune checkpoint proteins PD(L)1 or CTLA4 have been approved and/or are in advanced stages of clin. development for many cancers.  In addn., combination therapy with these agents and other immunomodulators is being intensively explored with the aim of improving primary response rates or prolonging overall survival.  The effectiveness of cancer immunotherapy with biologics is spurring research in alternate approaches including small-mol.-mediated targeting of intracellular pathways modulating the innate and adaptive immune response.  This focus of this review is on some of the key intracellular pathways where the development of a small-mol. therapeutic is attractive, tractable, and potentially synergistic with extracellular biol.-mediated immune checkpoint blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSIXjWBbl9wbVg90H21EOLACvtfcHk0liAOMLEWyZT6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFGgurnL&md5=7f0f2368bec10000a87a3234bb82c035</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.08.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.08.019%26sid%3Dliteratum%253Aachs%26aulast%3DDhanak%26aufirst%3DD.%26aulast%3DEdwards%26aufirst%3DJ.%2BP.%26aulast%3DNguyen%26aufirst%3DA.%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26atitle%3DSmall-molecule%2520targets%2520in%2520immuno-oncology%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2017%26volume%3D24%26spage%3D1148%26epage%3D1160%26doi%3D10.1016%2Fj.chembiol.2017.08.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span> <span> </span><span class="NLM_article-title">Transcriptional activation of PD-L1 by sox2 contributes to the proliferation of hepatocellular carcinoma cells</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">3061</span>– <span class="NLM_lpage">3067</span>, <span class="refDoi"> DOI: 10.3892/or.2017.5523</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.3892%2For.2017.5523" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28339084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVOhsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2017&pages=3061-3067&author=F.+Zhongauthor=X.+Chengauthor=S.+Sunauthor=J.+Zhou&title=Transcriptional+activation+of+PD-L1+by+sox2+contributes+to+the+proliferation+of+hepatocellular+carcinoma+cells&doi=10.3892%2For.2017.5523"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells</span></div><div class="casAuthors">Zhong, Feng; Cheng, Xinsheng; Sun, Shibo; Zhou, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">3061-3067</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies in the world.  Sox2 is a potential oncogene in the pathogenesis of HCC, however, the actual mechanisms of Sox2 functions in HCC has not emerged yet.  In this study, we explored the expression, function and the relationship between Sox2 and PD-L1 in HCC.  We found that both Sox2 and PD-L1 were expressed at a markedly higher level in HCC tissues in comparison to adjacent non-tumor tissues.  Moreover, the expression levels of both genes were correlated with each other.  Knockdown of Sox2 reduced the cell proliferation ability and induces apoptosis of HCC cells, suggesting the function of Sox2 in regulating both the cell proliferation and apoptosis.  Noteworthy, the depletion of Sox2 also reduced the expression of PD-L1.  Further anal. showed that there is a consensus Sox2 binding site in the promoter region of PD-L1.  Through in vitro EMSA assay and in vivo chromatin immunopptn. assays, we demonstrated that Sox2 directly bound to the PD-L1 promoter through the consensus Sox2 motif.  Further evidence by luciferase reporter assays revealed that Sox2 promoted the transcription activity of PD-L1 promoter region through the Sox2 motif.  Collectively, our data provide a novel insight into the function and the interplay of Sox2 and PD-L1 in HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPyoVYfudBKLVg90H21EOLACvtfcHk0liAOMLEWyZT6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVOhsLk%253D&md5=9f3b11a3e650a52c402cb66bd8e4e7c9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3892%2For.2017.5523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2017.5523%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DTranscriptional%2520activation%2520of%2520PD-L1%2520by%2520sox2%2520contributes%2520to%2520the%2520proliferation%2520of%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DOncol.%2520Rep.%26date%3D2017%26volume%3D37%26spage%3D3061%26epage%3D3067%26doi%3D10.3892%2For.2017.5523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>406</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2017.07.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.canlet.2017.07.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28797844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlWks7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2017&pages=27-35&author=X.+Shiauthor=X.+Zhangauthor=J.+Liauthor=H.+Zhaoauthor=L.+Moauthor=X.+Shiauthor=Z.+Huauthor=J.+Gaoauthor=W.+Tan&title=PD-1%2FPD-L1+blockade+enhances+the+efficacy+of+SA-GM-CSF+surface-modified+tumor+vaccine+in+prostate+cancer&doi=10.1016%2Fj.canlet.2017.07.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer</span></div><div class="casAuthors">Shi, Xiaojun; Zhang, Xinji; Li, Jinlong; Zhao, Hongfan; Mo, Lijun; Shi, Xianghua; Hu, Zhiming; Gao, Jimin; Tan, Wanlong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">27-35</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Program death receptor-1 (PD-1)/program death ligand 1 (PD-L1) signaling plays an important role in tumor adaptive immune resistance.  The streptavidin-granulocyte-macrophage colony stimulating factor (SA-GM-CSF) surface-modified tumor cells vaccine developed through our novel protein-anchor technol. could significantly promote the activation of dendritic cells.  Although GM-CSF vaccine could significantly increase the no. of tumor-specific CD8+T-cells, the majority of these CD8+T-cells expressed PD-1.  Moreover, GM-CSF vaccine up-regulated the PD-L1 expression of tumor cells, resulting in immune resistance.  Adding PD-1/PD-L1 blockade to GM-CSF vaccine therapy could significantly increase the population of CD4+ T, CD8+ T and CD8+ IFN-γ+ T but not CD4+ Foxp3+ T-cells and induced the highest prodn. of IFN-γ.  PD-1/PD-L1 blockade could effectively rescue the tumor-specific T lymphocytes generated by the GM-CSF vaccine, resulting in consistent tumor rejection.  Taken together, PD-1/PD-L1 blockade combined with SA-GM-CSF-modified vaccine could effectively induce a strong specific antitumor immune response against prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow34npepjP1rVg90H21EOLACvtfcHk0lhstCIvd2Mniw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlWks7%252FF&md5=4d35b9568bae551a53cdb4792de551e1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2017.07.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2017.07.029%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DMo%26aufirst%3DL.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DPD-1%252FPD-L1%2520blockade%2520enhances%2520the%2520efficacy%2520of%2520SA-GM-CSF%2520surface-modified%2520tumor%2520vaccine%2520in%2520prostate%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2017%26volume%3D406%26spage%3D27%26epage%3D35%26doi%3D10.1016%2Fj.canlet.2017.07.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S.</span></span> <span> </span><span class="NLM_article-title">Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer</span>. <i>Cancer Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">1753</span>– <span class="NLM_lpage">1763</span>, <span class="refDoi"> DOI: 10.1111/cas.13618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1111%2Fcas.13618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=29675979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvFWmuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2018&pages=1753-1763&author=Z.+Chenauthor=K.+Huauthor=L.+Fengauthor=R.+Suauthor=N.+Laiauthor=Z.+Yangauthor=S.+Kang&title=Senescent+cells+re-engineered+to+express+soluble+programmed+death+receptor-1+for+inhibiting+programmed+death+receptor-1%2Fprogrammed+death+ligand-1+as+a+vaccination+approach+against+breast+cancer&doi=10.1111%2Fcas.13618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Senescent cells re-engineered to express soluble programmed death receptor-1 for inhibiting programmed death receptor-1/programmed death ligand-1 as a vaccination approach against breast cancer</span></div><div class="casAuthors">Chen, Zehong; Hu, Kang; Feng, Lieting; Su, Ruxiong; Lai, Nan; Yang, Zike; Kang, Shijun</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1753-1763</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1349-7006</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Various types of vaccines have been proposed as approaches for prevention or delay of the onset of cancer by boosting the endogenous immune system.  We previously developed a senescent-cell-based vaccine, induced by radiation and veliparib, as a preventive and therapeutic tool against triple-neg. breast cancer.  However, the programmed death receptor-1/programmed death ligand-1 (PD-1/PD-L1) pathway was found to play an important role in vaccine failure.  Hence, we further developed sol. programmed death receptor-1 (sPD1)-expressing senescent cells to overcome PD-L1/PD-1-mediated immune suppression while vaccinating to promote dendritic cell (DC) maturity, thereby amplifying T-cell activation.  In the present study, sPD1-expressing senescent cells showed a particularly active status characterized by growth arrest and modified immunostimulatory cytokine secretion in vitro.  As expected, sPD1-expressing senescent tumor cell vaccine (STCV/sPD-1) treatment attracted more mature DC and fewer exhausted-PD1+ T cells in vivo.  During the course of the vaccine studies, we obsd. greater safety and efficacy for STCV/sPD-1 than for control treatments.  STCV/sPD-1 pre-injections provided complete protection from 4T1 tumor challenge in mice.  Addnl., the in vivo therapeutic study of mice with s.c. 4T1 tumor showed that STCV/sPD-1 vaccination delayed tumorigenesis and suppressed tumor progression at early stages.  These results showed that STCV/sPD-1 effectively induced a strong antitumor immune response against cancer and suggested that it might be a potential strategy for TNBC prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1aoZrIsOQ_7Vg90H21EOLACvtfcHk0lhstCIvd2Mniw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvFWmuro%253D&md5=dc9f8ab8a29bf8f8c8ca330ecdc2a6a9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fcas.13618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcas.13618%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DL.%26aulast%3DSu%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DKang%26aufirst%3DS.%26atitle%3DSenescent%2520cells%2520re-engineered%2520to%2520express%2520soluble%2520programmed%2520death%2520receptor-1%2520for%2520inhibiting%2520programmed%2520death%2520receptor-1%252Fprogrammed%2520death%2520ligand-1%2520as%2520a%2520vaccination%2520approach%2520against%2520breast%2520cancer%26jtitle%3DCancer%2520Sci.%26date%3D2018%26volume%3D109%26spage%3D1753%26epage%3D1763%26doi%3D10.1111%2Fcas.13618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bardhan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anagnostou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boussiotis, V. A.</span></span> <span> </span><span class="NLM_article-title">The PD-1:PD-L1/2 pathway from discovery to clinical implementation</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span> (<span class="NLM_issue">Article 550</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2016.00550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.3389%2Ffimmu.2016.00550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=26834743" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=1-17&issue=Article+550&author=K.+Bardhanauthor=T.+Anagnostouauthor=V.+A.+Boussiotis&title=The+PD-1%3APD-L1%2F2+pathway+from+discovery+to+clinical+implementation&doi=10.3389%2Ffimmu.2016.00550"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2016.00550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2016.00550%26sid%3Dliteratum%253Aachs%26aulast%3DBardhan%26aufirst%3DK.%26aulast%3DAnagnostou%26aufirst%3DT.%26aulast%3DBoussiotis%26aufirst%3DV.%2BA.%26atitle%3DThe%2520PD-1%253APD-L1%252F2%2520pathway%2520from%2520discovery%2520to%2520clinical%2520implementation%26jtitle%3DFront.%2520Immunol.%26date%3D2016%26volume%3D7%26issue%3DArticle%2520550%26spage%3D1%26epage%3D17%26doi%3D10.3389%2Ffimmu.2016.00550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2286</span>– <span class="NLM_lpage">2288</span>, <span class="refDoi"> DOI: 10.1002/anie.201307906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1002%2Fanie.201307906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A280%3ADC%252BC2czpvVOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=2286-2288&author=A.+Domlingauthor=T.+A.+Holak&title=Programmed+death-1%3A+therapeutic+success+after+more+than+100+years+of+cancer+immunotherapy&doi=10.1002%2Fanie.201307906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy</span></div><div class="casAuthors">Domling Alexander; Holak Tad A</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2286-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related.  Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies.  Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8kC5nL6VwzPcsfMJQC1ZdfW6udTcc2ebaKsfpFrEbJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2czpvVOhuw%253D%253D&md5=907c71bc856c102a3d93600aac71a2ea</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fanie.201307906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201307906%26sid%3Dliteratum%253Aachs%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DProgrammed%2520death-1%253A%2520therapeutic%2520success%2520after%2520more%2520than%2520100%2520years%2520of%2520cancer%2520immunotherapy%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2014%26volume%3D53%26spage%3D2286%26epage%3D2288%26doi%3D10.1002%2Fanie.201307906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drake, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">Immune checkpoint blockade: a common denominator approach to cancer therapy</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">450</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2015.03.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.ccell.2015.03.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=25858804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVaku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=450-461&author=S.+L.+Topalianauthor=C.+G.+Drakeauthor=D.+M.+Pardoll&title=Immune+checkpoint+blockade%3A+a+common+denominator+approach+to+cancer+therapy&doi=10.1016%2Fj.ccell.2015.03.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy</span></div><div class="casAuthors">Topalian, Suzanne L.; Drake, Charles G.; Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">450-461</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands.  These immune checkpoint pathways, which normally maintain self-tolerance and limit collateral tissue damage during anti-microbial immune responses, can be co-opted by cancer to evade immune destruction.  Drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, anti-PD-L1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions.  The complex biol. of immune checkpoint pathways still contains many mysteries, and the full activity spectrum of checkpoint-blocking drugs, used alone or in combination, is currently the subject of intense study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqb0YUggJYBrLVg90H21EOLACvtfcHk0lhoRXmCX3nsfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVaku7k%253D&md5=e42c02d50881184b78630e5dd23f7f2e</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.03.001%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DDrake%26aufirst%3DC.%2BG.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DImmune%2520checkpoint%2520blockade%253A%2520a%2520common%2520denominator%2520approach%2520to%2520cancer%2520therapy%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D450%26epage%3D461%26doi%3D10.1016%2Fj.ccell.2015.03.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassady, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span> <span> </span><span class="NLM_article-title">PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8<sup>+</sup> T cells</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">1960</span>– <span class="NLM_lpage">1977</span>, <span class="refDoi"> DOI: 10.1172/JCI91138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1172%2FJCI91138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28414296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A280%3ADC%252BC1cvotlShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=1960-1977&author=X.+Niauthor=Q.+Songauthor=K.+Cassadyauthor=R.+Dengauthor=H.+Jinauthor=M.+Zhangauthor=H.+Dongauthor=S.+Formanauthor=P.+J.+Martinauthor=Y.+Z.+Chenauthor=J.+Wangauthor=D.+Zeng&title=PD-L1+interacts+with+CD80+to+regulate+graft-versus-leukemia+activity+of+donor+CD8%2B+T+cells&doi=10.1172%2FJCI91138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells</span></div><div class="casAuthors">Ni Xiong; Song Qingxiao; Cassady Kaniel; Deng Ruishu; Jin Hua; Zhang Mingfeng; Dong Haidong; Forman Stephen; Martin Paul J; Chen Yuan-Zhong; Wang Jianmin; Zeng Defu</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1960-1977</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Programmed death ligand-1 (PD-L1) interacts with programmed death-1 (PD-1) and the immunostimulatory molecule CD80 and functions as a checkpoint to regulate immune responses.  The interaction of PD-L1 with CD80 alone has been shown to exacerbate the severity of graft-versus-host disease (GVHD), whereas costimulation of CD80 and PD-1 ameliorates GVHD.  Here we have demonstrated that temporary depletion of donor CD4+ T cells early after hematopoietic cell transplantation effectively prevents GVHD while preserving strong graft-versus-leukemia (GVL) effects in allogeneic and xenogeneic murine GVHD models.  Depletion of donor CD4+ T cells increased serum IFN-γ but reduced IL-2 concentrations, leading to upregulation of PD-L1 expression by recipient tissues and donor CD8+ T cells.  In GVHD target tissues, the interactions of PD-L1 with PD-1 on donor CD8+ T cells cause anergy, exhaustion, and apoptosis, thereby preventing GVHD.  In lymphoid tissues, the interactions of PD-L1 with CD80 augment CD8+ T cell expansion without increasing anergy, exhaustion, or apoptosis, resulting in strong GVL effects.  These results indicate that the outcome of PD-L1-mediated signaling in CD8+ T cells depends on the presence or absence of CD4+ T cells, the nature of the interacting receptor expressed by CD8+ T cells, and the tissue environment in which the signaling occurs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRj4Yk771GSWjDnmmyUf5qOfW6udTcc2eaOI6oEtGzxArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvotlShtQ%253D%253D&md5=39c5a3f1375dafd766a0ad4952f27dca</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1172%2FJCI91138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI91138%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DQ.%26aulast%3DCassady%26aufirst%3DK.%26aulast%3DDeng%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DH.%26aulast%3DForman%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%2BJ.%26aulast%3DChen%26aufirst%3DY.%2BZ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DD.%26atitle%3DPD-L1%2520interacts%2520with%2520CD80%2520to%2520regulate%2520graft-versus-leukemia%2520activity%2520of%2520donor%2520CD8%252B%2520T%2520cells%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D1960%26epage%3D1977%26doi%3D10.1172%2FJCI91138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span> <span> </span><span class="NLM_article-title">The systemic activation of programmed death 1-PD-L1 axis protects systemic lupus erythematosus model from nephritis</span>. <i>Am. J. Nephrol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">379</span>, <span class="refDoi"> DOI: 10.1159/000480641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1159%2F000480641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=29069649" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2017&pages=371-379&author=W.+Liaoauthor=H.+Zhengauthor=S.+Wuauthor=Y.+Zhangauthor=W.+Wangauthor=Z.+Zhangauthor=C.+Zhouauthor=H.+Wuauthor=J.+Min&title=The+systemic+activation+of+programmed+death+1-PD-L1+axis+protects+systemic+lupus+erythematosus+model+from+nephritis&doi=10.1159%2F000480641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The Systemic Activation of Programmed Death 1-PD-L1 Axis Protects Systemic Lupus Erythematosus Model from Nephritis</span></div><div class="casAuthors">Liao, Wenjun; Zheng, Hua; Wu, Sha; Zhang, Yanmei; Wang, Wei; Zhang, Zili; Zhou, Chenfei; Wu, Hongjun; Min, Jie</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Nephrology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">371-379</span>CODEN:
                <span class="NLM_cas:coden">AJNED9</span>;
        ISSN:<span class="NLM_cas:issn">0250-8095</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Systemic lupus erythematosus (SLE) is characterized by abnormal activated T cells, autoreactive B cells, and massive cytokines.  The CD4+ T cells detd. B-cells differentiation and cytokines prodn.  The programmed death 1 (PD-1) is the checkpoint immunoinhibitory receptor of activated T cells, and its engagement could exhaust T cells.  In this study, we investigated the role of PD-1 systemic engagement with PD-L1-Ig in lupus-like nephritis in SLE mice.  Methods: The murine PD-L1-Ig was injected into SLE-prone mice.  The proteinuria and survival ratio were monitored.  The prodn. of anti-dsDNA autoantibodies and cytokines in serum were measured by ELISA.  The cytokine-producing T cells (interferon-γ, IFN-γ and IL-17α) in kidney and spleen were detected with flowcytometry.  The pathol. evaluation of the Ig deposition in the glomeruliand was detd. with immunofluorescence.  Lymphocytes in 24-h urine were detected with flowcytometry.  Results: The systemic administration of PD-L1-Ig activated PD-1-PD-L1 axis of CD4+ T lymphocytes, suppressed Th17 formation in many organs, including the spleen and the kidney, demolished abnormal prodn. of cytokines (IFN-γ, IL-17, and IL-10) and anti-dsDNA autoantibodies in serum, inhibited IgG deposition in the glomeruli with the decrease of proteinuria, and activated T cells in urine.  Accordingly, the systemic conjugation of PD-L1-PD-1 impaired renal autoimmune injure and prolonged survival time.  Conclusion: Our research demonstrated that the protective function of systemic activation of PD-1-PD-L1 axis with PD-L1-Ig attenuates the nephritis in SLE-prone mice, which facilitates us to understand the suppressive function of PD-1-PD-L1 axis in the pathogenesis and progress of the lupus nephritis, and to explore a possible effective therapeutic strategy to SLE.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow--p2nB5yobVg90H21EOLACvtfcHk0lhoRXmCX3nsfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvV2gsbvO&md5=c555ef6c1df4bfdf86d582877e357d98</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1159%2F000480641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000480641%26sid%3Dliteratum%253Aachs%26aulast%3DLiao%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DMin%26aufirst%3DJ.%26atitle%3DThe%2520systemic%2520activation%2520of%2520programmed%2520death%25201-PD-L1%2520axis%2520protects%2520systemic%2520lupus%2520erythematosus%2520model%2520from%2520nephritis%26jtitle%3DAm.%2520J.%2520Nephrol.%26date%3D2017%26volume%3D46%26spage%3D371%26epage%3D379%26doi%3D10.1159%2F000480641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy: anti-PD-1 therapies-a new first-line option in advanced melanoma</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">625</span>– <span class="NLM_lpage">626</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnrclinonc.2015.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=26416151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A280%3ADC%252BC283ms1Wmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=625-626&author=R.+J.+Sullivanauthor=K.+T.+Flaherty&title=Immunotherapy%3A+anti-PD-1+therapies-a+new+first-line+option+in+advanced+melanoma&doi=10.1038%2Fnrclinonc.2015.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma</span></div><div class="casAuthors">Sullivan Ryan J; Flaherty Keith T</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Clinical oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">625-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQkbwjUIJOh8YUSrryheKE6fW6udTcc2eaOI6oEtGzxArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283ms1Wmsg%253D%253D&md5=015a1194cf584003c341b1315faa8669</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.170%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DImmunotherapy%253A%2520anti-PD-1%2520therapies-a%2520new%2520first-line%2520option%2520in%2520advanced%2520melanoma%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26spage%3D625%26epage%3D626%26doi%3D10.1038%2Fnrclinonc.2015.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khanna, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blais, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudreau, P. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corrales-Rodriguez, L.</span></span> <span> </span><span class="NLM_article-title">Immunotherapy comes of age in lung cancer</span>. <i>Clin. Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1016/j.cllc.2016.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.cllc.2016.06.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=27461776" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFKmtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=13-22&author=P.+Khannaauthor=N.+Blaisauthor=P.+O.+Gaudreauauthor=L.+Corrales-Rodriguez&title=Immunotherapy+comes+of+age+in+lung+cancer&doi=10.1016%2Fj.cllc.2016.06.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Immunotherapy Comes of Age in Lung Cancer</span></div><div class="casAuthors">Khanna, Priyanka; Blais, Normand; Gaudreau, Pierre-Olivier; Corrales-Rodriguez, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Lung Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">13-22</span>CODEN:
                <span class="NLM_cas:coden">CLCLCA</span>;
        ISSN:<span class="NLM_cas:issn">1525-7304</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Lung carcinoma is the leading cause of death by cancer worldwide.  When possible, surgery is the best treatment strategy for patients with non-small-cell lung cancer.  However, even with curative-intent therapy, most patients will develop local or systemic recurrence and, ultimately, succumb to their disease.  In recent years, evidence on the role of the antitumor activity of the immune system and the understanding of tumor immunosurveillance have resulted in the emergence of immunotherapy as a promising therapeutic approach in lung cancer.  The main approaches are immune checkpoint inhibition, such as blockade of the cytotoxic T-lymphocyte antigen-4 and programmed cell death-1 receptors and the programmed cell death-1 ligand, and vaccine therapy, which elicits specific antitumor immunity against relevant tumor-assocd. antigens.  We have reviewed recently reported results from clin. trials and the possible future role of vaccine therapy and immune checkpoint inhibition in the treatment of small cell lung cancer and non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGY02iVifEhLVg90H21EOLACvtfcHk0ljInKyAPo-KqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFKmtb7O&md5=c8e8688a720f582a30a7ef0601c18187</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.cllc.2016.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cllc.2016.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DKhanna%26aufirst%3DP.%26aulast%3DBlais%26aufirst%3DN.%26aulast%3DGaudreau%26aufirst%3DP.%2BO.%26aulast%3DCorrales-Rodriguez%26aufirst%3DL.%26atitle%3DImmunotherapy%2520comes%2520of%2520age%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Lung%2520Cancer%26date%3D2017%26volume%3D18%26spage%3D13%26epage%3D22%26doi%3D10.1016%2Fj.cllc.2016.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanghavi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, M.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacology considerations for the development of immune checkpoint inhibitors</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57 Suppl 10</i></span>,  <span class="NLM_fpage">S26</span>– <span class="NLM_lpage">S42</span>, <span class="refDoi"> DOI: 10.1002/jcph.990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1002%2Fjcph.990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28921644" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57+Suppl+10&publication_year=2017&pages=S26-S42&author=J.+Shengauthor=S.+Srivastavaauthor=K.+Sanghaviauthor=Z.+Luauthor=B.+J.+Schmidtauthor=A.+Belloauthor=M.+Gupta&title=Clinical+pharmacology+considerations+for+the+development+of+immune+checkpoint+inhibitors&doi=10.1002%2Fjcph.990"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2Fjcph.990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcph.990%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DJ.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DSanghavi%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DZ.%26aulast%3DSchmidt%26aufirst%3DB.%2BJ.%26aulast%3DBello%26aufirst%3DA.%26aulast%3DGupta%26aufirst%3DM.%26atitle%3DClinical%2520pharmacology%2520considerations%2520for%2520the%2520development%2520of%2520immune%2520checkpoint%2520inhibitors%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D57%2520Suppl%252010%26spage%3DS26%26epage%3DS42%26doi%3D10.1002%2Fjcph.990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taube, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anders, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardoll, D. M.</span></span> <span> </span><span class="NLM_article-title">Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.36</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnrc.2016.36" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=27079802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVOrurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=275-287&author=S.+L.+Topalianauthor=J.+M.+Taubeauthor=R.+A.+Andersauthor=D.+M.+Pardoll&title=Mechanism-driven+biomarkers+to+guide+immune+checkpoint+blockade+in+cancer+therapy&doi=10.1038%2Fnrc.2016.36"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy</span></div><div class="casAuthors">Topalian, Suzanne L.; Taube, Janis M.; Anders, Robert A.; Pardoll, Drew M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">275-287</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte assocd. antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and addnl. immune checkpoints being targeted clin., many questions still remain regarding the optimal use of drugs that block these checkpoint pathways.  Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests.  Here, we discuss biomarkers for anti-PD1 therapy based on immunol., genetic and virol. criteria.  The unique biol. of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development.  Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzuy2z2GgvObVg90H21EOLACvtfcHk0ljInKyAPo-KqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVOrurc%253D&md5=781c5a772910be415334b1ef2e247671</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.36&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.36%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DTaube%26aufirst%3DJ.%2BM.%26aulast%3DAnders%26aufirst%3DR.%2BA.%26aulast%3DPardoll%26aufirst%3DD.%2BM.%26atitle%3DMechanism-driven%2520biomarkers%2520to%2520guide%2520immune%2520checkpoint%2520blockade%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D275%26epage%3D287%26doi%3D10.1038%2Fnrc.2016.36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Small-molecule targets in tumor immunotherapy</span>. <i>Nat. Prod. Bioprospect.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">297</span>– <span class="NLM_lpage">301</span>, <span class="refDoi"> DOI: 10.1007/s13659-018-0177-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1007%2Fs13659-018-0177-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=29974338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht12lsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=297-301&author=H.+F.+Zhuauthor=Y.+Li&title=Small-molecule+targets+in+tumor+immunotherapy&doi=10.1007%2Fs13659-018-0177-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Targets in Tumor Immunotherapy</span></div><div class="casAuthors">Zhu, Hui-Fang; Li, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Natural Products and Bioprospecting</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">297-301</span>CODEN:
                <span class="NLM_cas:coden">NPBAAH</span>;
        ISSN:<span class="NLM_cas:issn">2192-2209</span>.
    
            (<span class="NLM_cas:orgname">Kunming Institute of Botany, Chinese Academy of Sciences</span>)
        </div><div class="casAbstract">A review.  Cancer immunotherapy has been widely recognized as a powerful approach to fight cancers.  To date, over 50 phase III trials in cancer immunotherapy are in progress.  Among the many immunotherapy approaches, immune checkpoint therapy has attracted considerable attention.  The reported clin. success of targeting the T cell immune checkpoint receptors PD-1 or CTLA4 by antibodies blockade in advanced stages of cancers has demonstrated the importance of immune modulation.  But antibodies-based immunotherapy confronted with some disadvantages, such as immunogenicity, stability, membrane permeability, and prodn. cost.  Therefore, alternative approaches including small-mol.-regulated immune response are being introduced.  In this review, we focused on some of the key intracellular pathways where small-mol. therapeutic is potential and attractive, which highlights the great potential of natural products in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrit8YB3mZAwLVg90H21EOLACvtfcHk0lg3L8NB80ceVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht12lsrvI&md5=1ce40d184a3dea755c98c949e851e929</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1007%2Fs13659-018-0177-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13659-018-0177-7%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DH.%2BF.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DSmall-molecule%2520targets%2520in%2520tumor%2520immunotherapy%26jtitle%3DNat.%2520Prod.%2520Bioprospect.%26date%3D2018%26volume%3D8%26spage%3D297%26epage%3D301%26doi%3D10.1007%2Fs13659-018-0177-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vladimer, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigenzahn, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardeau, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Fuente, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knobl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Global survey of the immunomodulatory potential of common drugs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnchembio.2360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28437395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=681-690&author=G.+I.+Vladimerauthor=B.+Snijderauthor=N.+Krallauthor=J.+W.+Bigenzahnauthor=K.+V.+M.+Huberauthor=C.+H.+Lardeauauthor=K.+Sanjivauthor=A.+Ringlerauthor=U.+W.+Berglundauthor=M.+Sablerauthor=O.+L.+de+la+Fuenteauthor=P.+Knoblauthor=S.+Kubicekauthor=T.+Helledayauthor=U.+Jagerauthor=G.+Superti-Furga&title=Global+survey+of+the+immunomodulatory+potential+of+common+drugs&doi=10.1038%2Fnchembio.2360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Global survey of the immunomodulatory potential of common drugs</span></div><div class="casAuthors">Vladimer, Gregory I.; Snijder, Berend; Krall, Nikolaus; Bigenzahn, Johannes W.; Huber, Kilian V. M.; Lardeau, Charles-Hugues; Sanjiv, Kumar; Ringler, Anna; Berglund, Ulrika Warpman; Sabler, Monika; de la Fuente, Oscar Lopez; Knoebl, Paul; Kubicek, Stefan; Helleday, Thomas; Jaeger, Ulrich; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">681-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drugs may complement antibody-based therapies in an immune-oncol. setting, yet systematic methods for the identification and characterization of the immunomodulatory properties of these entities are lacking.  We surveyed the immumomodulatory potential of 1,402 small chem. mols., as defined by their ability to alter the cell-cell interactions among peripheral mononuclear leukocytes ex vivo, using automated microscopy and population-wide single-cell image anal.  Unexpectedly, ∼10% of the agents tested affected these cell-cell interactions differentially.  The results accurately recapitulated known immunomodulatory drug classes and revealed several clin. approved drugs that unexpectedly harbor the ability to modulate the immune system, which could potentially contribute to their physiol. mechanism of action.  For instance, the kinase inhibitor crizotinib promoted T cell interactions with monocytes, as well as with cancer cells, through inhibition of the receptor tyrosine kinase MSTR1 and subsequent upregulation of the expression of major histocompatibility complex mols.  The approach offers an attractive platform for the personalized identification and characterization of immunomodulatory therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXf0_7KFGbY7Vg90H21EOLACvtfcHk0lg3L8NB80ceVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D&md5=c177974d4daf99d7a40b5c2a73c6504a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2360%26sid%3Dliteratum%253Aachs%26aulast%3DVladimer%26aufirst%3DG.%2BI.%26aulast%3DSnijder%26aufirst%3DB.%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DBigenzahn%26aufirst%3DJ.%2BW.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DLardeau%26aufirst%3DC.%2BH.%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DRingler%26aufirst%3DA.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DSabler%26aufirst%3DM.%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DO.%2BL.%26aulast%3DKnobl%26aufirst%3DP.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DJager%26aufirst%3DU.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520survey%2520of%2520the%2520immunomodulatory%2520potential%2520of%2520common%2520drugs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D681%26epage%3D690%26doi%3D10.1038%2Fnchembio.2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smothers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoos, A.</span></span> <span> </span><span class="NLM_article-title">Big opportunities for small molecules in immuno-oncology</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">603</span>– <span class="NLM_lpage">622</span>, <span class="refDoi"> DOI: 10.1038/nrd4596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnrd4596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=26228631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1KiurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=603-622&author=J.+L.+Adamsauthor=J.+Smothersauthor=R.+Srinivasanauthor=A.+Hoos&title=Big+opportunities+for+small+molecules+in+immuno-oncology&doi=10.1038%2Fnrd4596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Big opportunities for small molecules in immuno-oncology</span></div><div class="casAuthors">Adams, Jerry L.; Smothers, James; Srinivasan, Roopa; Hoos, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">603-622</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The regulatory approval of ipilimumab (Yervoy) in 2011 ushered in a new era of cancer immunotherapies with durable clin. effects.  Most of these breakthrough medicines are monoclonal antibodies that block protein-protein interactions between T cell checkpoint receptors and their cognate ligands.  In addn., genetically engineered autologous T cell therapies have also recently demonstrated significant clin. responses in haematol. cancers.  Conspicuously missing from this class of therapies are traditional small-mol. drugs, which have previously served as the backbone of targeted cancer therapies.  Modulating the immune system through a small-mol. approach offers several unique advantages that are complementary to, and potentially synergistic with, biol. modalities.  This Review highlights immuno-oncol. pathways and mechanisms that can be best or solely targeted by small-mol. medicines.  Agents aimed at these mechanisms - modulation of the immune response, trafficking to the tumor microenvironment and cellular infiltration - are poised to significantly extend the scope of immuno-oncol. applications and enhance the opportunities for combination with tumor-targeted agents and biol. immunotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBZyGzN4ec8bVg90H21EOLACvtfcHk0lhPkck6mDK49w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1KiurvE&md5=b6c9d41ae81a8c504ee6aac209ea0509</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd4596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4596%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DSmothers%26aufirst%3DJ.%26aulast%3DSrinivasan%26aufirst%3DR.%26aulast%3DHoos%26aufirst%3DA.%26atitle%3DBig%2520opportunities%2520for%2520small%2520molecules%2520in%2520immuno-oncology%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D603%26epage%3D622%26doi%3D10.1038%2Fnrd4596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Recent advances in small molecule based cancer immunotherapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">582</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.ejmech.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=30125720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=582-598&author=B.+Chengauthor=W.+E.+Yuanauthor=J.+Suauthor=Y.+Liuauthor=J.+Chen&title=Recent+advances+in+small+molecule+based+cancer+immunotherapy&doi=10.1016%2Fj.ejmech.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in small molecule based cancer immunotherapy</span></div><div class="casAuthors">Cheng, Binbin; Yuan, Wei-En; Su, Jing; Liu, Yao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">582-598</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Immunotherapy has been increasingly utilized for the treatment of cancer.  Currently available cancer immunotherapies mainly involve the use of antibodies, which have advantages in terms of pharmacodynamics such as efficacy and specificity, however, they exhibit disadvantages in regard to the pharmacokinetics including but not limited to poor tissue and tumor penetration, very long half-life, and the lack of oral bioavailability.  Also they are immunogenic and may cause undesired side effects.  In addn., they are difficult and expensive to produce.  In contrast to therapeutic antibodies, small mol. immuno-oncol. agents generally have favorable pharmacokinetics, for example, better oral bioavailability, higher tissue and tumor penetration, reasonable half-lives etc.  Furthermore, some small mols. are highly selective and efficacious with benign toxicity profiles.  Therefore, small mol. immuno-oncol. agents have the potential to overcome the drawbacks of therapeutic antibodies, and they can complement existing therapeutic antibodies and may also be used in combination with antibodies to achieve synergistic effects.  In this article, we summarize the current advances in the field of small mol. approaches in tumor immunol. which include the small mols. in clin. trials and preclin. studies, and the reported crystal structures of small mols. and their target proteins as well as the binding interactions between small mols. and the targets.  The tumorigenesis mechanism of different targets (the programmed cell death 1/programmed cell death ligand 1(PD1/PD-L1), retinoic acid-related orphan receptor-gamma t (RORγt), Chemokine receptor, Stimulator of Interferon Genes (Sting), Indoleamine 2,3-dioxygenase (IDO), toll-like receptors (TLR) etc.) are also elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvYDM1Fp9HUbVg90H21EOLACvtfcHk0lj73iotA0JAwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FP&md5=e15fa8048cf9b12ecd494d9ff8db8be5</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DW.%2BE.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DRecent%2520advances%2520in%2520small%2520molecule%2520based%2520cancer%2520immunotherapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D582%26epage%3D598%26doi%3D10.1016%2Fj.ejmech.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G. N.</span>; <span class="NLM_string-name">Ramachandra, M.</span>; <span class="NLM_string-name">Naremaddepalli, S. S. S.</span></span> <span> </span><span class="NLM_article-title">Immunomodulating peptidomimetic derivatives</span>. <span class="NLM_patent">WO2015036927</span>, 19 March, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=P.+G.+N.+Sasikumar&author=M.+Ramachandra&author=S.+S.+S.+Naremaddepalli&title=Immunomodulating+peptidomimetic+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%2BN.%26atitle%3DImmunomodulating%2520peptidomimetic%2520derivatives%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chupak, L.</span>; <span class="NLM_string-name">Zheng, X.</span></span> <span> </span><span class="NLM_article-title">Compounds useful as immunomodulators</span>. <span class="NLM_patent">WO2015034820</span>, March 12, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+Chupak&author=X.+Zheng&title=Compounds+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChupak%26aufirst%3DL.%26atitle%3DCompounds%2520useful%2520as%2520immunomodulators%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span>; <span class="NLM_string-name">Xiao, J.</span>; <span class="NLM_string-name">Liu, A.</span>; <span class="NLM_string-name">Wei, X.</span>; <span class="NLM_string-name">Zhong, W.</span>; <span class="NLM_string-name">Zheng, Z.</span>; <span class="NLM_string-name">Wang, X.</span>; <span class="NLM_string-name">Xie, Y.</span>; <span class="NLM_string-name">Zhao, G.</span>; <span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Resorcinol compound and medicinal use thereof</span>. <span class="NLM_patent">CN107286057</span>, October 24, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Li&author=J.+Xiao&author=A.+Liu&author=X.+Wei&author=W.+Zhong&author=Z.+Zheng&author=X.+Wang&author=Y.+Xie&author=G.+Zhao&author=H.+Li&title=Resorcinol+compound+and+medicinal+use+thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DS.%26atitle%3DResorcinol%2520compound%2520and%2520medicinal%2520use%2520thereof%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span> <span> </span><span class="NLM_article-title">Development of inhibitors of the programmed cell death-1/programmed cell death-ligand 1 signaling pathway</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1715</span>– <span class="NLM_lpage">1730</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00990</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00990" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1715-1730&author=T.+Wangauthor=X.+Wuauthor=C.+Guoauthor=K.+Zhangauthor=J.+Xuauthor=Z.+Liauthor=S.+Jiang&title=Development+of+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+signaling+pathway&doi=10.1021%2Facs.jmedchem.8b00990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway</span></div><div class="casAuthors">Wang, Tianyu; Wu, Xiaoxing; Guo, Changying; Zhang, Kuojun; Xu, Jinyi; Li, Zheng; Jiang, Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1715-1730</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The clin. success of inhibitors targeting the PD-1/PD-L1 pathway has made this an active field in cancer immunotherapy.  Currently, most drugs targeting this pathway are monoclonal antibodies.  Small-mol. inhibitors as the alternative to monoclonal antibodies are expected to overcome the disadvantages of mAbs which include prodn. difficulties and their long half-life.  Recently, progress has been reported on anti-PD-1/PD-L1 small-mol. inhibitors.  In this paper, we review the development of inhibitors targeting the PD-1/PD-L1 pathway, focusing mainly on peptide-based and nonpeptidic small-mol. inhibitors.  The structures and the preclin. and clin. studies of several peptide-based small-mol. candidate compds. in clin. trials are discussed.  We also illustrate the design strategies underlying reported nonpeptidic small-mol. inhibitors and provide insight into possible future exploration.  Development of small-mol. drugs for anti-PD-1/PD-L1 activity with specific cancer applications is a promising and challenging prospect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonItidshja8LVg90H21EOLACvtfcHk0likjc7GPr8w9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKqtLzL&md5=2fc7ee8e9bb8d37c7569913a4529d753</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00990%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DK.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26atitle%3DDevelopment%2520of%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520signaling%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1715%26epage%3D1730%26doi%3D10.1021%2Facs.jmedchem.8b00990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blevins, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolduc, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gignac, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carr, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hof, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulff, J. E.</span></span> <span> </span><span class="NLM_article-title">In vitro assessment of putative PD-1/PD-L1 inhibitors: suggestions of an alternative mode of action</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1187</span>– <span class="NLM_lpage">1192</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00221</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00221" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1187-1192&author=D.+J.+Blevinsauthor=R.+Hanleyauthor=T.+Bolducauthor=D.+A.+Powellauthor=M.+Gignacauthor=K.+Walkerauthor=M.+D.+Carrauthor=F.+Hofauthor=J.+E.+Wulff&title=In+vitro+assessment+of+putative+PD-1%2FPD-L1+inhibitors%3A+suggestions+of+an+alternative+mode+of+action&doi=10.1021%2Facsmedchemlett.9b00221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action</span></div><div class="casAuthors">Blevins, Derek J.; Hanley, Ronan; Bolduc, Trevor; Powell, David A.; Gignac, Michael; Walker, Kayleigh; Carr, Mark D.; Hof, Fraser; Wulff, Jeremy E.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1187-1192</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The programmed cell death protein 1 (PD-1) signaling axis is among the most important therapeutic targets in modern oncol.  Aurigene Discovery Technologies Ltd. (Aurigene) has patented a series of peptidomimetic small mols. derived from the PD-1 protein sequence for use in targeting the interaction between PD-1 and its ligand, PD-L1.  We evaluated three of Aurigene's most potent compds. in SPR binding assays.  Our results showed that these compds. each of which is known to be potently effective in a splenocyte recovery assay-do not directly inhibit the PD-1/PD-L1 interaction nor do they appear to bind to either of the constituent proteins, indicating that another mechanism is at play.  As a result of these studies and upon consideration of structural features within the PD-1/PD-L1 complex, we hypothesize that the Aurigene mols. may interact with a currently unknown protein capable of regulating the PD-1 axis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrekmaz9w_0ZrVg90H21EOLACvtfcHk0ljbU_ytNMXFgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsrbF&md5=a7d8471006f1fc6f7736be28c5ce8557</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00221%26sid%3Dliteratum%253Aachs%26aulast%3DBlevins%26aufirst%3DD.%2BJ.%26aulast%3DHanley%26aufirst%3DR.%26aulast%3DBolduc%26aufirst%3DT.%26aulast%3DPowell%26aufirst%3DD.%2BA.%26aulast%3DGignac%26aufirst%3DM.%26aulast%3DWalker%26aufirst%3DK.%26aulast%3DCarr%26aufirst%3DM.%2BD.%26aulast%3DHof%26aufirst%3DF.%26aulast%3DWulff%26aufirst%3DJ.%2BE.%26atitle%3DIn%2520vitro%2520assessment%2520of%2520putative%2520PD-1%252FPD-L1%2520inhibitors%253A%2520suggestions%2520of%2520an%2520alternative%2520mode%2520of%2520action%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1187%26epage%3D1192%26doi%3D10.1021%2Facsmedchemlett.9b00221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czub, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plewka, J.</span></span> <span> </span><span class="NLM_article-title">CA-170 - a potent small-molecule PD-L1 inhibitor or not?</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span> (<span class="NLM_issue">Article 2804</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.3390/molecules24152804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.3390%2Fmolecules24152804" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=1-13&issue=Article+2804&author=B.+Musielakauthor=J.+Kocikauthor=L.+Skalniakauthor=K.+Magiera-Mularzauthor=D.+Salaauthor=M.+Czubauthor=M.+Stecauthor=M.+Siedlarauthor=T.+A.+Holakauthor=J.+Plewka&title=CA-170+-+a+potent+small-molecule+PD-L1+inhibitor+or+not%3F&doi=10.3390%2Fmolecules24152804"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24152804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24152804%26sid%3Dliteratum%253Aachs%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DCzub%26aufirst%3DM.%26aulast%3DStec%26aufirst%3DM.%26aulast%3DSiedlar%26aufirst%3DM.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DPlewka%26aufirst%3DJ.%26atitle%3DCA-170%2520-%2520a%2520potent%2520small-molecule%2520PD-L1%2520inhibitor%2520or%2520not%253F%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26issue%3DArticle%25202804%26spage%3D1%26epage%3D13%26doi%3D10.3390%2Fmolecules24152804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of phospholipase A2 inhibitory biflavonoids</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2373</span>– <span class="NLM_lpage">2375</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.01.117</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2Fj.bmcl.2006.01.117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=16504502" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BD28XislChurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=2373-2375&author=J.+Chenauthor=H.+W.+Changauthor=H.+P.+Kimauthor=H.+Park&title=Synthesis+of+phospholipase+A2+inhibitory+biflavonoids&doi=10.1016%2Fj.bmcl.2006.01.117"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of phospholipase A2 inhibitory biflavonoids</span></div><div class="casAuthors">Chen, Jianjun; Chang, Hyeun Wook; Kim, Hyun Pyo; Park, Haeil</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2373-2375</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of C-C biflavones was designed to investigate the relationship between structural array of different flavone-flavone subunit linkage and the inhibitory activity against phospholipase A2 (PLA2).  Among six classes of C-C biflavones designed, four classes of C-C biflavones, which have flavone-flavone subunit linkages at A ring-A ring, A ring-B ring, B ring-B ring, and B ring-C ring, were synthesized.  The synthetic biflavones exhibited somewhat different inhibitory activities against sPLA2-IIA.  Among them, biflavone I a having a C-C 4'-4' linkage showed comparable inhibitory activity with that of the natural biflavonoid, ochnaflavone, and 7-fold stronger activity than that of amentoflavone.  Further chem. modification is being carried out in order to obtain the chem. optimized biflavonoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_3Q_1TIV67Vg90H21EOLACvtfcHk0lhmfVUTRbPT1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XislChurk%253D&md5=c08d5a23d6f0a5c8f2c33ed8d865a199</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.01.117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.01.117%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DH.%2BW.%26aulast%3DKim%26aufirst%3DH.%2BP.%26aulast%3DPark%26aufirst%3DH.%26atitle%3DSynthesis%2520of%2520phospholipase%2520A2%2520inhibitory%2520biflavonoids%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D2373%26epage%3D2375%26doi%3D10.1016%2Fj.bmcl.2006.01.117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5857</span>– <span class="NLM_lpage">5867</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5857-5867&author=K.+Guzikauthor=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Magieraauthor=B.+Musielakauthor=R.+Tornerauthor=L.+Skalniakauthor=A.+Domlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+death-ligand+1+%28PD-1%2FPD-L1%29+interaction+via+transiently+induced+protein+states+and+dimerization+of+PD-L1&doi=10.1021%2Facs.jmedchem.7b00293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1</span></div><div class="casAuthors">Guzik, Katarzyna; Zak, Krzysztof M.; Grudnik, Przemyslaw; Magiera, Katarzyna; Musielak, Bogdan; Torner, Ricarda; Skalniak, Lukasz; Domling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5857-5867</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances in cancer treatment.  The antibody-based immunotherapies carry a no. of disadvantages such as the high cost of the antibodies, their limited half-life, and immunogenicity.  Development of small-mol. PD-1/PD-L1 inhibitors that could overcome these drawbacks is slow because of the incomplete structural information for this pathway.  The first chem. PD-1/PD-L1 inhibitors have been recently disclosed by Bristol-Myers Squibb.  Here we present NMR and X-ray characterization for the two classes of these inhibitors.  The X-ray structures of the PD-L1/inhibitor complexes reveal one inhibitor mol. located at the center of the PD-L1 homodimer, filling a deep hydrophobic channel-like pocket between two PD-L1 mols.  Derivs. of (2-methyl-3-biphenylyl)methanol exhibit the structures capped on one side of the channel, whereas the compds. based on [3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methanol induce an enlarged interaction interface that results in the open "face-back" tunnel through the PD-L1 dimer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppmfSesG1M6rVg90H21EOLACvtfcHk0liMnk4i19ypdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D&md5=c039796cda3b9ef92a0ed3b10b11932b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DTorner%26aufirst%3DR.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DDomling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520%2528PD-1%252FPD-L1%2529%2520interaction%2520via%2520transiently%2520induced%2520protein%2520states%2520and%2520dimerization%2520of%2520PD-L1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5857%26epage%3D5867%26doi%3D10.1021%2Facs.jmedchem.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of [1,2,4]triazolo[4,3- a]pyridines as potent inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4703</span>– <span class="NLM_lpage">4715</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4703-4715&author=M.+Qinauthor=Q.+Caoauthor=S.+Zhengauthor=Y.+Tianauthor=H.+Zhangauthor=J.+Xieauthor=H.+Xieauthor=Y.+Liuauthor=Y.+Zhaoauthor=P.+Gong&title=Discovery+of+%5B1%2C2%2C4%5Dtriazolo%5B4%2C3-+a%5Dpyridines+as+potent+inhibitors+targeting+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction&doi=10.1021%2Facs.jmedchem.9b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Zheng, Shuaishuai; Tian, Ye; Zhang, Haotian; Xie, Jun; Xie, Hongbo; Liu, Yajing; Zhao, Yanfang; Gong, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4703-4715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction using small-mol. inhibitors is an emerging immunotherapeutic approach.  A novel series of [1,2,4]triazolo[4,3-a]pyridines were designed and found to be potent inhibitors of the PD-1/PD-L1 interaction.  Among them, compd. I exhibited the most potent activity, as assessed by homogeneous time-resolved fluorescence assay, with an IC50 of 92.3 nM.  Furthermore, I dose-dependent elevated interferon-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  The authors concluded that I is a promising lead compd. for the development of inhibitors of the PD-1/PD-L1 interaction.  In addn., the authors explored the structure-activity relationships of the newly synthesized [1,2,4]triazolo[4,3-a]pyridines and demonstrated that a ring fusion strategy can be employed for designing analogs of the Bristol-Myers Squibb chem. series.  These studies pave the way for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCgkEJ5SqGXLVg90H21EOLACvtfcHk0liMnk4i19ypdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D&md5=44d4ee689be577a86c16cc4da3edec71</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00312%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520%255B1%252C2%252C4%255Dtriazolo%255B4%252C3-%2520a%255Dpyridines%2520as%2520potent%2520inhibitors%2520targeting%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4703%26epage%3D4715%26doi%3D10.1021%2Facs.jmedchem.9b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Shen, B.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Liu, K.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic compounds as immunomodulators</span>. <span class="NLM_patent">WO2017070089</span>, April 27, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Wu&author=B.+Shen&author=J.+Li&author=K.+Liu&author=F.+Zhang&author=W.+Yao&title=Heterocyclic+compounds+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DHeterocyclic%2520compounds%2520as%2520immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lajkiewicz, N.</span>; <span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title">Heterocyclic compounds as immunomodulators</span>. <span class="NLM_patent">US20170174679</span>, June 22, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=N.+Lajkiewicz&author=L.+Wu&author=W.+Yao&title=Heterocyclic+compounds+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLajkiewicz%26aufirst%3DN.%26atitle%3DHeterocyclic%2520compounds%2520as%2520immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span>; <span class="NLM_string-name">Yu, Z.</span>; <span class="NLM_string-name">Zhang, F.</span>; <span class="NLM_string-name">Yao, W.</span></span> <span> </span><span class="NLM_article-title"><i>N</i>-phenyl-pyridine-2-carboxamide derivatives and their use as PD-1/PD-L1 protein/protein interaction modulators</span>. <span class="NLM_patent">WO2017106634</span>, June 22, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=L.+Wu&author=Z.+Yu&author=F.+Zhang&author=W.+Yao&title=N-phenyl-pyridine-2-carboxamide+derivatives+and+their+use+as+PD-1%2FPD-L1+protein%2Fprotein+interaction+modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DL.%26atitle%3DN-phenyl-pyridine-2-carboxamide%2520derivatives%2520and%2520their%2520use%2520as%2520PD-1%252FPD-L1%2520protein%252Fprotein%2520interaction%2520modulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K.-S.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Saulnier, M. G.</span>; <span class="NLM_string-name">Frennesson, D. B.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Hewawasam, P.</span>; <span class="NLM_string-name">Wang, T.</span>; <span class="NLM_string-name">Zhang, Z.</span>; <span class="NLM_string-name">Meng, Z.</span>; <span class="NLM_string-name">Sun, L.-Q.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Biaryl compounds useful as immunomodulators</span>. <span class="NLM_patent">WO2018044963</span>, March 08, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=K.-S.+Yeung&author=K.+A.+Grant-Young&author=J.+Zhu&author=M.+G.+Saulnier&author=D.+B.+Frennesson&author=D.+R.+Langley&author=P.+Hewawasam&author=T.+Wang&author=Z.+Zhang&author=Z.+Meng&author=L.-Q.+Sun&author=E.+Mull&author=P.+M.+Scola&title=Biaryl+compounds+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.-S.%26atitle%3DBiaryl%2520compounds%2520useful%2520as%2520immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K. S.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Saulnier, M. G.</span>; <span class="NLM_string-name">Frennesson, D. B.</span>; <span class="NLM_string-name">Meng, Z. X.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">1,3-dihydroxy-phenyl derivatives useful as immunomodulators</span>. <span class="NLM_patent">WO2018009505</span>, January 11, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=K.+S.+Yeung&author=K.+A.+Grant-Young&author=J.+Zhu&author=M.+G.+Saulnier&author=D.+B.+Frennesson&author=Z.+X.+Meng&author=P.+M.+Scola&title=1%2C3-dihydroxy-phenyl+derivatives+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.%2BS.%26atitle%3D1%252C3-dihydroxy-phenyl%2520derivatives%2520useful%2520as%2520immunomodulators%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, K.-S.</span>; <span class="NLM_string-name">Connolly, T. P.</span>; <span class="NLM_string-name">Frennesson, D. B.</span>; <span class="NLM_string-name">Grant-Young, K. A.</span>; <span class="NLM_string-name">Hewawasam, P.</span>; <span class="NLM_string-name">Langley, D. R.</span>; <span class="NLM_string-name">Meng, Z.</span>; <span class="NLM_string-name">Mull, E.</span>; <span class="NLM_string-name">Parcella, K. E.</span>; <span class="NLM_string-name">Saulnier, M. G.</span>; <span class="NLM_string-name">Sun, L.-Q.</span>; <span class="NLM_string-name">Wang, A. X.</span>; <span class="NLM_string-name">Xu, N.</span>; <span class="NLM_string-name">Zhu, J.</span>; <span class="NLM_string-name">Scola, P. M.</span></span> <span> </span><span class="NLM_article-title">Compounds useful as immunomodulators</span>. <span class="NLM_patent">WO2017066227</span>, April 20, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.-S.+Yeung&author=T.+P.+Connolly&author=D.+B.+Frennesson&author=K.+A.+Grant-Young&author=P.+Hewawasam&author=D.+R.+Langley&author=Z.+Meng&author=E.+Mull&author=K.+E.+Parcella&author=M.+G.+Saulnier&author=L.-Q.+Sun&author=A.+X.+Wang&author=N.+Xu&author=J.+Zhu&author=P.+M.+Scola&title=Compounds+useful+as+immunomodulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DYeung%26aufirst%3DK.-S.%26atitle%3DCompounds%2520useful%2520as%2520immunomodulators%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krupka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kufer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kischel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugmaier, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenegger, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohnke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vick, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeremias, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metzeler, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiegl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiekermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauerle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiddemann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riethmuller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subklewe, M.</span></span> <span> </span><span class="NLM_article-title">Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">484</span>– <span class="NLM_lpage">491</span>, <span class="refDoi"> DOI: 10.1038/leu.2015.214</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fleu.2015.214" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=26239198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2016&pages=484-491&author=C.+Krupkaauthor=P.+Kuferauthor=R.+Kischelauthor=G.+Zugmaierauthor=F.+S.+Lichteneggerauthor=T.+Kohnkeauthor=B.+Vickauthor=I.+Jeremiasauthor=K.+H.+Metzelerauthor=T.+Altmannauthor=S.+Schneiderauthor=M.+Fieglauthor=K.+Spiekermannauthor=P.+A.+Bauerleauthor=W.+Hiddemannauthor=G.+Riethmullerauthor=M.+Subklewe&title=Blockade+of+the+PD-1%2FPD-L1+axis+augments+lysis+of+AML+cells+by+the+CD33%2FCD3+BiTE+antibody+construct+AMG+330%3A+reversing+a+T-cell-induced+immune+escape+mechanism&doi=10.1038%2Fleu.2015.214"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism</span></div><div class="casAuthors">Krupka, C.; Kufer, P.; Kischel, R.; Zugmaier, G.; Lichtenegger, F. S.; Koehnke, T.; Vick, B.; Jeremias, I.; Metzeler, K. H.; Altmann, T.; Schneider, S.; Fiegl, M.; Spiekermann, K.; Bauerle, P. A.; Hiddemann, W.; Riethmueller, G.; Subklewe, M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">484-491</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bispecific T-cell engagers (BiTEs) are very effective in recruiting and activating T cells.  We tested the cytotoxicity of the CD33/CD3 BiTE antibody construct AMG 330 on primary acute myeloid leukemia (AML) cells ex vivo and characterized parameters contributing to antileukemic cytolytic activity.  The E:T ratio and the CD33 expression level significantly influenced lysis kinetics in long-term cultures of primary AML cells (n=38).  AMG 330 induced T-cell-mediated proinflammatory conditions, favoring the upregulation of immune checkpoints on target and effector cells.  Although not constitutively expressed at the time of primary diagnosis (n=123), PD-L1 was strongly upregulated on primary AML cells upon AMG 330 addn. to ex vivo cultures (n=27, P<0.0001).  This phenomenon was cytokine-driven as the sole addn. of interferon (IFN)-γ and tumor necrosis factor-α also induced expression.  Through blockade of the PD-1/PD-L1 interaction, AMG 330-mediated lysis (n=9, P=0.03), T-cell proliferation (n=9, P=0.01) and IFN-γ secretion (n=8, P=0.008) were significantly enhanced.  The combinatorial approach was most beneficial in settings of protracted AML cell lysis.  Taken together, we have characterized a crit. resistance mechanism employed by primary AML cells under AMG 330-mediated proinflammatory conditions.  Our results support the evaluation of checkpoint mols. in upcoming clin. trials with AMG 330 to enhance BiTE antibody construct-mediated cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqY6o4l8H8hXbVg90H21EOLACvtfcHk0lhK9nBk1tFdUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVWgtr%252FF&md5=c7cdddb37f2e034cdfde250a0aaf6ed0</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fleu.2015.214&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2015.214%26sid%3Dliteratum%253Aachs%26aulast%3DKrupka%26aufirst%3DC.%26aulast%3DKufer%26aufirst%3DP.%26aulast%3DKischel%26aufirst%3DR.%26aulast%3DZugmaier%26aufirst%3DG.%26aulast%3DLichtenegger%26aufirst%3DF.%2BS.%26aulast%3DKohnke%26aufirst%3DT.%26aulast%3DVick%26aufirst%3DB.%26aulast%3DJeremias%26aufirst%3DI.%26aulast%3DMetzeler%26aufirst%3DK.%2BH.%26aulast%3DAltmann%26aufirst%3DT.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DFiegl%26aufirst%3DM.%26aulast%3DSpiekermann%26aufirst%3DK.%26aulast%3DBauerle%26aufirst%3DP.%2BA.%26aulast%3DHiddemann%26aufirst%3DW.%26aulast%3DRiethmuller%26aufirst%3DG.%26aulast%3DSubklewe%26aufirst%3DM.%26atitle%3DBlockade%2520of%2520the%2520PD-1%252FPD-L1%2520axis%2520augments%2520lysis%2520of%2520AML%2520cells%2520by%2520the%2520CD33%252FCD3%2520BiTE%2520antibody%2520construct%2520AMG%2520330%253A%2520reversing%2520a%2520T-cell-induced%2520immune%2520escape%2520mechanism%26jtitle%3DLeukemia%26date%3D2016%26volume%3D30%26spage%3D484%26epage%3D491%26doi%3D10.1038%2Fleu.2015.214" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, Y.</span></span> <span> </span><span class="NLM_article-title">The IFN-gamma/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">UNSP 290</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1186/s12974-018-1330-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1186%2Fs12974-018-1330-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=29301548" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=1-13&issue=UNSP+290&author=J.+Qianauthor=C.+Wangauthor=B.+Wangauthor=J.+Yangauthor=Y.+Wangauthor=F.+Luoauthor=J.+Xuauthor=C.+Zhaoauthor=R.+Liuauthor=Y.+Chu&title=The+IFN-gamma%2FPD-L1+axis+between+T+cells+and+tumor+microenvironment%3A+hints+for+glioma+anti-PD-1%2FPD-L1+therapy&doi=10.1186%2Fs12974-018-1330-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1186%2Fs12974-018-1330-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12974-018-1330-2%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DChu%26aufirst%3DY.%26atitle%3DThe%2520IFN-gamma%252FPD-L1%2520axis%2520between%2520T%2520cells%2520and%2520tumor%2520microenvironment%253A%2520hints%2520for%2520glioma%2520anti-PD-1%252FPD-L1%2520therapy%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2018%26volume%3D15%26issue%3DUNSP%2520290%26spage%3D1%26epage%3D13%26doi%3D10.1186%2Fs12974-018-1330-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominy, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feeney, P. J.</span></span> <span> </span><span class="NLM_article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/S0169-409X(00)00129-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1016%2FS0169-409X%2800%2900129-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=11259830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2001&pages=3-26&author=C.+A.+Lipinskiauthor=F.+Lombardoauthor=B.+W.+Dominyauthor=P.+J.+Feeney&title=Experimental+and+computational+approaches+to+estimate+solubility+and+permeability+in+drug+discovery+and+development+settings&doi=10.1016%2FS0169-409X%2800%2900129-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span></div><div class="casAuthors">Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">3-26</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">A review with 50 refs.  Exptl. and computational approaches to est. soly. and permeability in discovery and development settings are described.  In the discovery setting 'the rule of 5' predicts that poor absorption or permeation is more likely when there are more than 5 H-bond donors, 10 H-bond acceptors, the mol. wt. (MWT) is greater than 500 and the calcd. Log P (CLogP) is greater than 5 (or MlogP >4.15).  Computational methodol. for the rule-based Moriguchi Log P (MLogP) calcn. is described.  Turbidimetric soly. measurement is described and applied to known drugs.  High throughput screening (HTS) leads tend to have higher MWT and Log P and lower turbidimetric soly. than leads in the pre-HTS era.  In the development setting, soly. calcns. focus on exact value prediction and are difficult because of polymorphism.  Recent work on linear free energy relationships and Log P approaches are critically reviewed.  Useful predictions are possible in closely related analog series when coupled with exptl. thermodn. soly. measurements.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYDqa02g16urVg90H21EOLACvtfcHk0lgYJEmT5Ce80g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXitVOhs7o%253D&md5=c60bb89da68f051c0ee7ac4c0468a0e4</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2800%2900129-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252800%252900129-0%26sid%3Dliteratum%253Aachs%26aulast%3DLipinski%26aufirst%3DC.%2BA.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DDominy%26aufirst%3DB.%2BW.%26aulast%3DFeeney%26aufirst%3DP.%2BJ.%26atitle%3DExperimental%2520and%2520computational%2520approaches%2520to%2520estimate%2520solubility%2520and%2520permeability%2520in%2520drug%2520discovery%2520and%2520development%2520settings%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2001%26volume%3D46%26spage%3D3%26epage%3D26%26doi%3D10.1016%2FS0169-409X%2800%2900129-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">International
Transporter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacomini, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benet, L. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwer, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillgren, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmaster, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keppler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niemi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polli, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaan, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamek-Gliszczynski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">Membrane transporters in drug development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1038/nrd3028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnrd3028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=20190787" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=215-236&author=C.+International%0ATransporterauthor=K.+M.+Giacominiauthor=S.+M.+Huangauthor=D.+J.+Tweedieauthor=L.+Z.+Benetauthor=K.+L.+Brouwerauthor=X.+Chuauthor=A.+Dahlinauthor=R.+Eversauthor=V.+Fischerauthor=K.+M.+Hillgrenauthor=K.+A.+Hoffmasterauthor=T.+Ishikawaauthor=D.+Kepplerauthor=R.+B.+Kimauthor=C.+A.+Leeauthor=M.+Niemiauthor=J.+W.+Polliauthor=Y.+Sugiyamaauthor=P.+W.+Swaanauthor=J.+A.+Wareauthor=S.+H.+Wrightauthor=S.+W.+Yeeauthor=M.+J.+Zamek-Gliszczynskiauthor=L.+Zhang&title=Membrane+transporters+in+drug+development&doi=10.1038%2Fnrd3028"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd3028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3028%26sid%3Dliteratum%253Aachs%26aulast%3DInternational%2BTransporter%26aufirst%3DC.%26aulast%3DGiacomini%26aufirst%3DK.%2BM.%26aulast%3DHuang%26aufirst%3DS.%2BM.%26aulast%3DTweedie%26aufirst%3DD.%2BJ.%26aulast%3DBenet%26aufirst%3DL.%2BZ.%26aulast%3DBrouwer%26aufirst%3DK.%2BL.%26aulast%3DChu%26aufirst%3DX.%26aulast%3DDahlin%26aufirst%3DA.%26aulast%3DEvers%26aufirst%3DR.%26aulast%3DFischer%26aufirst%3DV.%26aulast%3DHillgren%26aufirst%3DK.%2BM.%26aulast%3DHoffmaster%26aufirst%3DK.%2BA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DKeppler%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DR.%2BB.%26aulast%3DLee%26aufirst%3DC.%2BA.%26aulast%3DNiemi%26aufirst%3DM.%26aulast%3DPolli%26aufirst%3DJ.%2BW.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DSwaan%26aufirst%3DP.%2BW.%26aulast%3DWare%26aufirst%3DJ.%2BA.%26aulast%3DWright%26aufirst%3DS.%2BH.%26aulast%3DYee%26aufirst%3DS.%2BW.%26aulast%3DZamek-Gliszczynski%26aufirst%3DM.%2BJ.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DMembrane%2520transporters%2520in%2520drug%2520development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D215%26epage%3D236%26doi%3D10.1038%2Fnrd3028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lounkine, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhailov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doak, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, L.</span></span> <span> </span><span class="NLM_article-title">Large-scale prediction and testing of drug activity on side-effect targets</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>486</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1038/nature11159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnature11159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=22722194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=361-367&author=E.+Lounkineauthor=M.+J.+Keiserauthor=S.+Whitebreadauthor=D.+Mikhailovauthor=J.+Hamonauthor=J.+L.+Jenkinsauthor=P.+Lavanauthor=E.+Weberauthor=A.+K.+Doakauthor=S.+Coteauthor=B.+K.+Shoichetauthor=L.+Urban&title=Large-scale+prediction+and+testing+of+drug+activity+on+side-effect+targets&doi=10.1038%2Fnature11159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale prediction and testing of drug activity on side-effect targets</span></div><div class="casAuthors">Lounkine, Eugen; Keiser, Michael J.; Whitebread, Steven; Mikhailov, Dmitri; Hamon, Jacques; Jenkins, Jeremy L.; Lavan, Paul; Weber, Eckhard; Doak, Allison K.; Cote, Serge; Shoichet, Brian K.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7403</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Discovering the unintended off-targets' that predict adverse drug reactions is daunting by empirical methods alone.  Drugs can act on several protein targets, some of which can be unrelated by conventional mol. metrics, and hundreds of proteins have been implicated in side effects.  Here we use a computational strategy to predict the activity of 656 marketed drugs on 73 unintended side-effect' targets.  Approx. half of the predictions were confirmed, either from proprietary databases unknown to the method or by new exptl. assays.  Affinities for these new off-targets ranged from 1 nM to 30 μM.  To explore relevance, we developed an assocn. metric to prioritize those new off-targets that explained side effects better than any known target of a given drug, creating a drug-target-adverse drug reaction network.  Among these new assocns. was the prediction that the abdominal pain side effect of the synthetic estrogen chlorotrianisene was mediated through its newly discovered inhibition of the enzyme cyclooxygenase-1.  The clin. relevance of this inhibition was borne out in whole human blood platelet aggregation assays.  This approach may have wide application to de-risking toxicol. liabilities in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5sVjfn4mgLLVg90H21EOLACvtfcHk0lgklrX8FJbk5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D&md5=9c133b839d9527818a27a5834e4dfe11</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnature11159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11159%26sid%3Dliteratum%253Aachs%26aulast%3DLounkine%26aufirst%3DE.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DMikhailov%26aufirst%3DD.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DLavan%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DCote%26aufirst%3DS.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DLarge-scale%2520prediction%2520and%2520testing%2520of%2520drug%2520activity%2520on%2520side-effect%2520targets%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D361%26epage%3D367%26doi%3D10.1038%2Fnature11159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, evaluation, and structural studies of c2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7250</span>– <span class="NLM_lpage">7263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7250-7263&author=S.+Basuauthor=J.+Yangauthor=B.+Xuauthor=K.+Magiera-Mularzauthor=L.+Skalniakauthor=B.+Musielakauthor=V.+Kholodovychauthor=T.+A.+Holakauthor=L.+Hu&title=Design%2C+synthesis%2C+evaluation%2C+and+structural+studies+of+c2-symmetric+small+molecule+inhibitors+of+programmed+cell+death-1%2Fprogrammed+death-ligand+1+protein-protein+interaction&doi=10.1021%2Facs.jmedchem.9b00795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction</span></div><div class="casAuthors">Basu, Subhadwip; Yang, Jeffrey; Xu, Bin; Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Musielak, Bogdan; Kholodovych, Vladyslav; Holak, Tad A.; Hu, Longqin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7250-7263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of C2-sym. inhibitors was designed and evaluated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (PPI) in a homogeneous time-resolved fluorescence (HTRF) assay and PD-1 signaling in cell-based coculture assays.  C2-sym. inhibitors 2a (LH1306) and 2b (LH1307) exhibited IC50 values of 25 and 3.0 nM, resp., in the HTRF assay.  While 2a was ∼3.8-fold more potent than previously reported inhibitor 1a, 2b could not be differentiated from 1b due to their high potency and the limit of our HTRF assay conditions.  In one cell-based coculture PD-1 signaling assay, 2a and 2b were 8.2- and 2.8-fold more potent in inhibiting PD-1 signaling than 1a and 1b, resp.  NMR and X-ray cocrystal structural studies provided more structural insights into the interaction between 2b and PD-L1; 2b binds to PD-L1 at the PD-1 binding site and induces the formation of a more sym. arranged PD-L1 homodimer than that previously reported for other inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9fdh7FbNLLVg90H21EOLACvtfcHk0lhBKPThsTL0MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ&md5=0dae949116a4157a281802aea6d21b6c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00795%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DHu%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520structural%2520studies%2520of%2520c2-symmetric%2520small%2520molecule%2520inhibitors%2520of%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7250%26epage%3D7263%26doi%3D10.1021%2Facs.jmedchem.9b00795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S. D.</span></span> <span> </span><span class="NLM_article-title">Oral absorption and pharmacokinetics of rebamipide and rebamipide lysinate in rats</span>. <i>Drug Dev. Ind. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">869</span>– <span class="NLM_lpage">876</span>, <span class="refDoi"> DOI: 10.1081/DDC-200034577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1081%2FDDC-200034577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=15521332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotVektL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2004&pages=869-876&author=B.+S.+Shinauthor=C.+H.+Kimauthor=Y.+S.+Junauthor=C.+H.+Yoonauthor=J.+I.+Rhoauthor=K.+C.+Leeauthor=H.+S.+Hanauthor=S.+D.+Yoo&title=Oral+absorption+and+pharmacokinetics+of+rebamipide+and+rebamipide+lysinate+in+rats&doi=10.1081%2FDDC-200034577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Oral Absorption and Pharmacokinetics of Rebamipide and Rebamipide Lysinate in Rats</span></div><div class="casAuthors">Shin, Beom Soo; Kim, Chul Hwan; Jun, Yoon Sik; Yoon, Chi Ho; Rho, Jae Il; Lee, Kang Choon; Han, Hye Seon; Yoo, Sun Dong</div><div class="citationInfo"><span class="NLM_cas:title">Drug Development and Industrial Pharmacy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">869-876</span>CODEN:
                <span class="NLM_cas:coden">DDIPD8</span>;
        ISSN:<span class="NLM_cas:issn">0363-9045</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">Rebamipide is an anti-ulcer agent exhibiting a low aq. soly. and a poor oral bioavailability.  This study was conducted to examine if the rebamipide lysinate salt form would exhibit improved soly. profiles and higher oral bioavailability compared with rebamipide free acid.  Both compds. showed pH-dependent soly. profiles, with the soly. of rebamipide lysinate dramatically improved at a median pH of 5.1 (17-fold increases) over free acid, but the improvement in the soly. was not as pronounced in artificial gastric and intestinal fluids (1.4- and 1.9-fold increases, resp.).  The Cl, Vss and t1/2 in rats after i.v. injection of rebamipide (0.5 mg/kg) averaged 21.0±3.2 mL/min/kg, 0.3±0.0 L/kg, and 0.4±0.1 h, resp.  No significant difference was obsd. in these parameters between rebamipide and rebamipide lysinate.  Despite improved soly. profiles, the abs. oral bioavailability of rebamipide lysinate was not increased (5.1 vs. 4.8%) nor did AUC (407.8 vs. 383.6 ng.hr/mL) and Cmax (87.4 vs.77.0 ng/mL) compared with rebamipide free acid.  Rebamipide lysinate, however, showed a more rapid absorption, and initial serum drug concns. were higher than those found for rebamipide free acid.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUW1j5qxVyhLVg90H21EOLACvtfcHk0lid3kR3OgbqbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotVektL0%253D&md5=9fc40c2dbc9a997cc5807c13d84091bb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1081%2FDDC-200034577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FDDC-200034577%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DB.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BH.%26aulast%3DJun%26aufirst%3DY.%2BS.%26aulast%3DYoon%26aufirst%3DC.%2BH.%26aulast%3DRho%26aufirst%3DJ.%2BI.%26aulast%3DLee%26aufirst%3DK.%2BC.%26aulast%3DHan%26aufirst%3DH.%2BS.%26aulast%3DYoo%26aufirst%3DS.%2BD.%26atitle%3DOral%2520absorption%2520and%2520pharmacokinetics%2520of%2520rebamipide%2520and%2520rebamipide%2520lysinate%2520in%2520rats%26jtitle%3DDrug%2520Dev.%2520Ind.%2520Pharm.%26date%3D2004%26volume%3D30%26spage%3D869%26epage%3D876%26doi%3D10.1081%2FDDC-200034577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costello, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalton, J. T.</span></span> <span> </span><span class="NLM_article-title">Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3053</span>– <span class="NLM_lpage">3063</span>, <span class="refDoi"> DOI: 10.1007/s11095-012-0814-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1007%2Fs11095-012-0814-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=22760659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVSls7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=3053-3063&author=C.+M.+Liauthor=Y.+Luauthor=J.+Chenauthor=T.+A.+Costelloauthor=R.+Narayananauthor=M.+N.+Daltonauthor=L.+M.+Snyderauthor=S.+Ahnauthor=W.+Liauthor=D.+D.+Millerauthor=J.+T.+Dalton&title=Orally+bioavailable+tubulin+antagonists+for+paclitaxel-refractory+cancer&doi=10.1007%2Fs11095-012-0814-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Orally Bioavailable Tubulin Antagonists for Paclitaxel-Refractory Cancer</span></div><div class="casAuthors">Li, Chien-Ming; Lu, Yan; Chen, Jianjun; Costello, Terrence A.; Narayanan, Ramesh; Dalton, Mara N.; Snyder, Linda M.; Ahn, Sunjoo; Li, Wei; Miller, Duane D.; Dalton, James T.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3053-3063</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: To evaluate the efficacy and oral activity of two promising indoles, (2-(1H-indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl)methanone [compd. II] and (2-(1H-indol-5-ylamino)-thiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone [compd. IAT], in paclitaxel- and docetaxel-resistant tumor models in vitro and in vivo.  Methods: The in vitro drug-like properties, including potency, soly., metabolic stability, and drug-drug interactions were examd. for our two active compds.  An in vivo pharmacokinetic study and antitumor efficacy study were also completed to compare their efficacy with docetaxel.  Results: Both compds. bound to the colchicine-binding site on tubulin, and inhibited tubulin polymn., resulting in highly potent cytotoxic activity in vitro.  While the potency of paclitaxel and docetaxel was compromised in a multidrug-resistant cell line that overexpresses P-glycoprotein, the potency of compds. II and IAT was maintained.  Both compds. had favorable drug-like properties, and acceptable oral bioavailability (21-50 %) in mice, rats, and dogs.  Tumor growth inhibition of greater than 100 % was achieved when immunodeficient mice with rapidly growing paclitaxel-resistant prostate cancer cells were treated orally at doses of 3-30 mg/kg of II or IAT.  Conclusions: These studies highlight the potent and broad anticancer activity of two orally bioavailable compds., offering significant pharmacol. advantage over existing drugs of this class for multidrug resistant or taxane-refractory cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA2ZtCfxwTTrVg90H21EOLACvtfcHk0lid3kR3OgbqbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVSls7k%253D&md5=8063cbbcdd9ffaff2e84e4b53b704672</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0814-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0814-5%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%2BM.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCostello%26aufirst%3DT.%2BA.%26aulast%3DNarayanan%26aufirst%3DR.%26aulast%3DDalton%26aufirst%3DM.%2BN.%26aulast%3DSnyder%26aufirst%3DL.%2BM.%26aulast%3DAhn%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26atitle%3DOrally%2520bioavailable%2520tubulin%2520antagonists%2520for%2520paclitaxel-refractory%2520cancer%26jtitle%3DPharm.%2520Res.%26date%3D2012%26volume%3D29%26spage%3D3053%26epage%3D3063%26doi%3D10.1007%2Fs11095-012-0814-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gittis, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikami, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okazaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honjo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minato, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garboczi, D. N.</span></span> <span> </span><span class="NLM_article-title">The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">3011</span>– <span class="NLM_lpage">3016</span>, <span class="refDoi"> DOI: 10.1073/pnas.0712278105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1073%2Fpnas.0712278105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=18287011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=3011-3016&author=D.+Y.+Linauthor=Y.+Tanakaauthor=M.+Iwasakiauthor=A.+G.+Gittisauthor=H.+P.+Suauthor=B.+Mikamiauthor=T.+Okazakiauthor=T.+Honjoauthor=N.+Minatoauthor=D.+N.+Garboczi&title=The+PD-1%2FPD-L1+complex+resembles+the+antigen-binding+Fv+domains+of+antibodies+and+T+cell+receptors&doi=10.1073%2Fpnas.0712278105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors</span></div><div class="casAuthors">Lin, David Yin-Wei; Tanaka, Yoshimasa; Iwasaki, Masashi; Gittis, Apostolos G.; Su, Hua-Poo; Mikami, Bunzo; Okazaki, Taku; Honjo, Tasuku; Minato, Nagahiro; Garboczi, David N.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3011-3016</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Signaling via the programmed death 1 (PD-1) inhibitory receptor upon binding its ligand, PD-L1, suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance.  Release from PD-1 inhibitory signaling revives "exhausted" virus-specific T cells in chronic viral infections.  Here the authors present the crystal structure of murine PD-1 in complex with human PD-L1.  PD-1 and PD-L1 interact through the conserved front and side of their Ig variable (IgV) domains, as do the IgV domains of antibodies and T cell receptors.  This places the loops at the ends of the IgV domains on the same side of the PD-1/PD-L1 complex, forming a surface that is similar to the antigen-binding surface of antibodies and T cell receptors.  Mapping conserved residues allowed the identification of residues that are important in forming the PD-1/PD-L1 interface.  Based on the structure, the authors show that some reported loss-of-binding mutations involve the PD-1/PD-L1 interaction but that others compromise protein folding.  The PD-1/PD-L1 interaction described here may be blocked by antibodies or by designed small-mol. drugs to lower inhibitory signaling that results in a stronger immune response.  The immune receptor-like loops offer a new surface for further study and potentially the design of mols. that would affect PD-1/PD-L1 complex formation and thereby modulate the immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqbP0BPGxxELVg90H21EOLACvtfcHk0ljZCS_VvWa9Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSitr4%253D&md5=5ea708a1fdb0b926d109ec515c9b81cc</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0712278105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0712278105%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DD.%2BY.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DIwasaki%26aufirst%3DM.%26aulast%3DGittis%26aufirst%3DA.%2BG.%26aulast%3DSu%26aufirst%3DH.%2BP.%26aulast%3DMikami%26aufirst%3DB.%26aulast%3DOkazaki%26aufirst%3DT.%26aulast%3DHonjo%26aufirst%3DT.%26aulast%3DMinato%26aufirst%3DN.%26aulast%3DGarboczi%26aufirst%3DD.%2BN.%26atitle%3DThe%2520PD-1%252FPD-L1%2520complex%2520resembles%2520the%2520antigen-binding%2520Fv%2520domains%2520of%2520antibodies%2520and%2520T%2520cell%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D3011%26epage%3D3016%26doi%3D10.1073%2Fpnas.0712278105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Daud, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshua, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kefford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangadhar, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dronca, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarour, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roach, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toland, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunceford, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emancipator, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolled-Filhart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ebbinghaus, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span> <span> </span><span class="NLM_article-title">Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">4102</span>– <span class="NLM_lpage">4109</span>, <span class="refDoi"> DOI: 10.1200/JCO.2016.67.2477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1200%2FJCO.2016.67.2477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=27863197" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2016&pages=4102-4109&author=A.+I.+Daudauthor=J.+D.+Wolchokauthor=C.+Robertauthor=W.+J.+Hwuauthor=J.+S.+Weberauthor=A.+Ribasauthor=F.+S.+Hodiauthor=A.+M.+Joshuaauthor=R.+Keffordauthor=P.+Herseyauthor=R.+Josephauthor=T.+C.+Gangadharauthor=R.+Droncaauthor=A.+Patnaikauthor=H.+Zarourauthor=C.+Roachauthor=G.+Tolandauthor=J.+K.+Luncefordauthor=X.+N.+Liauthor=K.+Emancipatorauthor=M.+Dolled-Filhartauthor=S.+P.+Kangauthor=S.+Ebbinghausauthor=O.+Hamid&title=Programmed+death-ligand+1+expression+and+response+to+the+anti-programmed+death+1+antibody+pembrolizumab+in+melanoma&doi=10.1200%2FJCO.2016.67.2477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma</span></div><div class="casAuthors">Daud, Adil I.; Wolchok, Jedd D.; Robert, Caroline; Hwu, Wen-Jen; Weber, Jeffrey S.; Ribas, Antoni; Hodi, F. Stephen; Joshua, Anthony M.; Kefford, Richard; Hersey, Peter; Joseph, Richard; Gangadhar, Tara C.; Dronca, Roxana; Patnaik, Amita; Zarour, Hassane; Roach, Charlotte; Toland, Grant; Lunceford, Jared K.; Li, Xiaoyun Nicole; Emancipator, Kenneth; Dolled-Filhart, Marisa; Kang, S. Peter; Ebbinghaus, Scot; Hamid, Omid</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4102-4109</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker for response and outcome after treatment with anti-programmed death 1 (PD-1).  This study explored the relationship between anti-PD-1 activity and PD-L1 expression in patients with advanced melanoma who were treated with pembrolizumab in the phase Ib KEYNOTE-001 study (clin. trial information: NCT01295827).  Patients and Methods Six hundred fifty-five patients received pembrolizumab10 mg/kg once every 2 wk or once every 3 wk, or 2 mg/kg once every 3 wk.  Tumor response was assessed every 12 wk per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by independent central review.  Primary outcome was objective response rate.  Secondary outcomes included progression-free survival (PFS) and overall survival (OS).  Membranous PD-L1 expression in tumor and tumor-assocd. immune cells was assessed by a clin. trial immunohistochem. assay (22C3 antibody) and scored on a unique melanoma (MEL) scale of 0 to 5 by one of three pathologists who were blinded to clin. outcome; a score ≥ 2 (membranous staining in ≥ 1% of cells) was considered pos.  Results Of 451 patients with evaluable PD-L1 expression, 344 (76%) had PD-L1-pos. tumors.  Demog. and staging variables were equally distributed among PD-L1-pos. and -neg. patients.  An assocn. between higher MEL score and higher response rate and longer PFS (hazard ratio, 0.76; 95% CI, 0.71 to 0.82) and OS (hazard ratio, 0.76; 95% CI, 0.69 to 0.83) was obsd. (P≤ .001 for each).  Objective response rate was 8%, 12%, 22%, 43%, 57%, and 53% for MEL 0, 1, 2, 3, 4, and 5, resp.  Conclusion PD-L1 expression in pretreatment tumor biopsy samples was correlated with response rate, PFS, and OS; however, patients with PD-L1-neg. tumors may also achieve durable responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrICOQPJlNnLbVg90H21EOLACvtfcHk0ljghtjtp_1Mng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOqt7c%253D&md5=5be54952126630c646743b788c459a87</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1200%2FJCO.2016.67.2477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2016.67.2477%26sid%3Dliteratum%253Aachs%26aulast%3DDaud%26aufirst%3DA.%2BI.%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHwu%26aufirst%3DW.%2BJ.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26aulast%3DJoshua%26aufirst%3DA.%2BM.%26aulast%3DKefford%26aufirst%3DR.%26aulast%3DHersey%26aufirst%3DP.%26aulast%3DJoseph%26aufirst%3DR.%26aulast%3DGangadhar%26aufirst%3DT.%2BC.%26aulast%3DDronca%26aufirst%3DR.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DZarour%26aufirst%3DH.%26aulast%3DRoach%26aufirst%3DC.%26aulast%3DToland%26aufirst%3DG.%26aulast%3DLunceford%26aufirst%3DJ.%2BK.%26aulast%3DLi%26aufirst%3DX.%2BN.%26aulast%3DEmancipator%26aufirst%3DK.%26aulast%3DDolled-Filhart%26aufirst%3DM.%26aulast%3DKang%26aufirst%3DS.%2BP.%26aulast%3DEbbinghaus%26aufirst%3DS.%26aulast%3DHamid%26aufirst%3DO.%26atitle%3DProgrammed%2520death-ligand%25201%2520expression%2520and%2520response%2520to%2520the%2520anti-programmed%2520death%25201%2520antibody%2520pembrolizumab%2520in%2520melanoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2016%26volume%3D34%26spage%3D4102%26epage%3D4109%26doi%3D10.1200%2FJCO.2016.67.2477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowanetz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamid, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gettinger, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrt, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rost, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leabman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokatrin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koeppen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodi, F. S.</span></span> <span> </span><span class="NLM_article-title">Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>515</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">567</span>, <span class="refDoi"> DOI: 10.1038/nature14011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1038%2Fnature14011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=25428504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFanurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=515&publication_year=2014&pages=563-567&author=R.+S.+Herbstauthor=J.+C.+Soriaauthor=M.+Kowanetzauthor=G.+D.+Fineauthor=O.+Hamidauthor=M.+S.+Gordonauthor=J.+A.+Sosmanauthor=D.+F.+McDermottauthor=J.+D.+Powderlyauthor=S.+N.+Gettingerauthor=H.+E.+Kohrtauthor=L.+Hornauthor=D.+P.+Lawrenceauthor=S.+Rostauthor=M.+Leabmanauthor=Y.+Xiaoauthor=A.+Mokatrinauthor=H.+Koeppenauthor=P.+S.+Hegdeauthor=I.+Mellmanauthor=D.+S.+Chenauthor=F.+S.+Hodi&title=Predictive+correlates+of+response+to+the+anti-PD-L1+antibody+MPDL3280A+in+cancer+patients&doi=10.1038%2Fnature14011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</span></div><div class="casAuthors">Herbst, Roy S.; Soria, Jean-Charles; Kowanetz, Marcin; Fine, Gregg D.; Hamid, Omid; Gordon, Michael S.; Sosman, Jeffery A.; McDermott, David F.; Powderly, John D.; Gettinger, Scott N.; Kohrt, Holbrook E. K.; Horn, Leora; Lawrence, Donald P.; Rost, Sandra; Leabman, Maya; Xiao, Yuanyuan; Mokatrin, Ahmad; Koeppen, Hartmut; Hegde, Priti S.; Mellman, Ira; Chen, Daniel S.; Hodi, F. Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">515</span>
        (<span class="NLM_cas:issue">7528</span>),
    <span class="NLM_cas:pages">563-567</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumor progression.  These changes distinguish cancer cells from their normal counterparts, allowing tumors to be recognized as foreign by the immune system.  However, tumors are rarely rejected spontaneously, reflecting their ability to maintain an immunosuppressive microenvironment.  Programmed death-ligand 1 (PD-L1; also called B7-H1 or CD274), which is expressed on many cancer and immune cells, plays an important part in blocking the 'cancer immunity cycle' by binding programmed death-1 (PD-1) and B7.1 (CD80), both of which are neg. regulators of T-lymphocyte activation.  Binding of PD-L1 to its receptors suppresses T-cell migration, proliferation and secretion of cytotoxic mediators, and restricts tumor cell killing.  The PD-L1-PD-1 axis protects the host from overactive T-effector cells not only in cancer but also during microbial infections.  Blocking PD-L1 should therefore enhance anticancer immunity, but little is known about predictive factors of efficacy.  This study was designed to evaluate the safety, activity and biomarkers of PD-L1 inhibition using the engineered humanized antibody MPDL3280A.  Here we show that across multiple cancer types, responses (as evaluated by Response Evaluation Criteria in Solid Tumors, version 1.1) were obsd. in patients with tumors expressing high levels of PD-L1, esp. when PD-L1 was expressed by tumor-infiltrating immune cells.  Furthermore, responses were assocd. with T-helper type 1 (TH1) gene expression, CTLA4 expression and the absence of fractalkine (CX3CL1) in baseline tumor specimens.  Together, these data suggest that MPDL3280A is most effective in patients in which pre-existing immunity is suppressed by PD-L1, and is re-invigorated on antibody treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWwkJV0J8Y_bVg90H21EOLACvtfcHk0ljghtjtp_1Mng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFanurbM&md5=1a5efa7b5929ca48ed17cb530e4f7916</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fnature14011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature14011%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DKowanetz%26aufirst%3DM.%26aulast%3DFine%26aufirst%3DG.%2BD.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DGordon%26aufirst%3DM.%2BS.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26aulast%3DGettinger%26aufirst%3DS.%2BN.%26aulast%3DKohrt%26aufirst%3DH.%2BE.%26aulast%3DHorn%26aufirst%3DL.%26aulast%3DLawrence%26aufirst%3DD.%2BP.%26aulast%3DRost%26aufirst%3DS.%26aulast%3DLeabman%26aufirst%3DM.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DMokatrin%26aufirst%3DA.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DHegde%26aufirst%3DP.%2BS.%26aulast%3DMellman%26aufirst%3DI.%26aulast%3DChen%26aufirst%3DD.%2BS.%26aulast%3DHodi%26aufirst%3DF.%2BS.%26atitle%3DPredictive%2520correlates%2520of%2520response%2520to%2520the%2520anti-PD-L1%2520antibody%2520MPDL3280A%2520in%2520cancer%2520patients%26jtitle%3DNature%26date%3D2014%26volume%3D515%26spage%3D563%26epage%3D567%26doi%3D10.1038%2Fnature14011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juneja, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manguso, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFleur, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haining, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1084/jem.20160801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=10.1084%2Fjem.20160801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=28302645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2ju7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2017&pages=895-904&author=V.+R.+Junejaauthor=K.+A.+McGuireauthor=R.+T.+Mangusoauthor=M.+W.+LaFleurauthor=N.+Collinsauthor=W.+N.+Hainingauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-L1+on+tumor+cells+is+sufficient+for+immune+evasion+in+immunogenic+tumors+and+inhibits+CD8+T+cell+cytotoxicity&doi=10.1084%2Fjem.20160801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity</span></div><div class="casAuthors">Juneja, Vikram R.; McGuire, Kathleen A.; Manguso, Robert T.; LaFleur, Martin W.; Collins, Natalie; Haining, W. Nicholas; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-904</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">It is unclear whether PD-L1 on tumor cells is sufficient for tumor immune evasion or simply correlates with an inflamed tumor microenvironment.  We used three mouse tumor models sensitive to PD-1 blockade to evaluate the significance of PD-L1 on tumor vs. nontumor cells.  PD-L1 on nontumor cells is crit. for inhibiting antitumor immunity in B16 melanoma and a genetically engineered melanoma.  In contrast, PD-L1 on MC38 colorectal adenocarcinoma cells is sufficient to suppress antitumor immunity, as deletion of PD-L1 on highly immunogenic MC38 tumor cells allows effective antitumor immunity.  MC38-derived PD-L1 potently inhibited CD8+ T cell cytotoxicity.  Wild-type MC38 cells outcompeted PD-L1-deleted MC38 cells in vivo, demonstrating tumor PD-L1 confers a selective advantage.  Thus, both tumor- and host-derived PD-L1 can play crit. roles in immunosuppression.  Differences in tumor immunogenicity appear to underlie their relative importance.  Our findings establish reduced cytotoxicity as a key mechanism by which tumor PD-L1 suppresses antitumor immunity and demonstrate that tumor PD-L1 is not just a marker of suppressed antitumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOvfjGoOhPg7Vg90H21EOLACvtfcHk0ljZSSat4SqugQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2ju7nJ&md5=95ceac8e66dd13f327bfc0eb3dab42c1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1084%2Fjem.20160801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20160801%26sid%3Dliteratum%253Aachs%26aulast%3DJuneja%26aufirst%3DV.%2BR.%26aulast%3DMcGuire%26aufirst%3DK.%2BA.%26aulast%3DManguso%26aufirst%3DR.%2BT.%26aulast%3DLaFleur%26aufirst%3DM.%2BW.%26aulast%3DCollins%26aufirst%3DN.%26aulast%3DHaining%26aufirst%3DW.%2BN.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-L1%2520on%2520tumor%2520cells%2520is%2520sufficient%2520for%2520immune%2520evasion%2520in%2520immunogenic%2520tumors%2520and%2520inhibits%2520CD8%2520T%2520cell%2520cytotoxicity%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2017%26volume%3D214%26spage%3D895%26epage%3D904%26doi%3D10.1084%2Fjem.20160801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5J89','PDB','5J89'); return false;">PDB: 5J89</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIX','PDB','5NIX'); return false;">PDB: 5NIX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIU','PDB','5NIU'); return false;">PDB: 5NIU</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i105"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00574">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_65827"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00574?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00574</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H NMR, <sup>13</sup>C NMR, and LCMS spectra, as well as figures generated from pharmacokinetic studies (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_001.pdf">PDF</a>)</p></li><li><p class="inline">(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_002.pdb">PDB</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_001.pdf">jm0c00574_si_001.pdf (14.54 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_002.pdb">jm0c00574_si_002.pdb (727.34 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00574/suppl_file/jm0c00574_si_003.csv">jm0c00574_si_003.csv (9.38 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-15%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00574%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00574" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                11MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67995aa70f1b3c64","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
